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I Summary 
 
CRISPR-Cas systems are adaptive immune systems, found in bacteria and archaea that 
provide inheritable resistance against mobile genetic elements, e.g. viruses and plasmids. 
CRISPR-Cas systems comprise one or more CRISPR loci that contain virus-derived DNA 
sequences (spacers) that are interspaced by identical repeat sequences (repeats), and a set 
of cas genes. The degradation of nucleic acid targets is mediated by ribonucleoprotein 
(RNP) complexes, formed by Cas proteins, that are guided by small CRISPR RNA 
molecules (crRNAs). A Cas protein classification has been established which reflects the 
diversification of CRISPR systems during the co-evolution of phages and their respective 
hosts. In this study, the type I-B CRISPR-Cas system of the thermophilic bacterium 
Clostridium thermocellum was investigated.  
CRISPR loci are transcribed into precursor-crRNAs and individual crRNAs are produced 
by Cas6 endonucleases. C. thermocellum contains two Cas6 proteins and the recombinant 
enzymes exclusively process their respective precursor transcripts in vitro. RNA-Seq 
analyses confirmed crRNA maturation and highlighted crRNA abundance differences in 
vivo. These analyses identified internal promotion of precursor-crRNA transcription and 
reverse crRNA transcripts (anti-crRNAs). Anti-crRNAs display a distinct processing 
pattern and the abundance of the complementary crRNA is often reduced in vivo. Cleavage 
assays with crRNAs and double-stranded crRNA/anti-crRNA hybrids identified RNase III 
to be capable of anti-crRNA processing. RNase III cleavage is mediated by recognition 
motifs within the repeat RNA duplexes. 
In type I-B systems, CRISPR interference is mediated by a dsDNA targeting crRNP 
complex, termed Cascade, which consists of the Cas proteins Cas3, Cas5, Cas6, Cas7 and 
the subtype-specific Cas8b subunit. All five recombinant Cascade subunits were produced 
in Escherichia coli. Cascade assembly studies revealed that a stable core-complex is 
formed by Cas5, Cas7, Cas8b and crRNA in vitro. Cas3 does not assemble with the 
complex. Cas6 is a temporarily associated subunit. Mass-spectrometric analyses confirmed 
protein interactions between Cas5, Cas7 and Cas8b and determined an uneven complex 
stoichiometry of 1:1:6:2.5 for Cas5:Cas6:Cas7:Cas8b. The large subunit Cas8b forms an 
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additional small C-terminal protein fragment that is also observed in C. thermocellum cell 
extracts and assembles with the complex.  
This thesis provides details for the in vitro assembly of individual Cas proteins into type I-
B Cascade. Furthermore, RNA-Seq analyses of the CRISPR arrays highlight the impact of 
individual spacer and repeat sequences on the functionality of CRISPR-Cas systems.  
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II Zusammenfassung 
 
CRISPR-Cas Systeme stellen adaptive Abwehrsysteme dar, die in Bakterien und Archaeen 
gefunden werden und vererbbare Resistenz gegen mobile genetische Elemente wie z.B. 
Viren und Plasmide vermitteln. CRISPR-Cas Systeme bestehen aus einem oder mehreren 
CRISPR-Loci und assoziierten cas Genen. CRISPR-Loci enthalten virale DNA-Sequenzen 
(Spacer) die durch identische, repetitive Sequenzen (Repeats) getrennt werden. Cas-
Proteine bilden Ribonukleoproteinkomplexe (RNP-Komplexe) mit kleinen CRISPR RNAs 
(crRNAs), die als Zielerkennungsmoleküle Nukleinsäuren detektieren und zum Verdau 
markieren. Die Einführung einer Nomenklatur zur Klassifizierung der Cas-Proteine 
verdeutlicht die Diversität von CRISPR-Cas Systemen, die durch die Co-Evolution von 
Phage und Wirt angetrieben wird. In der vorliegenden Arbeit wurde ein Typ I-B CRISPR-
Cas System des thermophilen Bakteriums Clostridium thermocellum untersucht.  
CRISPR-Loci werden in Precursor-crRNAs transkribiert und anschließend von Cas6 
Endonukleasen zu individuellen crRNAs prozessiert. C. thermocellum enthält zwei Cas6 
Proteine, die als rekombinante Enzyme in vitro ausschließlich die ihnen zugehörigen 
Precursor-Transkripte schneiden. RNA-Seq-Analysen bestätigten die Produktion von 
crRNAs und belegten variable Transkriptmengen individueller crRNAs in vivo. Es konnten 
Promotoren innerhalb von CRISPR-Loci beobachtet werden. Des Weiteren wurden 
entgegengesetzte crRNA-Transkripte (Anti-crRNAs) identifiziert, die ein deutliches 
Prozessierungsmuster aufweisen. Die Transkriptmenge der komplementären crRNAs ist 
häufig reduziert. Aktivitätsassays mit doppelsträngigen crRNA/Anti-crRNA-Hybriden 
zeigten, dass RNase III imstande ist, Anti-crRNAs zu schneiden. Diese Aktivität wird 
durch Erkennungsmotive in der Sequenz von Repeat-RNA-Hybriden vermittelt. 
Typ I-B CRISPR Interferenz wird durch crRNP-Komplexe vermittelt, die doppelsträngige 
Fremd-DNA erkennen und als Cascade-Komplexe bezeichnet werden. Diese Cascade-
Komplexe setzten sich aus den Cas-Proteinen Cas3, Cas5, Cas6, Cas7 und der Subtyp-
spezifischen Untereinheit Cas8b zusammen. Alle fünf rekombinanten Cascade-
Untereinheiten wurden in Escherichia coli hergestellt. In vitro-Studien zur Assemblierung 
von rekombinanten Cascade-Komplexen zeigten, dass Cas5, Cas7, Cas8b und crRNA 
stabile Untereinheiten sind. Cas3 ist kein fester Bestandteil des Komplexes und Cas6 
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interagiert nur zeitweise mit anderen Cas-Komponenten. Massenspektrometrische 
Analysen belegten die Interaktion zwischen Cas5, Cas7 und Cas8b, und ermittelten eine 
ungerade Komplexstöchiometrie von 1:1:6:2,5 für Cas5:Cas6:Cas7:Cas8b. Die große 
Untereinheit Cas8b weist ein zusätzliches C-terminales Proteinfragment auf, welches im 
Zellextrakt von C. thermocellum nachgewiesen wurde und ebenfalls mit dem Cascade-
Komplex assembliert. 
Die Ergebnisse dieser Studie ermöglichen einen Einblick in die Assemblierung der 
einzelnen Cas-Proteine zu einem Typ I-B Cascade in vitro. Des Weiteren verdeutlichen 
RNA-Seq Analysen der CRISPR-Arrays den Einfluss von individuellen Spacer-und-
Repeat-Sequenzen auf die Funktionalität von CRISPR-Cas Systemen. 
 
 ____________________________________________________________________________Abbreviations 
 
 
III Abbreviations 
 
aa amino acid dsDNA double-stranded DNA 
APS ammonium persulfate dsRNA double-stranded RNA 
ATP adenosine triphosphate DTT dithiothreitol 
β-Me β-mercaptoethanol e.g. for example 
bp basepair(s) EDTA ethylene-diamine-tetraacetic 
acid 
BSA bovine serum albumin EMSA electrophoretic mobility shift 
assay 
C-terminal carboxy-terminal EtBr ethidium bromide 
Cam chloramphenicol et al. et alteri = and others 
Cas CRISPR-associated protein Fig. figure 
Cascade CRISPR-associated complex for 
antiviral defense 
FPLC Fast Protein Liquid 
Chromatography 
cpm counts per minute g gram 
CRISPR Clustered Regulary Interspaced 
Short Palindromic Repeats 
x g gravitational acceleration 
crRNA CRISPR-RNA h hour(s) 
Da Dalton HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid 
DEPC diethylpyrocarbonate (6x) His-tag (hexa) histidine tag 
DMSO dimethyl sulfoxide IPTG isopropyl β-D-1-
thiogalactopyranoside 
DNA deoxyribonucleic acid Kan kanamycin 
kb kilobases L liter 
kDa kilo Dalton LB lysogeny broth 
M molar (mol/L) ssDNA single-stranded-DNA 
min minutes ssRNA single-stranded-RNA 
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MOPS 3-(N-
morpholino)propanesulfonic acid 
SDS sodium dodecyl sulfate 
MW molecular weight T7 
polymerase 
RNA polymerase of the T7 
bacteriophage 
µ micro (10 -6) tRNA transfer-RNA 
N-terminal amino-terminal TAE trist-acetate EDTA-buffer 
Ni-NTA nickel-nitrilotriacetic acid TCA trichloroacedic acid 
nt nucleotides TBE tris-borate EDTA-buffer 
NTP nucleoside triphosphate TEMED N,N,N’;N’-
tetramethylethylenediamide 
OD600 optical density at 600 nm Tris tris-(hydroxymethyl)-
aminomethane 
ORF open reading frame U unit (enzyme activity) 
PAGE polyacrylamide gel Vol volume 
PCR polymerase chain reaction W Watt 
pH negative logarithm of the 
hydrogen ion (H+) concentration 
% (v/v) percent by volume 
Phusion Pyrococcus-like DNA 
polymerase fused to a 
processivity-enhancing domain 
% (w/v) percent by weight 
RNA ribonucleic acid > higher than 
RNase ribonuclease < lower than 
rpm rounds per minute   
RT room temperature   
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1. Introduction 
1.1 Prokaryotic defence mechanisms 
Bacteriophages and their respective hosts are co-evolving in natural environments. Phages 
are the most abundant entities on our planet and it has been estimated that they outnumber 
their prokaryotic hosts by approximately tenfold 1. Thus, bacteria have evolved or acquired 
protective mechanisms that can be classified as innate or adaptive anti-phage systems 2. 
The innate immune systems prevent phage adsorption, cleave phage nucleic acids or abort 
phage infection 3. One mechanism to escape phage adsorption is to modify the cell surface 
receptors 4. Restriction-modification systems protect the cell by recognizing and degrading 
unmethylated phage DNA 5. Finally, abortive infection systems lead to the death of a cell 
after recognizing its infection 3. Adaptive immunity on the other hand is provided by 
CRISPR-Cas systems 6. Phages have also evolved strategies to overcome bacterial 
protection resulting in a continuous arms race between the two populations.  
 
1.2 The CRISPR-Cas immune system 
CRISPR (Clustered_regularly_interspaced_short_palindromic_repeats) - Cas (CRISPR-
associated) are widespread adaptive and inheritable immune systems found in 45 % of 
bacterial and 84 % of archaeal genomes that have been sequenced (CRISPRdb status 
August 2014) 7. CRISPR systems are formed by one or more CRISPR loci together with a 
set of cas genes that are often found in close proximity to the CRISPR locus (fig 1.1) 8.  
 
 
Figure 1.1: Common features of a CRISPR system. A CRISPR system consists of a CRISPR locus (repeat 
elements that are interspaced by spacer sequences) flanked by a leader sequence and a set of cas genes. 
(Modified from 9). 
 
A CRISPR locus consists of short identical repeat sequences (R) that were first discovered 
in E. coli by Ishino et al. in 1987 10. Based on sequence similarity, repeat sequences were 
initially organized into 12 clusters 11. A recent bioinformatical classification identified 6 
superclasses with 40 conserved sequence families and 33 potential structure motifs based 
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on the repeat sequence and potential secondary structures within the repeats 12. In the 
CRISPR locus, the repeat elements are interspaced by unique spacer sequences that were 
found to be mostly derived from extrachromosomal DNA, e.g. from viruses or plasmids 13-
15. CRISPR loci are flanked by 300-500 bp leader sequences that display the same 
orientation as the repeats 8. CRISPR leaders are AT-rich sequences that contain promoter 
elements that direct CRISPR locus transcription 16, 17. The leader-end is also the integration 
site of new spacers 18, 19. CRISPR, together with the associated cas genes, provides 
resistance against mobile genetic elements based on sequence-complementarity between 
spacer sequences and invader DNA 6. The Cas proteins that are associated with the 
CRISPR loci are fundamental components of the prokaryotic defence system 8, 20, 21. 
CRISPR-Cas activity starts with the recognition of a short sequence of viral DNA termed 
protospacer by the adaptation complex which is integrated into the hosts CRISPR array, 
generating a new spacer 6, 22, 23. The CRISPR array is transcribed into long precursor 
crRNA (pre-crRNA) and further processed into mature CRISPR RNA (crRNAs) 24-26. The 
mature crRNAs are incorporation into CRISPR ribonucleoprotein complexes (crRNPs) and 
are then used as guide molecules to target and degrade the foreign DNA or RNA via base-
complementarity in case of a repeated infection 27-29. 
 
1.3 CRISPR-Cas diversification 
CRISPR-Cas systems are highly diverse as the selective pressure of invaders drives the 
evolution of the prokaryotic immune systems 30. Jansen et al. first discovered a link 
between CRISPR loci and four associated cas genes 8. Comparative analyses of CRISPR 
systems revealed major differences in Cas protein sequences, repeat sequences and cas 
operon architecture 20, 21. A Cas protein nomenclature has been developed by Makarova et 
al. based on these differences. CRISPR-Cas systems are classified into three distinct major 
types (I, II and III) and 11 subtypes (I A-F, II A-C, III A-B) 21, 31 (fig 1.2). Cas1 and Cas2 
form the adaptation complex, which is responsible for spacer acquisition and are conserved 
in all active CRISPR-Cas systems, constituting the core of the major types. Each type as 
well as each subtype is defined by conserved signature genes (fig 1.2). Type I systems 
contain the cas3 gene which encodes a DNase with helicase activity. The type I crRNPs 
are termed Cascade (CRISPR-associated-complex for antiviral defence) and target 
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dsDNA27. cas9 is the signature gene of type II CRISPR-Cas systems, a stand-alone 
nuclease that is sufficient for dsDNA target cleavage 32. Type III CRISPR systems contain 
the type- specific gene cas10. The type III crRNP complexes are known as Csm (type III-
A), targeting DNA and Cmr (type III-B), targeting RNA 33, 34.  
 
Figure 1.2: Classification of CRISPR-Cas systems by Makarova et al.: The typical architecture of cas 
operons is shown for each CRISPR-Cas subtype. The type-specific genes are boxed in green, the subtype-
specific genes are shown in red boxes. Major Cas protein categories are depicted in letters above the genes: 
L=large crRNP complex subunit, S=small crRNP complex subunit, R=RAMP (repeat-associated mysterious 
protein) crRNP complex subunit. RE=RNases of the RAMP family that are associated with crRNA 
processing, T=transcriptional regulators 21.  
 
In contrast to type I and type III CRISPR systems which are distributed among both, 
bacteria and archaea, type II CRISPR systems have been exclusively found in bacterial 
genomes 20, 35. Type I and type III systems encode Cas proteins of a superfamily classified 
as RAMP (repeat-associated mysterious proteins) (fig 1.2, genes marked with “R”), 
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including the proteins Cas5, Cas6 and Cas7. These proteins contain an RRM (RNA 
recognition motif) domain, a widespread RNA-binding domain, and interact with the 
crRNA. This suggests an evolutionary relationship between these Cas proteins and hints at 
a shared origin of type I and type III CRISPR systems 21, 31. Often, one genome encodes 
CRISPR systems of more than one type and phylogenetically distant organisms can contain 
CRISPR systems of the same subtype. This highlights the mobility of CRISPR systems 
that are frequently exchanged via horizontal gene transfer. Thus, it is proposed that 
different CRISPR subtypes evolved independently (RAMPs and subtype specific proteins) 
in selected lineages, probably resulting from the selective pressure caused by phage 
predation 36-38.  
1.4 Type I CRISPR-Cas action 
CRISPR-Cas adaptive immunity comprises three stages of activity: acquisition, processing 
and interference (fig 1.3). The acquisition stage starts with a viral infection. A short stretch 
of viral DNA, termed protospacer, is recognized and integrated into the host’s CRISPR 
array. Thus, a newly acquired spacer is formed and spacer sequences can maintain a 
chronological record of recent invaders (fig 1.3 (1), (2)) 6, 22, 23, 39. The new spacer is 
integrated directly downstream of the leader sequence by nicking the repeat element on 
opposite sites on both strands. The repeat sequence is subsequently duplicated 22, 23, 39-41.  
Protospacers are selected for integration into the CRISPR-array via the detection of PAM 
(protospacer adjacent motif) sequences. PAMs are 2-5 nt long sequences, located adjacent 
of the protospacer. They are found only in type I and type II systems and are located at the 
3'-end of the protospacer on target strand complementary to the crRNA. The PAM 
sequences are subtype-specific 19, 22, 23, 42. PAMs are crucial element for ‘self”- versus ‘non-
self’ DNA discrimination in the host, as it does not base-pair with the respective positions 
of the repeat sequences next to corresponding spacer elements 13, 19, 37. Hence, PAMs also 
play an important role in the Cascade interference reaction 43-45. Cas1 and Cas2 are 
conserved in all systems and have been shown to mediate the acquisition of new spacers, 
but their exact function in the mechanism is still unknown. It is possible that additional 
proteins are involved in the adaptation process, as the cas gene architecture of type-I 
systems reveal a conserved gene clustering of cas1 and cas2 e.g. with  
cas4 (fig 1.2) 21, 23, 39.  
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Figure 1.3: Schematic overview of CRISPR-Cas activity. A viral DNA sequence (protospacer, red) is 
inserted into the CRISPR locus (adaptation 1, 2). This is followed by the transcription of the array into pre-
crRNA and subsequent processing into mature crRNAs (3, 4). Then, the crRNA is taken up into the Cascade 
complex (5) and, in case of a repeated infection, interference can be triggered by sequence complementarity 
between crRNA and protospacer. (Modified from 9).  
 
The next stage, termed CRISPR expression, covers transcription of the CRISPR array 
followed by pre-crRNA processing (fig 1.3 (3), (4)). The entire CRISPR locus is 
transcribed into a long pre-crRNA starting from the CRISPR leader 16, 18. The pre-crRNA 
transcript is then processed at a single phosphodiester bond within the repeat sequences 
that is hydrolyzed by metal-independent Cas6 endonucleases. As a result, mature crRNAs 
are obtained that contain spacer sequences flanked by a repeat-derived 5'-terminal tag of 8 
nucleotides and a longer repeat-derived 3'-tag 26, 27, 46-48. Cas6 cleavage generates crRNAs 
that encompass a 5'-terminal hydroxyl and a 3'-terminal 2'-3' cyclic phosphate end 26, 49. 
Type-I Cas6 enzymes usually comprise a catalytic triad with one invariant histidine 
residue, even though the relative positions of the catalytic amino acids are poorly 
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conserved 26, 46, 47, 50-52. The Cas6 homologues belong to the RAMP superfamily and share 
a common RRM motif, but their amino acid sequence was found to be very diverse and 
their protein structures vary. These divergences are thought to be responsible for the 
variability in recognition mechanisms of RNA substrates with different structures by 
different Cas6 homologues 26, 48, 51-53. As an example, in type I-E and I-F systems, the 
respective Cas6 enzymes (Cas6f and Cas6e) bind repeat sequences that potentially form a 
hairpin structure. After Cas6 processing, the mature crRNAs are loaded into Cascade 45, 49 
(fig 1.3 (5)). Cas6f and Cas6e are single-turnover enzymes that stay firmly associated with 
the repeat hairpin and form a stable Cascade subunit after crRNA delivery 11, 26, 51-56. In 
contrast, other type-I variants are associated with repeat elements that are predicted to be 
unstructured and display mature crRNAs that harbor trimmed 3'-terminal ends. This 
suggests that the respective Cas6 variants are not a permanent subunit of Cascade, but 
function as stand-alone nucleases that only deliver the crRNAs to Cascade, which are then 
accessible for further enzymatic and/or chemical  trimming 12, 43, 50. The evolutionary basis 
for these mechanistic differences are not fully understood 57. After associating with 
Cascade, mature crRNAs are used as guide molecules to target foreign DNA in case of a 
repeated infection via base complementaryty, which then results in the degradation of the 
viral DNA by a helicase/endonuclease called Cas3 (fig 1.3 (5), (6)). Experimental insights 
into type I-A, I-C, I-F and I-E Cascades have been published. These Cascades display 
similarities in the protein composition as they all share the three RAMP-containing Cas5, 
Cas6 and Cas7 variants, even though they differ in the subtype specific proteins that 
represent the large (and small) subunit of the complex (Cas8a and Csa5 for type I-A, Cas8c 
for type I-C, Cse1 and Cse2 for type I-E and Csy1 for type I-F, see fig 1.2). A major 
difference that can be observed between the Cascades is the composition of subunits that 
are permanently or temporarily associated components of the complexes (Cas6 and Cas3 
variants) 21, 27, 43, 46, 48, 49, 55, 58, 59. The type I-E Cascade was first described for E. coli and is 
the best studied Cascade in terms of structure and function 45, 54, 59, 60. Its structure 
highlighted an uneven stoichiometry of: (Cse1)1-(Cse2)2-(Cas5)1-(Cas7)6-(Cas6)1 49, 61. 
Cryo-electron microscopy (cryo-EM) revealed an overall seahorse-shaped architecture 62. 
Recently, the crystal structure of Cascade containing crRNA (and ssDNA) was solved by 
Jackson et al., Mulepati et al. and Zhao et al. 54, 60, 63 (fig 1.4). Cas6e and Cas5e anchor the 
crRNA repeat termini forming the head and tail of the complex. Cas6e is bound to the stem 
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loop structure at the 3'-end of the crRNA and Cas5e reveals base-specific interactions at 
the 8 nt 5'-tag of the crRNA, kinking the nucleotide at position -1 with its thumb domain. 
Six subunits of Cas7 form the backbone along the spacer element. Each thumb domain of 
the Cas7 subunits kinks at every sixth position of the spacer sequence. Cas5e and Cas7, as 
well as the Cas7 subunits interact via palm and thumb domains. The thumb domain of 
Cas7.1 finally folds into a protein cleft of Cas6. The large subunit (Cse1) interacts with the 
Cas5 tail, Cas7 and Cse1. The small subunits (Cse2) display protein contact with the Cas7 
backbone 54, 57, 60, 63.  
 
 
Figure 1.4: Type I-E Cascade structures in 2D and 3D. A) and B) Cas6e binds the hairpin structure at the 
3'-terminal end of the crRNA (black) forming the head of the complex. The backbone consists of six Cas7 
subunits that oligomerize along the spacer sequence (red). Cas5e caps the 5'-terminal repeat tag of the crRNA 
(black) as the tail. The large subunit Cse1 is associated with the tail and interacts with Cas5e, Cas7 and Cse2. 
The two Cse2 small subunits interact with Cas7 and form the belly of the complex (modified from 54). 
 
The fully assembled Cascade scans dsDNA for a potential PAM sequence. Cse1 is 
responsible for PAM identification 59, 64. The PAMs that are crucial for target interference 
can differ from the PAMs that are required for spacer acquisition. Few motif variants of 2-
3 bp are tolerated for interference 44, 65, 66. Cse1 interacts with the PAM, which might 
destabilize the invader DNA and enable base-pairing between crRNA and target DNA 67, 
68. Base-pair complementarity between protospacer and the seed region of the crRNA 
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(nucleotides 1-5 and 7-8 at the 5'-end of the spacer sequence) is required, whereas a limited 
number of mismatches in the remaining spacer sequence is tolerated 55, 69-71. The non-target 
strand of the invader DNA is displaced, generating an R-loop 62. The R-loop formation 
triggers a major conformational change of Cascade, which mediates the recruitment of the 
metal-dependent nuclease and ATP-dependent helicase Cas3 that interacts with the base of 
Cse1 49, 59. Cas3 nicks the displaced strand which induces a conformational change of the 
protein and activates the helicase domain 45, 72. The target DNA is unwound and 
exonucleolytically degraded in 3' to 5' direction 45, 57, 59, 72, 73.  
 
1.5 CRISPR-Cas subtype I-B 
CRISPR-Cas systems of subtype I-B are distributed among archaea and bacteria. 
According to an older nomenclature by Haft et al., two I-B subtypes exist: I-B Tneap and 
I-B Hmari. These subtypes are named after a species that contains such a system 
(Thermotoga neapolitana and Haloarcula marismortui) 20.  
Type I-B systems consist of Cas1, Cas2 and Cas4 that are proposed to be involved in the 
acquisition process, and the putative Cascade forming proteins Cas3, Cas5, Cas6, Cas7 and 
Cas8b. Cas3 represents the type I specific helicase, containing an N-terminal HD nuclease 
domain. The protein can also be found to be split into separated HD and helicase domains 
21. In Methanococcus maripaludis, Thermococcus kodakarensis, Haloferax volcanii and 
Haloferax mediterranii type I-B systems, the Cas6b endonuclease was shown to processes 
pre-crRNA transcripts into mature crRNAs that comprise an 8 nt 5'-terminal repeat tag and 
a spacer sequence followed by a 3'-terminal repeat handle 50, 74, 75. In Haloferax volcanii, 
Cas7 and Cas5 were identified as type I-B Cascade subunits that interact with Cas6 and 
stabilize the mature crRNAs 75, 76.  A recent study identified a type I-B complex formed by 
Cas5 and Cas7 from Pyrococcus furiosus via immunopurification 77. Cas8b is the subtype-
specific protein and predicted to form the large Cascade subunit. A multiple alignment of 
representative sequences and predicted secondary structures of proposed type I large 
subunits by Makarova et al. is shown in figure 1.5. All large subunits are predicted to 
contain a finger, palm and thumb domain, and a zinc-finger domain is present in most 
proteins. These domains are shared by DNA polymerases and their shape resembles a right 
hand 78. The large subunits of type I-B (Cas8b) and I-C (Cas8c) display a thumb domain 
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with an extra alpha-helical region. In these subtypes, the small subunit, typically an alpha-
helical protein (Cse2 in type I-E and Csa5 in type I-A), is not encoded in the Cas operons. 
It is possible that this C-terminal region is compatible with a small Cascade subunit 
according to size and structure 79. However, structural and functional data on Cas8b 
proteins are not yet available. 
 
 
Figure 1.5: Alignment of large type-I Cascade subunits. Domain organization of different large type-I 
subunits is color-coded. S = regions that could be homologous to the small subunits encoded as separate 
genes in type I-A and I-E. Additional protein designation originates from an older nomenclature by Haft et 
al. 2004. (Modified from 79). 
 
1.6 Endoribonuclease III and its role in CRISPR-Cas 
The bacterial endoribonuclease III (RNase III) is a double-stranded (ds) RNA-specific 
endonuclease that is characterized by a specialized endonuclease domain known as the 
RNase III domain. Many bacterial RNase III enzymes also display a dsRNA-binding 
domain (dsRBD) 80. RNase III cleavage is metal-dependent (Mg2+) and generates dsRNA 
products comprising 5'-phosphoryl and 3'-hydroxyl termini and a 2 nt 3'-overhang 81, 82. 
The RNase III protein family includes bacterial RNase III enzymes as well as the 
eukaryotic proteins Dicer and Drosha that contain a more complex RNase III domain and 
are involved in the RNA interference mechanism (RNAi), mediating the production of 
small interfering RNAs (siRNAs) and the maturation of micro RNAs (miRNAs). Among 
the members of the endoribonuclease III family, the respective enzyme from E. coli is the 
most comprehensively studied protein 83-86. Bacterial RNase III is involved in 
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posttranscriptional gene expression, ribosomal RNA (rRNA) processing and the defence 
against viral infection 32 87, 88. It is a global regulator and controls gene expression by 
processing mRNAs 89. This includes dsRNA cleavage of RNA hybrids formed by mRNA 
and small regulatory RNAs, such as anti-sense RNAs or stem-loops within the mRNA 90, 
91. This cleavage can occur within the coding region, the 5' or 3' untranslated region (UTR) 
and can cause structural changes of an mRNA, resulting in promoted degradation or a 
more efficient translation. Gene expression might also be regulated by protein binding in 
the 3' and 5' UTRs 92. RNase III forms a homo-dimer that comprises a catalytic valley 
which is formed by two RNase III domains and comprises two symmetric cleavage sites 93. 
Nucleotides have been identified at specific positions in a dsRNA substrate that inhibit 
protein binding or allow binding, but prevent cleavage 94. 
In type II CRISPR-Cas systems, RNase III is involved in crRNA maturation. Type II 
systems encode a trans-activating crRNA termed tracrRNA, in the vicinity of the CRISPR 
loci. The tracrRNA contains an anti-CRISPR repeat that pairs with the repeat sequences of 
the pre-crRNA transcripts 32. The resulting RNA heteroduplexes are stabilized by Cas9 and 
subsequently cleaved by RNase III 95. After additional processing of the crRNA, the 
mature crRNA-tracrRNA hybrid is used to direct the interference reaction, mediated by the 
Cas9 RNP complex 32, 95.  
The RNase III domain, as well as the dsRBD are conserved and present in RNase III 
family proteins (RNase III, Dicer, Drosha). These endoribonuclease homologues are used 
in both, type II CRISPR-Cas systems as well as in the RNAi mechanism, to generate anti-
invader guide RNAs 92.  
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1.7 Clostridium thermocellum 
Clostridium thermocellum is a gram-positive bacterium with a rod-shaped cell body (fig 
1.6). It is a strictly anaerobic and thermophilic (60°C) bacterium that is found in places 
with rotting biomass 96, 97. C. thermocellum has gained biotechnological interest as it 
produces an active cellulase enzyme complex known as the “cellulosome” which is 
organized on the outer surface of the bacterium 98. It enables the fermentation of cellulosic 
biomass to ethanol, acetic acid, lactic acid, CO2 and H2, suggesting future applications of 
this organism for biomass conversion 98, 99.  
 
 
Figure 1.6: DIC picture of Clostridium thermocellum. Differential interference contrast microscopy of 
C. thermocellum reveals a rod-shaped cell body. Scale bar = 10µm. (Janine Haueisen, MPI Marburg). 
 
The whole genome sequence of Clostridium thermocellum ATCC 27405 is available 
(GenBank no. CP000568; DOE Joint Genome Institute) and enabled the identification of 
two type I-B CRISPR-Cas systems. Computational analyses revealed that one of the 
CRISPR systems shares similarities with the archaeal type I-B CRISPR system of 
Methanococcus maripaludis which was previously analyzed in our laboratory, indicating a 
potential horizontal gene transfer event between Clostridia and methanogens. 
C. thermocellum can be used to study a bacterial type I-B CRISPR-Cas system and allows 
a comparison with the archaeal I-B system of M. maripaludis.  
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1.8 Aim of the study 
The main focus of this study is placed on the in vitro characterization of a recombinant 
type I-B Cascade from Clostridium thermocellum. This necessitates the production of the 
Cascade forming proteins Cas3, Cas5, Cas6, Cas7 and Cas8b. Additionally, mature 
crRNAs are generated from pre-crRNA by the endonuclease Cas6. The assembly of the 
Cas proteins into Cascade is used to determine permanent or temporarily associated 
complex subunits. Furthermore, Cascade assemblies with modified crRNAs provide 
information about the Cascade loading mechanism. The protein stoichiometry of the 
complex, as well as the protein interaction sites are investigated via mass-spectrometric 
techniques in collaboration with Kundan Sharma (MPI Göttingen). RNA-Seq methodology 
is utilized to analyze small RNAs isolated from C. thermocellum. These data allow the 
characterization of the cellular crRNA pool. Together, these studies aim to provide 
information about crRNA processing and subsequent crRNP complex formation of a 
bacterial type I-B CRISPR system. The comparison of the respective mechanisms with 
other CRISPR-Cas subtypes will contribute to our understanding of CRISPR functionality 
and diversification. 
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2. Results 
 
2.1 Genomic context of CRISPR-Cas subtype I-B in Clostridium 
thermocellum 
In Clostridium thermocellum ATCC 27405, five CRISPR loci are annotated in the 
CRISPRdb database (fig 2.1) 7. The loci 1-3 contain repeat sequences of 30 bp, whereas 
the repeat elements of locus 4 and 5 are 37 bp long. All five CRISPR arrays are flanked by 
transposase and integrase genes, which highlights the mobility of these systems. Two sets 
of cas genes were identified using the CRISPR interactive database “CRISPI” 100. Each set 
is associated with CRISPR loci that comprise repeat elements of identical length. Several 
classification systems have been introduced based on the Cas protein composition 
independent from the repeats. According to the nomenclature by Makarova et al., both sets 
of cas genes were classified as type I-B CRISPR systems that are defined by the subtype 
specific protein Cas8b and the presence of the type-specific cas3 gene that is fused to a 
sequence encoding an additional HD nuclease domain. The subtype I-B Cas protein 
organization in C. thermocellum includes the adaptation proteins Cas1, Cas2 and Cas4, the 
crRNA processing endonuclease Cas6 and the proposed Cascade forming proteins Cas3, 
Cas5, Cas7 and Cas8b (Cthe_2296-2303 associated with loci 1-3, and Cthe_3201-3205 
together with Cthe_3218-3220 associated with loci 4-5). However, according to an older 
nomenclature by Haft et al. of 2004, the two CRISPR systems would have been classified 
as type “I-B Tneap” (Cthe_2296-2303) and type “I-B Hmari” (Cthe_3201-3205, 3218-
3220), which have been later summarized into subtype I-B. In this older nomenclature, 
each subtype is named after a species containing a genome with the single subtype. In 
general, the subtype Tneap (Thermotoga neapolitana) seems to be more distributed among 
bacteria, whereas subtype Hmari (Haloarcula marismortui) can rather be found in archaeal 
organisms. The distinction between these subtype I-B systems in C. thermocellum was 
based on a BLAST analysis of Cas8b, Cas7 and Cas5, known as either Csh1, Csh2 and 
Cas5/Hmari of subtype Hmari, or Cst1, Cst2 and Cas5/Tneap of subtype Tneap, as well as 
the analysis of organisms that contain homologous proteins.  
Computational analyses also revealed that some of the closest relatives of the type I-B 
Hmari Cas proteins are also found in the archaeal model system Methanococcus 
maripaludis that is also analyzed in our laboratory. The high similarity between the cas 
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genes of both organisms indicates a potential horizontal gene transfer event. The type I-B 
Hmari Cascade proteins (fig 2.1, black box) were chosen to be investigated in this study to 
allow the comparison of highly related CRISPR systems in the two prokaryotic domains of 
life.
 
Figure2.1: Genomic context and type I-B cas gene organization. Two sets of cas genes are organized in 
operons, encoding the Cas proteins that are involved in CRISPR interference (Cas3, 5, 6, 7, 8b) and proteins 
that mediate CRISPR adaptation (Cas1, 2, 4). One set of cas genes is located adjacent to CRISPR locus 3 
(30 bp repeats), whereas the other set is associated with the CRISPR loci 4 and 5 (37 bp repeats). (Modified 
from 50). 
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2.2 CRISPR RNA processing 
CRISPR RNA processing was analyzed both in vitro and in vivo for the two CRISPR-Cas 
subtype I-B systems of Clostridium thermocellum. 
2.2.1 CRISPR RNA processing in vitro 
Clostridium thermocellum contains two cas genes that encode putative Cas6 proteins (fig 
2.1). Cas6 Cthe_2303 is associated with the 30 nt repeat sequences and Cas6 Cthe_3205 
with the 37 nt repeat sequences. Both genes were cloned into a pET20b vector and 
recombinant protein with a C-terminal 6-fold His tag was produced in E. coli. Both 
proteins were purified using a nickel-NTA column.  
First, purified Cas6 Cthe_2303 (fig 2.2 A) was used for nuclease assays with 5'-terminal 
radiolabeled pre-crRNA and repeat RNA substrates and in vitro endonuclease activity 
could be shown (fig 2.2. B). Different RNA transcripts were analyzed (fig 2.2. C), 
consisting of a single 30 nt repeat element, a repeat sequence with a deoxyribonucleotide 
substitution at position -9 and a spacer145-repeat146-spacer146 sequence of CRISPR 
locus 3. The repeat, as well as the pre-crRNA substrates, were cleaved within the repeat 
sequence, whereas Cas6 endonuclease activity could not be detected for the modified RNA 
substrate. It has been shown that Cas6 creates mature crRNAs that contain a spacer unit 
and 8 nucleotides of the 5' repeat element as a 5' terminal tag 26, 27, 48. This could be 
validated for Cas6 Cthe_2303 cleavage using the modified repeat RNA with a 
deoxyribonucleotide introduced at the proposed cleavage site (-9) which abolished Cas6 
cleavage. Subsequently, the chimeric oligonucleotide could not only be used as a negative 
control, but also pinpointed and confirmed the Cas6 Cthe_2303 cleavage site within the 
repeat sequence in C. thermocellum 9. In agreement with this, Cas6 Cthe_3205 nuclease 
assays with modified and unmodified 37 nt long repeat RNA substrates also revealed a 
cleavage site at position -9, generating crRNAs with an 8 nt 5'-terminal tag as well (data 
not shown).  
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Figure 2.2: Cas6 Cthe_2303 purification and endonuclease assay. A) SDS-PAGE of a Cas6 Cthe_2303 
(28 kDa) after nickel-NTA chromatography (Ni-NTA). B) Detection of endonucleolytic Cas6 activity for the 
5'-terminal labeled repeat (R) and pre-crRNA (S-R-S) in vitro transcripts. The introduction of a dNTP at 
position -9 in the repeat sequence (Rd9) abolished Cas6 cleavage. The bands were separated on a denaturing 
8 M urea 12 % polyacrylamide gel and visualized by autoradiography. C) The following RNA substrates 
were used: R = 30 nt repeat sequence, Rd9 = 30 nt repeat sequence including a dNTP at position -9 (red), S-
R-S = spacer145 (blue) - repeat146 - spacer146 (blue) sequence. (Modified from 9). 
 
To obtain further information about the presence of two different types of repeat elements 
(30 nt and 37 nt) that are associated with different Cas6 homologous (Cthe_2303 and 
Cthe_3205) in C. thermocellum (fig 2.1), both purified Cas6 proteins (fig 2.2 A, 2.3 A) 
were used for nuclease assays with single 30 nt and 37 nt repeat elements (fig. 2.3 B). Both 
substrates were exclusively cleaved only by their corresponding Cas6 enzyme. The fact 
that both enzymes cleave two different repeat substrates at the same position (-9) and 
generate a 5'-terminal crRNA tag that is identical in sequence and length (fig B, red 
arrows) indicates a substrate recognition mechanism based on structure, repeat-length or 
the sequence upstream of the cleavage site. Computational analysis of both Cas6 enzymes 
revealed their very limited sequence homology. Cas6 Cthe_3205 showed high homology to 
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the Cas6 protein found in the archaeon M. maripaludis (40 % AA identity and 62 % AA 
similarity). In contrast, BLAST search results of Cas6 Cthe_2303 identified it to be rather 
similar to Cas6 proteins found in bacteria (e.g. Thermodesulfobacterium hveragerdense, 
Bacillus coagulans, Thermoanaerobacterium thermosaccharolyticum). This might indicate 
that C. thermocellum contains two CRISPR-Cas systems that originate from the two 
prokaryotic domains of life (archaea and bacteria). 
 
Figure 2.3: Cas6 Cthe_3205 purification and endonuclease assay with repeat RNA. A) SDS-PAGE of a 
Cas6 Cthe_3205 (27 kDa) after nickel-NTA chromatography (Ni-NTA). B) Detection of endonucleolytic 
Cas6 (Cthe_2303 and Cthe_3205) activity for the 5'-terminal labeled 30 nt and 37 nt repeat RNA substrates. 
Both enzymes preferably cleave their respective substrate. The cleavage sites are marked within the sequence 
(red arrows). The bands were separated on a denaturing 8 M urea 12 % polyacrylamide gel and visualized by 
autoradiography. 
 
2.2.2 CRISPR RNA processing in vivo 
RNA-Seq methodology was used to analyze the cellular crRNA pool of Clostridium 
thermocellum to gain a more detailed insight into the transcription and the processing of 
crRNAs in vivo. Therefore, total small RNA (up to 200 nt) of C. thermocellum was 
isolated. Since mature crRNAs comprise 5'-hydroxy and 2'-3'-cyclic phosphate termini 
created by Cas6 cleavage, 5' phosphorylation and 3' dephosphorylation of the isolated 
RNA via T4 polynucleotid kinase (PNK) was performed to ensure proper adapter ligation.  
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Figure 2.4: RNA-Seq data for C. thermocellum CRISPR loci. Illumina HiSeq2000 sequencing reads were 
mapped to the C. thermocellum ATCC 27405 reference genome to illustrate crRNA abundance and 
processing. A) CRISPR locus 3 reveals a proposed internal promoter located in spacer 103 (adjacent repeat 
sequences are underlined). B) Bidirectional transcription was exemplified for Loci 1, 2 and 4. Forward and 
reverse coverage was separated to highlight anti-crRNA promotion that can start within and at the leader-
distal end of the locus (black arrows). The occurrence of anti-crRNAs is proposed to correlate with the 
abundance of crRNAs. C) The indicated crRNA of locus 2 is highly transcribed in reverse direction and 
complementary to a crRNA of locus 5 (black arrows). (Modified from 101). 
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The small RNA libraries were sequenced via Illumina HiSeq2000 102. All sequence reads 
were trimmed to remove adapter sequences and individual sequence reads were mapped to 
the reference genome. The small RNA analysis revealed that all five CRISPR loci are 
constitutively transcribed and processed (fig 2.4). Nearly all crRNAs display the same 5'-
terminal 8 nt tag (5'-AUUGAAAC-3') which shows that processing of both repeat elements 
(30 nt and 37 nt) yields the same crRNA 5'-tag in vivo. The 3'-termini are trimmed leaving 
tags of various length. The overall crRNA abundance follows the commonly observed 
trend which is a gradual decline in the abundance from the leader-proximal to the leader-
distal region of the CRISPR loci. There are two plausible explanations for the variability in 
abundance i) the increase of the pre-crRNA transcript length provokes RNA polymerase 
stalling as well as premature termination of transcription or ii) the crRNAs that contain 
spacers from the leader-proximal region of the locus are needed in greater amounts to 
target the most recent invaders. An exception to commonly observed abundance pattern 
apparent in locus 3 (fig 2.4 A) where an internal promotion of transcription within the 
CRISPR array can be observed that is mediated by a spacer element. The overall crRNA 
abundance declines from crRNA 1 to crRNA 103 and then peaks again for crRNA 104 (fig 
2.4 A). A closer analysis of this region revealed a potential -35 element (TTGAAA) 
encoded by the repeat elements and a putative pribnow box (-10), provided by spacer 103. 
Together, these two elements form a promoter that seems to be stronger than the promoter 
encoded in the leader region of CRISPR locus 3. One thing that should be noted is that the 
8 nt 5'-terminal tags are not identical for all crRNAs of locus 3. Starting from repeat 115, 
the final U base changes to C which indicates that CRISPR loci might have recombined. 
By sequencing this particular genome region upstream of spacer 104, errors in the initial 
genome assembly during whole genome sequencing could be excluded.  
The RNA-Seq data also provide evidence for bidirectional transcription of the CRISPR 
arrays (fig. 2.4 B), starting from regions within the clusters (CRISPR locus 4) or from the 
leader-distal ends (CRISPR loci 1, 2 and 5). Even though the number of anti-crRNAs is 
very small in comparison to the amount of crRNAs, in some cases the high abundance of 
anti-crRNAs correlates with the reduced amount of their crRNA counterparts, e.g. spacer 2 
from locus 2 or spacer 6 from locus 4 (fig 2.4 B&C). 
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Another interesting aspect was found by analyzing the origin of these spacers from the 
CRISPR loci. CRISPR loci 2 and 5 harbor spacer sequences that are identical (locus 5, 
spacer 3 “crRNA 3”) and complementary (locus 2, spacer 19 “crRNA 19”) to parts of the 
anticodon arm, T arm and the acceptor stem of the single-host tRNAPro (GGG) isoacceptor 
RNA (fig 2.5).  
 
Figure 2.5: Host tRNAPro with matching crRNA spacers. CRISPR loci 2 and 5 comprise spacer sequences 
that are identical and complementary to the C. thermocellum ATCC 27405 tRNAPro (GGG) isoacceptor 
(outlined regions) 101. 
 
These spacer sequences might either originate from the host tRNAPro gene or from viral 
attachment sites that target tRNA genes. The abundance of the complementary crRNA 19 
might be problematic for the cell, as it potentially targets the essential host tRNA. This 
could inhibit precursor-tRNA folding and/or induce dsRNA cleavage. The RNA-Seq data 
(fig 2.4 C) show that crRNA 19 is nearly eliminated from the RNA pool, whereas crRNA 3 
is highly abundant. This could indicate that crRNA 3 binds crRNA 19 and acts as an “RNA 
sponge” to prevent this tRNAPro targeting. In addition to this, antisense transcripts of 
spacer 19 could form hybrids with this problematic crRNA and induce dsRNA cleavage. In 
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agreement with this, the RNA-Seq data reveal a great amount of anti-crRNA transcript for 
spacer 19 of locus 2 (fig 2.4 C). 
 
2.2.3 Anti-crRNA processing in vivo 
RNA-Seq data were used to analyze the reverse CRISPR transcripts in vivo. Individual 
anti-crRNAs show a conserved processing pattern within the repeat sequences that differs 
from the pattern of mature crRNAs (fig 2.6). The pattern of the anti-crRNAs from loci 1 
and 2 (30 bp repeats) comprise an 18 nt 5ʹ -terminal repeat fragment and a randomly 
processed 3ʹ -end (fig 2.6 A), whereas the anti-crRNA processing within the 37 nt repeat 
elements yields a 22 nt 5ʹ -tag and a randomly processed 3ʹ -end (fig 2.6 B). It is plausible 
that CRISPR precursor RNAs in forward and reverse direction form double-stranded RNA 
(dsRNA) in the cell. These RNA duplexes could serve as substrates for dsRNA cleaving 
enzymes. The presence of distinct processed anti-crRNAs, together with the observation 
that complementary crRNAs are highly reduced in abundance (fig. 2.4 B, C), could 
indicate that anti-crRNAs neutralize crRNAs via base-pairing.  
 
Figure 2.6: Processing pattern of anti-crRNAs in vivo. A) anti-crRNA 33 exemplifies processing within 
the 30 bp repeat elements leaving an 18 nt 5ʹ -and a randomly processed 3ʹ -end B) anti-crRNAs from loci 4 
and 5 (37 bp repeats) display a 22 nt 5ʹ-tag and a randomly processed 3ʹ-end. (Modified from 50). 
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2.2.4 RNase III cleaves anti/crRNA duplexes 
To gain further insights into the processing of anti-crRNAs, double-stranded anti-/crRNA 
hybrids were produced and used for cleavage assays with recombinant RNase III from 
C. thermocellum.  
RNase III was chosen as the candidate endonuclease, as it is a dsRNA specific nuclease 
and plays a major role in crRNA maturation in bacterial CRISPR-Cas type II systems. 
Type II crRNA maturation involves a trans-encoded small RNA (tracrRNA) that is partly 
base-complementary to the repeat regions of crRNA precursor transcripts 32. The tracrRNA 
forms dsRNA with the precrRNA and is processed by RNase III, which serves as a host 
factor in type II crRNA maturation. Additionally, bacterial RNase III belongs to the same 
protein family as Dicer and Drosha, two well-studied type III nucleases that process short 
interfering (si) RNAs and micro (mi) RNAs which are involved in eukaryotic gene 
silencing103-105. Hence, the requirement of RNase III in a potential crRNA regulatory 
mechanism seemed reminiscent of the key roles of these related nucleases.  
The RNase III gene from C. thermocellum was cloned into a pET20b vector with a C-
terminal 6-fold His-tag. Recombinant RNase III was produced in E. coli and purified using 
nickel-NTA affinity chromatography (fig 2.7 A). An endonuclease assay using Cas6 
Cthe_2303 and RNase III was performed on 5'-terminal labeled single-stranded (ss) and 
double-stranded (ds) RNA substrates in forward and reverse direction (fig 2.7 B, C). The 
RNA substrates consisted of a slightly truncated (25 nt instead of 30 nt) repeat 32 followed 
by spacer 33 and repeat 33 of CRISPR locus 1. RNase III endonuclease activity was 
observed on both sense- and antisense strands in a double-strand dependent manner. In 
contrast, Cas6 cleaves single-stranded repeat RNA as expected. An RNase T1 digest 
(RNase T1 cleaves upstream of every G residue) of the single-stranded sense-substrate as 
well as an alkaline ladder were used as size markers to pinpoint the cleavage sites. These 
sites were identified within the repeat sequences of the RNA substrates, showing the 
RNase III characteristic 2 nt 3'-overhang (fig 2.7 C). This cleavage pattern observed in 
vitro, confirms the 5'-terminal processing site of anti-crRNAs in vivo (fig 2.6). The 
cleavage products were sized in dependence on the Cas6 cleavage product and differed by 
1 nt from the RNase T1 digest marker.  
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Figure 2.7: RNase III purification and endonuclease assay with anti-/crRNA hybrids. A) SDS-PAGE of 
RNase III after nickel-NTA purification. B) 5'-terminal labeled repeat-spacer-repeat substrates, both single-
stranded (ss) and double-stranded (ds) in sense and reverse direction were used for an endonuclease assay 
with Cas6 (Cthe_2303) and RNase III. Endonucleolytic activity of Cas6 could be detected for the ss sense 
RNA substrate. RNase III cleavage was observed on both strands of the RNA hybrid. Bands were separated 
on a denaturing 8 M urea 12% PAA gel and visualized by autoradiography. C) RNA substrates in sense and 
antisense direction. Arrows denote specific enzymatic cleavage (red arrows = RNase III cleavage, black 
arrow = Cas6 cleavage). 
As described in section 2.2.2, the CRISPR loci of C. thermocellum contain two spacer 
sequences that are complementary and identical with parts of the host tRNAPro (fig 2.5). 
The two crRNAs containing these spacers could form double-stranded RNA in the cell to 
prevent hybridization between the tRNA and the complementary crRNA, which would 
disturb translation in the cell. Either way, double-stranded RNA would be formed that 
could be a target for ds-RNA specific cleaving enzymes. To test whether RNase III could 
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play a role in this scenario, an endonuclease assay was performed using RNA-hybrids that 
comprise the spacer sequence that is complementary to the tRNA (fig 2.5, spacer 19) in 
forward and reverse direction, resembling the tRNA-identical and tRNA-complementary 
parts (fig 2.8 A).  
 
Figure 2.8: RNase III endonuclease assay with an RNA hybrid that resembles parts of the tRNAPro. A) 
A double-stranded RNA that comprises spacer 19 of CRISPR locus 2 in forward and reverse direction was 
used as a substrate. The RNA hybrid resembles a region that is identical to the tRNAPro isoacceptor in C. 
thermocellum and its complementary counterpart. B) Endonuclease assay with 5'-terminal labeled dsRNA 
using RNase III (III) and a cleavage-deficient RNase III mutant (E129A). Endonucleolytic cleavage by 
RNase III can be observed on both strands (identical and complementary, III), whereas cleavage is abolished 
by the site directed-mutagenesis E129 to A. Bands were separated on a denaturing 8 M urea 12% PAA gel 
and visualized by autoradiography. 
 
It has been shown for the E. coli RNase III that the glutamic acid E117 is a highly 
conserved and a functionally essential residue of the active site. It is coordinated with 
divalent metal ions (Mg2+) that participate in the hydrolysis of the RNA phosphodiester 106, 
107. Site-directed mutagenesis of this residue abolishes cleavage activity, probably due to 
the disruption of metal binding in the active site 108. An alignment of the RNase III amino 
acid sequences from E. coli and C. thermocellum identified the glutamic acid E129 from C. 
thermocellum as the essential active-site residue. A mutation of E129 to alanine was 
introduced into RNase III to generate a catalytically inactive mutant (E129A). This mutant 
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was also used in the cleavage assay and shown to be deficient of cleavage activity. RNase 
III cleavage activity could be observed on both strands, the tRNA-identical and 
complementary one (fig 2.8 B). This indicates that both i) the tRNA-crRNA hybrid as well 
as ii) the crRNA-crRNA hybrid could be targeted by RNase III. 
2.3 RNase III substrate recognition of CRISPR repeat elements 
Structure and sequence elements, so-called reactivity epitopes, determine the cleavage sites 
of bacterial RNase III 80, 109. Two double-helical segments termed proximal-box (pb) and 
distal-box (db) that represent sites of enzyme-substrate contact participate in controlling 
substrate reactivity. It was proposed that in E.coli, RNase III substrate recognition is based 
on the absence of specific base pair elements (antideterminants) that inhibit substrate 
cleavage reactivity, limiting RNase III processing to a single target site 110. In addition, 
specific base pair sequences have been identified that act as positive recognition 
determinants and cooperate with the antideterminants to control enzyme reactivity. The db 
is a 2 bp element positioned 11 bp away from the RNase III cleavage site. The db functions 
as a positive recognition determinant and base pair substitutions weakens the RNase III 
binding. Its sequence is not conserved. The pb is a 4 bp segment. Base pair substitutions at 
positions 1 and 3 reduce RNase III binding affinity. A strong inhibitory effect on binding 
can be observed for position 2 by a base pair substitution of AU, UA against GC or CG. 
Base pair substitution at position 4 causes a qualitatively different inhibition of RNase III 
reactivity. Here, the substitution of a GC or CG base pair suppresses cleavage without 
affecting substrate binding of the E. coli RNaseIII and therefore function as catalytic 
antideterminants 94.  
As described in 2.2.4 C. thermocellum contains two types of repeat elements (30 bp and 
37 bp) that can be processed by RNase III, once they form anti-/crRNA hybrids (in vivo fig 
2.6. and in vitro fig 2.7). It was possible to identify two potential db/pb sets within each 
double-stranded repeat sequences as they can be positioned relative to the RNase III 
cleavage site on both strands (fig. 2.9). Both potential pb of the 37 bp repeat duplex are 
very similar to an optimal E. coli pb with AU/UA base pairs at position 2 and 4. In 
contrast, both potential pb in the 30 bp hybrid comprise AU/UA base pairs at position 2 but 
display GC/CG at position 4 which strongly inhibits E. coli RNase III cleavage reactivity. 
This indicates sequence variations across species. 
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Figure 2.9: Potential RNase III substrate recognition motifs in double-stranded 30 bp and 37 bp repeat 
elements of C. thermocellum. Both ds-repeat sequences contain two potential proximal (pb) and distal (db) 
boxes that are depicted in grey, adjacent to the RNase III cleavage site indicated with black arrows. Within 
the proximal boxes, essential base pairs at position 2 and 4 that influence E. coli RNase III reactivity are 
marked in red.  
In order to identify the essential set of distal and proximal boxes and investigate the 
sequence requirements for RNase III processing reactivity in C. thermocellum, RNA 
substrates were designed comprising the 30 nt repeat element in forward and reverse 
direction that differ in the nucleotide composition of the respective regions (fig 2.10 A). 
These included a wild-type substrate, a dsRNA substrate displaying a base pair substitution 
at positions 2 and 4 within the left pb and a repeat RNA duplex with substituted base pairs 
at position 2 and 4 of the right pb. An endonuclease assay was performed with 5ʹ -terminal 
labeled RNA hybrids and RNase III (fig 2.10 B). With the use of an RNase T1 digest and 
an alkaline hydrolysis marker, the prominent cleavage products were sized and marked in 
the respective substrate sequences (fig 2.10 A). Cleavage products were sized according to 
figure 2.7. The RNase III processing pattern of the wild type substrate is consistent with 
the cleavage sites observed in vivo (fig 2.6). Additional cleavage products (fig 2.10 A) 
were also observed in vitro (fig 2.7 B), indicating variability of the RNase III cleavage site 
in the 30 bp repeat element. The substitution of the base pairs at position 2 and 4 in both pb 
causes a modified cleavage pattern. Extra cleavage products that are unique for the altered 
RNA substrates (fig 2.10 B) were marked in the substrate sequences (fig 2.10 A). The 
nucleotide exchange in the left pb results in the addition of one unique cleavage site in the 
forward and reverse strand (fig 2.10 A).Alterations in the nucleotide composition of the 
right pb cause two additional unique cleavage sites on both strands (fig 2.10 A). The 
wildtype cleavage products remain, which indicates that both sets of pb and db are 
recognized by RNase III in C. thermocellum. 
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Figure 2.10: Identification of essential RNase III recognition elements in double-stranded 30 nt repeat 
elements. A) Double-stranded RNA substrates comprising the 30 bp repeat (WT) with base pair substitutions 
at position 2 and 4 within the left proximal box (left KO) and the right proximal box (right KO) were used for 
RNase III assays. B) Endonuclease assay using the 5'-terminal labeled dsRNA substrates and RNase III from 
C. thermocellum. An RNase T1 digest (T1) and Alkaline hydrolysis (AH) with single-stranded WT substrate 
in sense direction (S) was used as RNA size markers. Empty lanes are marked with e. The WT substrate 
displays the predefined (A black arrows) as well as an additional processing sites (A grey arrows). Unique 
cleavage products were depicted (B red bars) and marked in the RNA sequences (A red arrows). Bands were 
separated on a denaturing 8 M urea 12% PAA gel and visualized by autoradiography. 
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2.4 Type I-B Cascade 
In Clostriudium thermocellum, the five putative Cas proteins Cas3, Cas5, Cas6, Cas7 and 
Cas8b (Cthe_3201-3205) are proposed to form a type I-B Cascade complex that mediates 
the antiviral defense. However, the assembly of a functional type I-B complex has not been 
observed. In order to investigate the assembly and functionality of this CRISPR 
ribonucleoprotein complex (crRNP), the Cascade protein candidates were produced in E. 
coli. Since the expression of soluble Cas proteins in E. coli is often difficult due to 
insolubility issues, all five genes were cloned in their naturally occurring order into a 
single expression vector. The “Gateway cloning” technique was utilized for the generation 
of the expression construct. This method is based on homologous recombination of 
specific recombination sites that are introduced at the terminal ends of the genes during 
PCR amplification. This allows a simultaneous assembly of the genes of interest in the 
order of choice. However, this cloning strategy was not successful, and the “Golden Gate 
shuffling” cloning method was used to proceed. This technique also allows the 
simultaneous assembly of the genes of interest in the order of choice, but is based on a 
type II restriction enzyme digestion and a simultaneous ligation reaction which enables the 
generation of a construct lacking the original restriction sites 111. For this approach, all five 
cas gene sequences were supplied with the respective terminal ends, codon-optimized for 
E. coli codon usage and commercially synthesized into pUC57 plasmids. This attempt did 
not yield any plasmid containing the five cas genes. Therefore, five individual expression 
constructs were generated containing the single cas genes (Bachelorthesis of Laura Penkert 
and Mastermodule of Franka Schreiner). For cas gene expression in E. coli, the codon-
optimized versions of cas3, cas5, cas7 and cas8b were utilized. A cas6 codon-optimized 
expression construct could not be obtained and the native sequence was used for Cas6 
protein expression. Toxicity of this endonuclease for E. coli cells could be a possible 
reason for the inability to clone a cas6 codon-optimized variant into an expression vector 
and might explain complications during the cas gene assembly techniques.  
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2.4.1 Production of Cas proteins and Cascade assembly 
For the recombinant production of all five Cas proteins in E. coli, optimal gene expression 
conditions were tested for each protein using two different expression vectors 
(Bachelorthesis of Laura Penkert and Mastermodule of Franka Schreiner).  
 
Figure 2.11: Cas protein purification and Cas6 pre-crRNA processing. A) SDS-PAGE of Cas3, Cas5, 
Cas6, Cas7 and Cas8b after nickel-NTA purification. Cas8b is purified with an additional 17 kDa protein 
fragment B) SDS-PAGE of Cas8b together with the protein fragment after cation exchange chromatography, 
used as an additional purification step to remove co-purified nucleic acids. C) Generation of a pre-crRNA 
comprising 3 spacers (S) that are interspaced by 37 nt repeat elements (R). Cas6 processing (black arrows) 
yields crRNAs and cleavage intermediates, respectively. Bands were separated on a denaturing 8 M urea 
12 % PAA gel. (C) Bachelorthesis of Laura Penkert). 
 
The pET20b vector generates protein with an N-terminal 6-fold His-tag, whereas the pEC-
A-HI-SUMO vector provides an N-terminal His-tag and a SUMO protein fusion. This tag 
can be cleaved off using a SUMO protease which results in tag-free proteins. To yield 
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sufficient amounts of Cas3, Cas6 and Cas8b, these proteins were produced from pET20b 
vectors. The individual SUMO protein fusions of these three proteins either increased the 
amount of protein impurities or rendered the proteins inaccessible for the SUMO protease. 
However, Cas5 and Cas7 expression was found to rely on the fusion to the SUMO protein, 
as it enhances protein stability. All five proteins were purified via affinity chromatography 
using a nickel-NTA column. Afterwards, the SUMO tags of Cas5 and Cas7 were removed 
(fig 2.11 A). Cas8b is purified with an additional 17 kDa protein fragment that comprises 
the C-terminal sequence of Cas8b which was verified by mass-spectrometry 
(Bachelorthesis of Laura Penkert). The Cas8b protein will be described in detail in section 
2.4.4. Agarose gel-electrophoresis of all individual Cas proteins revealed that Cas8b is 
highly contaminated with nucleic acids. Hence, cation exchange chromatography with a 
Heparin column was used to remove the co-purified nucleic acids (fig 2.11 B). Finally, a 
pre-crRNA substrate containing three spacer sequences interspaced by 37 nt repeat 
elements was generated (fig 2.11 C). The RNA substrate was cleaved by Cas6 which 
resulted in the generation of one mature crRNA (74 nt) and processing intermediates.  
In order to reconstitute the Cascade complex, the recombinant Cas proteins Cas5, Cas7, 
Cas8b and Cas6 with RNA cleavage products (fig 2.11) were mixed, incubated at 50°C and 
subjected to size-exclusion chromatography on a Superdex 200 column. Cas3 was not 
added to the mixture as it was shown that it is not tightly associated with Cascade during 
complex assembly (Mastermodule of Franka Schreiner), which was also observed for the 
type I-E Cascade 49. 1 mL chromatography fractions from an elution volume of 6,6 to 13,6 
mL (A7 to B12) were analyzed with respect to protein and RNA content via TCA-/ethanol 
precipitation and subsequent SDS-/urea-PAGE. Representative results are shown in fig 
2.12 A. To generate a standard curve, a mix of protein standards (with known molecular 
weights) was subjected to gel-filtration chromatography under identical running 
conditions. With the logarithmic illustration of the molecular weights in relation to the 
elution volumes, an equation is obtained (e-function) to calculate the molecular weight of 
any molecule eluting from the gel-filtration column at a given volume. According to this, 
an elution volume of 8.6 mL to 10.6 mL corresponds to a molecular weight of 416 kDa to 
194 kDa that is collected in the chromatography fractions A9 and A10. The assumed 
molecular weight of the type I-B Cascade (described in 2.4.6) lies within this range and a 
distinct protein peak can be observed eluting at around 9 mL (fig 2.12 A). 
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Figure 2.12: Cascade assembly with and without RNA. A) Cas proteins and processed pre-crRNA (pp) 
were mixed and subjected to gel-filtration chromatography. Fractions A7 to B12 (marked in the elution 
profile) were analyzed via TCA-/ethanol precipitation and subsequent SDS-/urea-PAGE. A protein peak 
around 9 mL that corresponds to the fractions A9 and A10 is marked with an arrow. The SDS- and urea-
PAGE show a complex formed by Cas8b and the protein fragment, Cas7, Cas6, Cas5 and mature crRNA that 
elute in the respective fractions. B) Cas proteins were mixed without RNA and subjected to gel-filtration 
chromatography. Fractions A7 to B12 (6.6-13.6 mL) were analyzed via TCA-/ethanol precipitation and 
subsequent SDS-/urea-PAGE. The elution profile does not display a protein peak at an elution volume 
between 8.6-10.6 mL and the corresponding fractions A9 and A10. C) Gel-filtration chromatogram of a 
standard protein mixture that was used as a calibration curve for the calculation of a standard curve.  
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The corresponding fractions A9 and A10 contain the Cas proteins Cas8b, Cas7, Cas6 and 
Cas5 that co-elute with mature crRNA. An overrepresentation of the Cas7 protein can be 
observed, which is in agreement with the stoichiometry that was determined via mass-
spectrometry described in section 2.4. A great protein peak can be observed eluting at 
around 11 to 13.5 mL that corresponds to the fractions A11 to B12. Gel-filtration 
chromatography of the individual Cas proteins showed that Cas8b elutes as a monomer at 
around 12 mL and that Cas7 forms multimers that elute between 11 and 13 mL. Thus, the 
peak represents unassembled Cas8b protein as well as Cas7 multimers that have been 
observed to interact with Cas5. Monomeric Cas7 protein elutes around 15 mL followed by 
monomeric Cas5 protein at 17 mL (Mastermodule of Franka Schreiner). 
The next approach was to reconstitute the Cas proteins without adding RNA to the mixture 
to analyze whether RNA is required for proper complex formation. Representative results 
are shown in fig. 2.12 B. However, this approach did not yield any assembled complex. 
The protein peak resembling the complex is missing in the gel-filtration elution profile and 
SDS-PAGE of fractions A7 to B12 only revealed mainly unassembled protein. An 
increased amount of protein elutes at the void volume in fraction A7 that contains Cas7 
multimers that interact with Cas8b. Compared to the assembly with crRNA, the amount of 
monomeric Cas7 protein eluting around 15 mL is increased.  
In order to investigate whether Cas6 is required for Cascade formation, the recombinant 
proteins Cas8b, Cas7, Cas5 and pre-crRNA cleavage products were assembled without 
Cas6. A precursor-RNA was used that comprised a 3'-terminal repeat sequence that was 
shortened to 4 nt, as observed for the trimmed crRNAs in vivo. After Cas6 cleavage, the 
RNA products were phenol:chloroform extracted to efficiently remove the protein from the 
sample. After protein assembly, gel-filtration chromatography was performed and 
representative results are shown in figure 2.13. A distinct protein peak can be observed 
eluting around 10 mL and the corresponding fractions A9 and A10 show a stable complex 
formed by the subunits Cas5, Cas7, Cas8b and crRNA. Hence, Cas6 seems to be a 
temporarily associated Cascade subunit that dissociates after crRNA delivery. 
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Figure 2.13: Cascade assembly without Cas6. Cas proteins and processed pre-crRNA with a shortened 3' 
end (4 nt) were mixed and subjected to gel-filtration chromatography. Fractions A7 to B12 that correspond to 
6.8-13.8 mL elution volume were analyzed via TCA-/ethanol precipitation and subsequent SDS-/urea-PAGE. 
A protein peak around 10 mL (arrow) that is collected in the fractions A9 and A10 contains Cas8b, Cas7 and 
Cas5 that coelute with crRNA.  
 
2.4.2 crRNA binding by Cascade 
To prove that the crRNA is bound by Cascade, an Electrophoretic Mobility Shift Assay 
(EMSA) was performed (fig 2.14). Therefore, a 5ʹ-terminal radiolabeled crRNA was 
incubated with different concentrations of the Cascade complex. The crRNA-protein 
complexes were separated from free crRNA on a native 6 % PAA gel (fig 2.14). The 
EMSA shows a crRNA mobility shift, representing an RNA:protein complex. The shift 
starts to appear at a protein concentration of 250 nM which is indicated by the reduction of 
free crRNA. A large excess of yeast RNA (~200 fold) was used in each reaction as a 
competitor, showing that the crRNA binding by Cascade is specific. Noteworthy, the 
radiolabeled crRNA is bound by a Cascade that was assembled in the presence of 
unlabeled crRNA as this is needed for proper complex formation. One plausible 
explanation is that the used Cascade sample contains a certain amount of unassembled 
Cascade subunits that form a crRNP complex with the added radiolabeled crRNA. It could 
also be an indication for “crRNA cycling” which would mean that the crRNA bound by 
Cascade can be replaced by a radiolabeled one.  
 __________________________________________________________________________________Results 
34 
 
 
Figure 2.14: EMSA using crRNA and Cascade. Different concentrations (0-2 µM) of assembled I-B 
Cascade (without Cas6) were used for an EMSA with 5'-terminal radiolabeled crRNA (1,6 nM). A mobility 
shift can be observed starting at a 250 nM protein concentration which indicates RNA-protein complex 
formation. Bands were separated on a native 6 % PAA gel and visualized by autoradiography. 
 
2.4.3 Cascade loading 
Recently, the first crystal structure of a type I Cascade complex was obtained for the 
subtype I-E Cascade from E. coli 54, 60. The backbone structure displays one copy of Cas5, 
capping the 5ʹ-terminal end of the crRNA, six copies of Cas7 that oligomerize along the 
crRNA and form the backbone of the complex and one permanently associated Cas6 
subunit sitting at the 3ʹ-terminal end of the crRNA. In order to investigate crRNA loading 
of the type I-B complex, Cascade assemblies were performed using the purified Cas 
proteins Cas8b, Cas7, Cas5, Cas6 and pre-crRNA variants with modified repeat tags to 
analyze their role and identify their interaction partners in the complex. Two pre-crRNA 
variants were designed in a way that mature crRNAs were generated with modified repeat 
tags at both ends (fig 2.15).  
 __________________________________________________________________________________Results 
35 
 
 
Figure 2.15: Cascade assembly with modified crRNAs. Cas proteins and processed pre-crRNA variants 
(pp) were mixed and subjected to gel-filtration chromatography. Fractions A7-A12 that correspond to 6.6-
13.6 mL elution volume were analyzed by TCA/ethanol precipitation and SDS-/urea-PAGE. A) Gel-filtration 
elution profile of Cascade assembly with 3'-terminal modified crRNA (3'G RNA). The black arrow indicates 
the protein peak that corresponds to fractions A9 and A10 that contain assembled Cascade complex. B) The 
elution profile from gel-filtration purification of the Cascade assembly with 5'-terminal modified crRNA (5'G 
RNA). The black arrow indicates the region corresponding to fractions A9 and A10 where assembled 
complex would elute.  
One pre-crRNA variant (fig 2.15 A) comprised a 37 nt repeat element and a spacer 
sequences followed by 29 G residues (R-S-29xG). Cas6 cleavage of this pre-crRNA 
produced a crRNA (3'G RNA) that contained an intact 5ʹ-terminal tag and a modified 3ʹ-
end with 29 G residues instead of 29 repeat-derived nucleotides. In order to generate the 
pre-crRNA, in vitro run-off transcription was utilized that yielded transcripts of varying 
length. Analysis of the RNA production showed the formation of a double-band, 
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presumably due to the 29 consecutive G residues that are difficult to transcribe for the T7 
RNA polymerase. Hence, Cas6 processing of the precursor also generated crRNAs of 
different length in the form of a double band (fig. 2.15 A). The gel-filtration purification 
chromatogram of the Cascade assembly using the 3ʹG RNA displays a protein peak at an 
elution volume around 10 mL. The corresponding fractions A9 and A10 display all 
Cascade subunits. The derived pattern and the intensities of the individual bands are 
comparable to a Cascade assembly with wildtype crRNA (fig 2.12 A). The mature 
3ʹG RNA is enriched in the respective fractions. Taken together, these results show the 
formation of a protein-RNA complex, indicating that the modification of the 3ʹ-terminal 
repeat sequence of the crRNA does not interfere with crRNA loading or the assembly of 
Cas proteins.  
The second pre-crRNA variant used for Cascade assembly contained 8 G residues followed 
by a spacer element and a 37 nt repeat sequence (8xG-S-R). Cas6 processing of the 
precursor generated a crRNA (5ʹG RNA) consisting of a modified 8 nt 5ʹ-terminal tag and 
an unchanged 3ʹ-end. It should be mentioned that the 5ʹG RNA contains a 5'-terminal 
triphosphate resulting from the generation via run-off transcription and therefore differs 
from the natural crRNAs that are processed by Cas6 and encompass a 5'-terminal hydroxyl 
group. After assembling the Cas proteins with this crRNA variant, gel-filtration 
purification was performed and representative results are shown in fig 2.15 B. The 
chromatogram displays a gradual increase instead of a distinct peak of protein between 8.6-
10.6 mL elution volume. After TCA/ethanol precipitation and subsequent SDS-/UREA-
PAGE, the respective fractions A9 and A10 contained Cas8b with the protein fragment, 
Cas7, Cas5 and mature 5ʹG RNA. The amount of Cas6 protein seems to be highly reduced 
indicating that the modification of the 5ʹ-tag interferes with its complex association. The 
relative amount of Cas5 protein is slightly reduced, which suggests that the modification of 
the 5ʹ-tag might reduce its ability to bind the crRNA. This would be in agreement with the 
observation made for the I-E Cascade, where Cas5 caps the 5ʹ-terminal end of the crRNA. 
The fact that a significant amount of protein eluted within the void volume (elution volume 
around 7 mL, fractions A7 and A8) could indicate difficulties of the Cas proteins to 
assemble around the 5ʹG RNA.  
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As described in section 2.2.2, mature crRNAs display a gradually processed 3'-ends in 
vivo. To investigate whether the trimming of the 3'-terminal repeat sequence affects Cas6 
loading ability, an assembly was performed with pre-crRNAs of different length (fig 2.16). 
One pre-crRNA substrate consisted of a 145 nt long spacer-repeat-spacer-repeat-spacer 
sequence that can be used to obtain an 74 nt long crRNA and cleavage intermediates via 
Cas6 processing and was also used for the wildtype assembly in fig 2.12. Another pre-
crRNA substrate of 81 nt was used that consisted of the same spacer sequence, flanked by 
an intact 5'-terminal repeat and a 3'-terminal repeat shortened to 4 nt as observed for most 
of the crRNAs containing this spacer in vivo. Cas6 cleavage of this modified pre-crRNA 
generates 49 nt long crRNAs that were shown to assemble with Cascade (figure 2.13).  
 
Figure 2.16: Cascade assembly with crRNAs of varying length. Equimolar ratios of two pre-crRNA 
variants (145 nt and 81 nt) were used to generate mature crRNAs via Cas6 cleavage that comprise either a 
full-length or shortened 4 nt 3'-terminal repeat ends. Processed crRNAs were mixed with Cas proteins and 
subjected to size-exclusion chromatography. The black arrow in the elution profile indicates the protein peak 
that corresponds to fractions A9 and A10 containing assembled complex. SDS- and urea-PAGE show the 
complex formed by Cas8b, Cas7, Cas6 and Cas5 in the respective fractions A9 and A10.  
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Equal molar amounts of both pre-crRNA transcripts were simultaneously processed using 
Cas6, assembled with Cascade and subsequently subjected to gel-filtration 
chromatography. The elution profile shows a protein peak at around 9 mL that corresponds 
to size of a fully assembled complex. SDS-/UREA PAGE of the respective fractions A9 
and A10 displays all four Cas proteins and the crRNA of 74 nt. Additionally, RNA of 
around 50 nt can be observed that could correspond to either the 49 nt crRNA or an 
intermediate cleavage product (48 nt) that results from Cas6 cleavage of the 145 nt long 
pre-crRNA as observed in the wildtype assembly (fig 2.12). Nevertheless, the crRNA 49 
that contains the shortened 3'-terminal repeat tag is less efficiently assembled with 
Cascade. This indicates that crRNAs comprising a full length 3'-terminal tag are preferably 
incorporated by the complex.  
As described in section 2.1, C. thermocellum encodes two type I-B CRISPR systems 
(Hmari and Tneap) that are associated with CRISPR loci of 30 nt and 37 nt repeat 
elements. In section 2.2.1, it was shown that two Cas6 enzymes exclusively process their 
respective repeat substrates and generate crRNAs with identical 8 nt 5ʹ-teminal tags. To 
investigate whether the studied Cascade (type I-B Hmari) could be loaded with a crRNA 
and associate with the Cas6 subunit of the other system (type I-B Tneap), recombinant 
Cascade assembly was performed using a pre-crRNA containing three spacer sequences 
that are interspaced by two 30 nt repeat elements that were processed by Cas6 Cthe_2303 
(Tneap) shown in fig 2.17. The elution profile of the gel-filtration purification revealed a 
peak “shoulder” at the respective elution volume, indicating the potential formation of a 
complex. The SDS-/UREA PAGE analysis of the precipitated fraction A7 to A12 reveals 
the presence of all utilized Cas proteins and mature crRNA in fractions A9 and A10. The 
fact that Cas6_2303 can be observed in fractions A9 and A10 indicates that the Tneap 
Cas6 subunit interacts with the Hmari Cascade. The significant amount of protein in the 
void volume shown in fractions A7 and A8, as well as the elution profile that lacks the 
distinct complex protein peak and the small amount of crRNA that can be detected could 
be an indication of hindered crRNA loading conditions though.  
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Figure 2.17: Cascade assembly using Cas6 of type I-B Tneap (Cthe_2303). Cas proteins Cas8b, Cas7 and 
Cas5 (type I-B Hmari) and pre-crRNA (p) processed by Cas6 of type I-B Tneap (pp) were mixed and 
subjected to gel-filtration chromatography. The black arrow in the chromatogram indicates the region, where 
assembled complex typically elutes. Fractions A7-A12 (elution volume 6.6-12.6 mL) were analyzed via 
TCA/ethanol precipitation and SDS-/urea-PAGE.  
 
2.4.4 Characterization of Cas8b 
The recombinant production of Cas8b and subsequent affinity chromatography using 
nickel-NTA revealed that soluble protein was co-purified with a small fragment of 17 kDa 
(section 2.4.1). This small protein fragment could not be removed via cation exchange 
chromatography or gel-filtration chromatography. When subjected to gel-filtration 
chromatography, both proteins co-elute at 12.5 mL elution volume which corresponds to a 
molecular weight of 90 kDa. A mass-spectrometric analysis identified the 72 kDa as the 
full-length Cas8b protein and the 17 kDa protein to be a C-terminal fragment of Cas8b 
(Kundan Sharma, MPI Göttingen).   
Recombinant production and subsequent purification of the Cas8b protein (76 kDa) from 
Methanococcus maripaludis also yields the additional 17 kDa C-terminal fragment of 
Cas8b (fig 2.18 A), even though the proteins share only 17% amino acid homology. N-
terminal Edman sequencing of 10 amino acids of the small fragment from M. maripaludis 
identified the amino acid sequence to start with a methionine residue at position 511 of the 
full-length protein (PhD thesis of Hagen Richter). An amino acid sequence alignment with 
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Cas8b of C. thermocellum identified this methionine residue at position 476 of the full-
length protein as the potential first amino acid of the C-terminal fragment. Accordingly, 
the theoretical molecular weight of the C-teminal fragment would be 17.6 kDa. Mass-
spectrometric analysis using MALDI-TOF (Matrix_assisted_laser_desoption_ionization–
time_of_flight) of purified Cas8b revealed a molecular weight of 17.5 kDa that 
corresponds to the fragment (fig 2.18 B), confirming the start site of the amino acid 
sequences covering the C-terminal part of the full-length protein. Two masses of 53.1 kDa 
and 70.9 kDa could also be detected with very low relative intensities. These masses could 
correspond to the full-length protein (theoretical Mw: 72.6k Da) and a potential protein 
fragment covering the remaining N-terminal sequence (theoretical Mw: 54.9 kDa). The 
mass aberration of around 2 kDa is remarkable, but could be explained with the limited 
ability of the MALDI-TOF instrument to ionize large proteins that causes a significant 
decrease in the accuracy of mass determination of large molecules.  
 
 
Figure 2.18: Recombinant production of Cas8b subunits and identification of the small protein 
fragment. A) Affinity purification of Cas8b proteins from Clostridium thermocellum (Cthe) and 
Methanococcus maripaludis (Mmari) that were expressed in E. coli yields similar protein patterns separated 
via SDS-PAGE. B) Mass-spectrometric analysis using MALDI-TOF of the Cas8b protein from C. 
thermocellum was used for identification and mass determination of the small protein fragment. (A) 
Bachelorthesis of Laura Penkert, B) Masterthesis of Kristina Rau, Jörg Kahnt, MPI Marburg). 
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To find out whether the appearance of the C-terminal Cas8b fragment is linked to the 
recombinant production in E. coli, the Cas8b protein of C. thermocellum was investigated 
in vivo. Therefore, a manufactured polyclonal antibody against the Cas8b protein was used. 
Western blot analysis using C. thermocellum cell extract together with this polyclonal 
antibody revealed that the C-terminal Cas8b fragment is also produced in vivo 
(Masterthesis of Kristina Rau). Together with the fact that the fragment also assembles 
with the Cascade in vitro (fig 2.12), this suggests a functional role of the 17 kDa C-
terminal Cas8b protein in complex formation and/or interference.  
 
2.4.5 Cascade interference 
In order to perform in vitro DNA interference assays, 500 nM of purified Cascade complex 
(Cas8b, Cas7, Cas5, Cas6 and crRNA) was mixed with freshly prepared Cas3 protein in an 
equimolar ratio. A 5ʹ-terminal radiolabeled double-stranded DNA target resembling viral 
DNA was provided. The DNA target contained both a protospacer and a PAM (protospacer 
adjacent motif), flanked by random DNA sequences in both directions (fig 2.19 A). The 
protospacer sequence on the DNA target strand is complementary to the crRNA assembled 
with the complex. It was shown that after PAM recognition by Cascade, the crRNA and 
the target strand base-pair, which leads to the displacement of the non-target strand and the 
formation of an R-loop 49. The PAM sequence that is essential for target recognition by 
Cascade is not known for type I-B from C. thermocellum. Therefore, five different DNA 
substrates were tested that varied in the potential PAM sequence (table 1.1). AAG and 
GGT PAMs have been determined for type I-B systems from other organisms. In order to 
identify more potential PAM sequences, the CRISPRtarget tool was utilized 112. This 
program aligns sequences with viral/phage genomes and all spacer sequences from loci 1-5 
of C. thermocellum were analyzed. Three targets were detected that displayed at least 15 
consecutive spacer-protospacer base-pairs. AAC, TTA and AGT were identified as 
potential PAM sequences downstream of the spacer-protospacer duplex on the DNA target 
strand. 
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Table 1.1: Potential type I-B PAM sequences. * 
* status october, 2013. 
A DNA target containing a CCC PAM was used as a substrate with a potential non-PAM 
to prove target specificity in case of an interference reaction. The divalent metal ions 
magnesium and manganese were added to the assay to induce Cas3 nuclease activity as 
described for the type I-A Cascade interference reactions 43. Unfortunately, significant 
Cascade interference could not be detected for any of the five different DNA targets. 
Representative results are shown in figure 2.19 B for the substrates comprising the PAMs 
AAG, AGT, TTA and CCC. 
The in vitro interference activity is determined by several parameters. It was shown for the 
type I-E CRISPR system of Streptococcus thermophilus, that after PAM recognition 
Cascade binds to the target DNA, generating an R-loop that is bound by Cas3 45. The 
active site of the Cas3 nuclease is responsible for divalent metal binding that is essential 
for ssDNA hydrolysis 72. Therefore, metal-dependence of the Cas3 nuclease activity from 
C. thermocellum was tested using different combinations of magnesium, manganese, 
calcium, cobalt and copper ions with 5ʹ-terminal radiolabeled ssDNA (fig 2.20 A). The 
substrate was most efficiently cleaved with the addition of magnesium ions together with 
manganese ions. Thus, these conditions were used in the interference assays.  
3ʹ-PAM-5ʹ  Source 
AAG Identified for type I-B of Haloferax volcanii 113  
GGT Identified for type I-B of Listeria monocytogenes 114 
AAC 
CRISPRtarget: complementarity of spacer 25 from locus 1 to 
Clostridium kluyveri prophage 
TTA 
CRISPRtarget: complementarity of spacer from locus 2 to 
Clostridium periferengens plasmid 
AGT 
CRISPRtarget: complementarity of spacer 34 from locus 4 to 
Clostridium thermocellum prophage 
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Figure 2.19: Interference assay using type I-B Cascade with double-stranded target DNA. A) R-loop 
formation of crRNA and double-stranded DNA target. The spacer sequence of the crRNA assembled with 
Cascade basepairs with the protospacer sequence of the DNA target strand. The non-target DNA strand is 
displaced. B) Interference assay using 5'-terminal radiolabeled dsDNA substrates that vary in the PAM 
sequence (AAG, AGT, TTA, CCC). X =no protein added, 3 = Cas3 added, cc = Cascade (Cas8b, Cas7, Cas6, 
Cas5 and crRNA) added, 3cc = Cas3 together with Cascade added. Bands were separated on a denaturing 8 
M urea 12 % PAA gel and visualized by autoradiography. (A) Modified from 43). 
 
Cas3 cleavage activity was also investigated for different protein concentrations on ssDNA 
after addition of magnesium and manganese (fig 2.20 B). However, only low cleavage 
activity can be observed using magnesium/manganese and a 4 µM Cas3 concentration. 
This indicates that recombinant Cas3 protein from C. thermocellum has little activity under 
these conditions and could explain unsuccessful interference assays. Recombinant Cas3 
starts precipitating shortly after affinity-chromatography, which hints at problems of 
protein stability or folding. 
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Figure 2.20: Cas3 nuclease activity on 5'-terminal radiolabeled ssDNA. A) Cas3 cleavage activity using 
different divalent metal ions (5mM). Weak nuclease activity revealed that the DNA substrate is most 
efficiently cleaved in the presence of Mg/Mn ions. B) Impact of Cas3 protein concentration from 0,25 – 
4 µM on ssDNA cleavage. Bands were separated on a denaturing 8 M urea 12 % PAA gel and visualized by 
autoradiography. 
 
2.4.6 Cascade stoichiometry and protein interaction sites 
Assembled Cascade complex formed by Cas8b, Cas7, Cas6, Cas5 and crRNA was sent to 
Kundan Sharma (group of Prof. Urlaub, Max-Plank Institute Göttingen) to determine the 
stoichiometry of the complex and to analyze protein:protein interactions via mass-
spectrometry.  
Intensity-based absolute quantification (iBAQ) of proteins was used to identify the protein 
stoichiometry. This label-free method determines the abundance of a particular protein by 
calculating the sum of all peptide peak intensities obtained via mass-spectrometry 
matching to a specific protein divided by the number of theoretically observable peptides. 
This provides an accurate proxy for the number of protein copies 115, 116. A ratio of 
1 : 1 : 6 : 2.5 of the proteins Cas5 : Cas6 : Cas7 : Cas8b was obtained which correlates with 
the intensity of the protein bands of assembled Cascade (fig 2.12 A). Chemical cross-
linking of the protein complex was obtained using a BS3 cross-linker which links lysine 
residues. After in-gel digestion of the cross-linked complex, the respective cross-linked 
peptides were analyzed via mass-spectrometry. It should be noted that cross-linked 
residues provide information about proximal locations, not direct contact sites 117.  
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Figure 2.20: Inter-protein cross-links of the Cascade complex. A BS3 cross-linker was used to cross-link 
Cas protein lysine residues located in close proximity within Cascade. Inter-protein cross-links between 
Cas8b, Cas7, Cas6 and Cas5 are depicted as orange lines between respective amino acid residues represented 
by the bars. A score cut off of 4.0 was used that is based on the number of MS spectra counts that do not 
include low quality spectra. (Kundan Sharma, MPI Göttingen). 
 
Inter-protein cross-links were identified for all four Cas proteins depicted in figure 2.20 
with a relatively high score cutoff of 4.0. Most of the inter-protein cross-links between 
Cas7 and Cas8b are located within the N-terminal part of Cas7 forming two prominent 
clusters, whereas the corresponding cross-linked sites within Cas8b are widely distributed 
throughout the protein sequence. These two cross-link hot-spots within the Cas7 sequence 
are also the main cross-link sites between the lysine residues of Cas7 and Cas5. Cas5 inter-
protein cross-links formed with Cas7 are centered in the middle of the amino acid 
sequence. Cas8b and Cas5 display cross-linked residues also in the middle of the sequence. 
Only two single residues of Cas6 could be observed that were cross-linked to Cas8b and 
Cas7, underlining the hypothesis that Cas6 is not a permanent Cascade subunit as 
described in 2.4.1 for the type I-B Cascade assembly.  
2.4.7 Cas6-repeat RNA interaction 
Purified Cas6_3205 protein and its corresponding 37 nt deoxy-repeat RNA was sent to 
Kundan Sharma (group of Prof. Urlaub, Max-Plank Institute Göttingen) to determine the 
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protein:RNA interaction sites using UV-induced cross-linking. After UV irradiation of 
protein and RNA, cross-linked complexes were hydrolysed with trypsin. The resulting 
peptide:RNA conjugates were identified via mass-spectrometry and subsequent database 
search. Figure 2.21 A shows the spectrum of a peptide derived from Cas6 that was 
unambiguously identified as MIGFK by b- and y-type ions (resembling N- and C-terminal 
peptide fragments), with M (184) being cross-linked to the nucleotides UGA.  
 
Figure 2.21: Cas6_3205 - repeat RNA interaction sites. A) Spectrum of the Cas6 peptide MFIGFK cross-
linked to UGA RNA nucleotides. Identified fragment ions are indicated as y- and b-ions. Blue numbers 
indicate fragments with adducts. B) Predicted secondary structure of 37 nt repeat sequence. UGA protein 
interactionsites are indicated with grey boxes. (A)Kundan Sharma, MPI Göttingen). 
An alignment of the Cas6 amino acid sequences from C. thermocellum and M. maripaludis 
identified an identical methionin residue at position 185 in the M. maripaludis Cas6 that 
was also determined as the interacting amino acid with the corresponding repeat RNA 
using the same method. It was shown that site-specific mutation of M. maripaludis Cas6 
drastically decreases Cas6 binding of the corresponding repeat RNA (PhD thesis of Hagen 
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Richter). The 37 nt repeat element of C. thermocellum displays seven UGA sequences in 
different orders that could be potential interaction sites (fig 2.21 B). 
2.4.8 Structure predictions of Cas5 and Cas7 and their Cascade interaction sites 
The amino acid sequences of Cas5 and Cas7 were submitted to protein structure prediction 
tools. A model for the Cas5 protein was obtained using phyre2 118, whereas the I-TASSER 
software was used for the structure prediction of Cas7 119. These models display structural 
similarities to the E. coli crystal structures of Cas5e and Cas7e (fig 2.22) that were 
crystallized in the Cascade complex 54, 63, 68.  
The C. thermocellum Cas5 model reveals a thumb domain as well as a palm domain with a 
modified RRM motif (RNA recognition motif) as observed in the E. coli Cas5e structure 
(fig 2.22 A, B). Cas7 from C. thermocellum displays thumb, palm and finger domains that 
are also present in the Cas7e structure (fig 2.22 C, D). In the E.coli Cascade model, Cas5e 
forms the tail of the complex and protects the 5ʹ-terminal tag of the crRNA. The central 
bases of the 5ʹ- terminal tag are positioned between the palm domains of Cas5e and the 
neighboring Cas7 protein. The thumb of Cas5e interacts with the finger domain of the 
adjacent Cas7 subunit. Cse1 is the large subunit of the E. coli Cascade and forms contact 
sites with the Cas5 RRM and the Cas7 thumb at the tail of the complex. The inter-protein 
lysine cross-links of Cas5, Cas7 and Cas8b (fig 2.20) of C. thermocellum were marked in 
the predicted structure models (fig 2.22 B, D). Within the Cas5 model, five regions were 
identified in the predicted thumb and palm domains that cross-linked with Cas7. Of these 
five regions, three were also found to cross-link with Cas8b that are mainly located in the 
thumb domain of Cas5. In the Cas7 model, nine regions all over the thumb, finger and 
palm domain were found to cross-link with Cas8b. Ten regions were found to cross-link 
with Cas5, partly overlapping with the cross-links observed with Cas8b. According to the 
E.coli Cascade structure, in C. thermocellum, the Cas5 thumb domain could interact with 
the Cas7 finger and the palm domains of both proteins could be located in cross-linkable 
proximity. The Cas5 thumb is also cross-linked to Cas8b, indicating protein contact. Cross-
links between Cas8b and the Cas7 thumb and finger domain can be observed as well. As 
the Cascade of C. thermocellum reveals multiple copies of Cas7, it has to be noted that the 
distribution of cross-linked regions could spread over multiple protein copies. Therefore, 
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the large Cas8b protein could interact with multiple Cas7 copies of the Cascade backbone 
or a Cas7 thumb and finger from different copies that are located in close proximity. 
 
Figure 2.22: Predicted 3D structured of Cas5 and Cas7 from C. thermocellum and crystal structures of 
the homologous E. coli Cas proteins. A) and C) Cas5 and Cas7 from the Cascade crystal structure of 
E. coli. B) Phyre2 model of C. thermocellum Cas5. Red = lysine residues cross-linked with Cas8b and Cas7, 
yellow = lysine residues cross-linked with Cas7. D) I-TASSER structure prediction for Cas7 from 
C. thermocellum. Red = lysine residues cross-linked with Cas8b and Cas5, yellow = lysine residues cross-
linked with Cas5, purple = lysine residues cross-linked with Cas8b. 
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3. Material and Methods 
3.1 Material and sources of supply 
 
3.1.1 Chemicals and enzymes 
The chemicals and enzymes used in this work were supplied by the companies AppliChem 
GmbH (Darmstadt), BioRad Laboratories GmbH (München), Biozym GmbH (Hessisch-
Oldendorf), Difco Laboratories GmbH (Augsburg), Fermentas GmbH (St. Leon-Rot), 
Merck KGaA (Darmstadt), Roche GmbH (Mannheim), Roth GmbH (Karlsruhe), SERVA 
GmbH (Heidelberg) and Sigma-Aldrich Co. (Deisenhofen). Restriction endonucleases, T4-
Ligase, Phusion DNA polymerase, murine RNase Inhibitor, dNTPs, 2-log DNA ladder, 
low range ssRNA ladder and Color-Plus protein marker were obtained from New England 
Biolabs GmbH (Frankfurt). Radioactive labeling of oligonucleotides was conducted using 
T4-Polynucleotide Kinase from Ambion/Life Technologies GmbH (Darmstadt). DNA and 
RNA oligonucleotides were obtained from Eurofins MWG GmbH (Ebersberg). 
3.1.2 Kits 
For the preparation of plasmid DNA from E. coli cells the Mini- and Maxi-Prep Kits from 
QIAGEN GmbH (Hilden) were used. The QIAquick Gel Extraction Kit from QIAGEN 
was utilized to extract DNA from agarose gels. Special kits are mentioned in the respective 
method chapters. 
3.1.3 Buffers and solutions 
Standard buffers and solutions were prepared according to Ausubel and Sambrook 120, 121. 
Special buffers and solutions are mentioned in the chapter of the respective method. All 
media, solutions and buffers were, if necessary, autoclaved for 5 min at 121°C prior to 
usage. Heat sensitive solutions were sterilized using a sterile filter (Pore size 0.2 µm from 
Merck, Darmstadt) and a vacuum pump.  
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3.2 Culture conditions 
3.2.1 Escherichia coli 
Aerobic cultivation of E. coli cultures (3-800 mL) was performed in Erlenmeyer flasks by 
shaking in a rotatory shaker at 200 rpm and 37°C in lysogeny broth (LB) medium (1 % 
tryptone (w/v), 0.5 % yeast extract, 1 % NaCl (w/v), pH 7.2) or on solid medium plates 
(LB medium containing 1.5 % (w/v) agar-agar). Liquid LB medium containing the 
corresponding plasmid-encoded antibiotics (chloramphenicol 34 µg/mL), kanamycin 
50 µg/mL, ampicillin 100 µg/mL and spectinomycin 50 µg/mL) was inoculated with a pre-
culture (2 % (v/v)) and growth was monitored at 600 nm using a photometer NovaspecII 
device (Pharmacia Biotech/GE Life Science, München). Culture stocks were obtained by 
adding 40 % (v/v) glycerol and stored at -80°C. Protein expression was induced at 
OD600=0.5-0.8 by the addition of 1 mM IPTG. After incubation of 3-4 hours at 37°C, cells 
were harvested via centrifugation (6,000 x g, 10 min, 4°) and stored at -80°C.  
3.2.2 Clostridium thermocellum 
Anaerobic cultivation of C. thermocellum cultures was performed at 50°C in a complex 
medium (modified from 122) containing (per liter): 0.3 g NaH2PO4, 0.7 g K2HPO4, 10 g 
MOPS, 5 g yeast extract, 5 g cellobiose, 0.2 g MgCl2 x 6H2O, 0.1 g CaCl2 x 2H2O, 0.4 g 
cysteine HCl as a reducing agent, 0.01 g FeSO4, 1.3 g (NH4)2SO4 and 1.2 mL resazurin. 
The pH was adjusted to 7.0 using NaOH. 100 mL or 2 l bottles were filled with 20 or 500 
mL of the medium, closed gastight and autoclaved. To obtain an anaerobic atmosphere, the 
bottles were flushed with N2. The medium was incubated with 1 % of a primary culture 
and incubated at 50°C, agitating at 200 rpm. After incubating over-night, cells were 
centrifugated at 10,000 x g, 15 min at 4°C and stored at -80°C.  
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3.3 Strains and plasmids 
3.3.1 Strains 
The E. coli K12 DH5α strain 123 with the genotype F- Φ80lacZΔM15 
(ΔlacZYAargF)U169 recA1 endA1 hsdR17(rK-,mK+) phoA supE44λ-thi-1 gyrA96 
relA1, was used for cloning, storage and preparation of plasmid DNA.  
Heterologous production of recombinant proteins from C. thermocellum was carried out in 
the E. coli strains Rosetta2(DE3)pLysS(Camr) with the genotype F-ompT hsdSB(rB- mB-) 
gal dcm (DE3) pLysSRARE2 (CamR) from Novagen and BL21(DE3)pLysS(Specr) with 
the genotype F-ompT hsdSB(rB- mB-) gal dcm (DE3) pLysS (Specr) from Invitrogen. In 
both strains, a T7 RNA polymerase under control of a lacUV-promoter is chromosomally 
encoded that can be induced via IPTG.  
3.3.2 Plasmids and constructed recombinant vectors 
Table 3.1: Sources of the used plasmids 
Vector Resistance Application Source 
pUC19 Ampr in vitro transcription  
pRSF Kanr in vitro transcription  
pET20b Ampr 
heterologous gene 
expression 
 
Pec-A-HI-SUMO Ampr 
heterologous gene 
expressio 
Kind gift of Prof. Dr. 
Elena Conti (MPI 
Martinsried) 
 
Table 3.2: Synthesized plasmids obtained from genscript with C. thermocellum genes 
modified for optimal codon usage in E. coli 
Vector Resistance Description 
pUC57+cas8b Kanr cas8b gene Cthe_3201 in pUC57 
pUC57+cas7 Kanr cas7 gene Cthe_3202 in pUC57 
pUC57+cas5 Kanr cas5 gene Cthe_3203 in pUC57 
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pUC57+cas3 Kanr cas3 gene Cthe_3204 in pUC57 
pUC57+cas6 Kanr cas6 gene Cthe_3205 in pUC57 
 
Table 3.3: Constructed recombinant vectors for protein expression 
Plasmid + Insert Description 
pET20b+cas6 Tneap 
cas6 gene Cthe_2303 in pET20b, restriction sites NdeI / 
EcoRV 
pET20b+cas6 Hmari cas6 gene Cthe_3205 in pET20b, restriction sites NdeI / XhoI 
pET20b+cas8b cas8b gene Cthe_3201 codon optimized for E.coli in pET20b, 
restriction sites NdeI / XhoI 
pET20b+cas7 cas7 gene Cthe_3202 codon optimized for E.coli in pET20b, 
restriction sites NdeI / NcoI 
pET20b+cas5 
cas5 gene Cthe_3203 codon optimized for E.coli in pET20b, 
restriction sites NdeI / XhoI 
pET20b+cas3 cas3 gene Cthe_3204 codon optimized for E.coli in pET20b, 
restriction sites NdeI / XhoI 
pEC-A-HI-
SUMO+cas8b 
cas8b gene Cthe_3201 codon optimized for E.coli in pEC-A-
HI-SUMO 
pEC-A-HI-SUMO+cas7 cas7 gene Cthe_3202 codon optimized for E.coli in pEC-A-
HI-SUMO 
pEC-A-HI-SUMO+cas5 cas5 gene Cthe_3203 codon optimized for E.coli in pEC-A-
HI-SUMO 
pEC-A-HI-SUMO+cas3 cas3 gene Cthe_3204 codon optimized for E.coli in pEC-A-
HI-SUMO 
pET20b+RNase III RNase III gene Cthe_0931 in pET20b, restriction sites NdeI / 
XhoI 
pET20b+RNaseIIIE129A RNase III E129A gene Cthe_0931 in pET20b, restriction sites 
NdeI / XhoI 
 
 ______________________________________________________________________Material and Methods 
53 
 
Table 3.4 Constructed vectors for in vitro run-off transcription 
Plasmid + Insert Description 
pUC19+R-S-R lo1 
C. thermocellum repeat33-spacer33-repeat34 of CRISPR 
locus 1 (30nt) with T7 promoter in pUC19, restiction sites 
BamHI / HindIII 
pUC19+R-S-R lo1 
reverse 
C. thermocellum repeat33-spacer33-repeat34 of CRISPR 
locus 1 (30nt) in reverse direction with T7 promoter in 
pUC19, restiction sites BamHI / HindIII 
pUC19+Spacer19 lo2 C. thermocellum spacer19 of CRISPR locus 2 (30nt) with T7 
promoter in pUC19, restiction sites BamHI / HindIII 
pUC19+Spacer19 lo2 
reverse 
C. thermocellum spacer19 of CRISPR locus 2 (30nt) in 
reverse direction with T7 promoter in pUC19, restiction sites 
BamHI / HindIII 
pUC19+S-R-S lo3 
C. thermocellum spacer145-repeat146-spacer146 of CRISPR 
locus 3 (30nt) with T7 promoter in pUC19, restriction sites 
BamHI / HindIII 
pUC19+S-R-S-R-S lo3 
C. thermocellum spacer23-repeat24-spacer24-repeat25-
spacer25 of CRISPR locus 3 (30nt) with T7 promoter in 
pUC19, restiction sites BamHI / HindIII 
pRSF+S-R-S-R-S lo4 
C. thermocellum spacer2-repeat3-spacer3-repeat4-spacer4 of 
CRISPR locus 4 (37nt) with T7 promoter in pRSF, restriction 
sites PfoI / Eco0109 
pUC19+R-S-(37xG) lo4 
C. thermocellum repeat3-spacer3-37xG-residues of CRISPR 
locus 4 (37nt) with T7 promoter in pUC19, restiction sites 
BamHI / HindIII 
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3.3.3 Oligonucleotides 
Table 3.5: Oligonucleotides uses for the amplification of genomic DNA from C. 
thermocellum, codon-optimized (co) gene sequences and site-directed mutagenesis of 
recombinant plasmid DNA. The exchanged base-pair is indicated in red. T7 promoter 
sequences are underlined. 
Name Sequence 5'-3' Genomic region /target vector 
Cas6_Tneap_fwd GTAGGGCATATGAGGTTTAAAGTTGGTAT 
cas6 
Cthe_2303,pET20b 
Cas6_Tneap_rev GCAGCAGATATCTATTAACTTAAAACACCCAAA 
cas6 Cthe_2303, 
pET20b 
Cas6_Hmari_fwd GTAGGGCATATGGATATTAAGATATTAACGGTAAG 
cas6 Cthe_3205, 
pET20b 
Cas6_Hmari_rev GCAGCACTCGAGTACAAAACCTTTACCAACTC 
cas6 Cthe_3205, 
pET20b 
Cas8b_fwd GTAGGGCATATGCTGGCTGGTGTGCTGCAA 
cas8b Cthe_3201, 
co, pET20b 
Cas8b_rev GCAGCACTCGAGTTCTTCATCTTCACCGTCTTTCT 
cas8b Cthe_3201, 
co, pET20b 
Cas7_fwd 
GTAGGGCCATGGGGATGATCAAAAACCGCCAAGA
AATCC 
cas7 Cthe_3202, 
co, pET20b 
Cas7_rev 
GCAGCACTC GAG 
GAACGTTTTTTCTTCGAAGCGGAT 
cas7 Cthe_3202, 
co, pET20b 
Cas5_fwd GTAGGGCATATG GTGGAAAAATACCTGGTGTTCG 
cas5 Cthe_3203, 
co, pET20b 
Cas5_rev 
GCAAAGCACCGGCCTCGTTAAATAATCAGAATGTT
TTCATCAATACCTT 
cas5 Cthe_3203, 
co, pET20b 
Cas3_fwd GTAGGGCATATGCTGCTGTCTCACCCGGGC 
cas3 Cthe_3204, 
co, pET20b 
Cas3_rev 
GCAGCACTCGAGGAAGAAGTAATCTTTTTCCAGGT
CAC 
cas3 Cthe_3204, 
co, pET20b 
Cas8b_fwd 
ACCAGGAACAAACCGGCGGCCGCTCGATGCTGGC
TGGTGTGCTGCAA 
cas8b Cthe_3201, 
co, SUMO 
Cas8b_rev 
GCAAAGCACCGGCCTCGTTATTCTTCATCTTCACC
GTCTTTCT 
cas8b Cthe_3201, 
co, SUMO 
Cas7_fwd ACCAGGAACAAACCGGCGGCCGCTCGATGATCAA cas7 Cthe_3202, 
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AAACCGCCAAGAAATC   co, SUMO 
Cas7_rev 
GCAAAGCACCGGCCTCGTTAGAACGTTTTTTCTTC
GAAGCGGAT 
cas7 Cthe_3202, 
co, SUMO 
Cas5_fwd 
ACCAGGAACAAACCGGCGGCCGCTCGATGGTGGAA
AAATACCTGGTGTTCG 
cas5 Cthe_3203, 
co, SUMO 
Cas5_rev 
GCAAAGCACCGGCCTCGTTAAATAATCAGAATGTT
TTCATCAATACCTT 
cas5 Cthe_3203, 
co, SUMO 
Cas3_fwd 
ACCAGGAACAAACCGGCGGCCGCTCGATGCTGCT
GTCTCACCCGGGC 
cas3 Cthe_3204, 
co, SUMO 
Cas3_rev 
GCAAAGCACCGGCCTCGTTAGAAGAAGTAATCTTT
TTCCAGGTCAC 
cas3 Cthe_3204, 
co, SUMO 
Cas6_Hmari_fwd 
ACCAGGAACAAACCGGCGGCCGCTCGATGATCAA
AAACCGCCAAGAAATC   
cas6 Cthe_3205, 
co, SUMO 
Cas6_Hmari_rev 
GCAAAGCACCGGCCTCGTTACACGAAACCTTTACC
CACACG 
cas6 Cthe_3205, 
co, SUMO 
RNase III_fwd GTAGGGCATATGTTTGATTTGGAAAGTTTTATGG 
rnase III 
Cthe_0931, pET20b 
RNase III_rev GCAGCACTCGAGCGCATTAATATTCTCCAAAGAC 
rnase III 
Cthe_0931, pET20b 
RNase III_E129A_fwd ACTTTCAGATGCCGTTGCAGCGTTAATAGGGGCTA 
rnase III Cthe_0931 
E129A, pET20b 
RNase III_E129A_rev TAGCCCCTATTAACGCTGCAACGGCATCTGAAAGT 
rnase III Cthe_0931 
E129A, pET20b 
S/R 2-4_lo4_fwd 
GTAGGGGCTCCGGGATAATACGACTCACTATAGCT
GTATCCGCATGTCC 
Spacer/repeat 2-4, 
CRISPR locus 4, 
pRSF 
S/R 2-4_lo4_rev AGCAGCAGGCCCCGATGTTTGCAGCACTGT 
Spacer/repeat 2-4, 
CRISPR locus 4, 
pRSF 
S/R 145/146_lo3_fwd 
GCAGCAGGATCCTAATACGACTCACTATAGAGATT
CAGGCGAAAATCTGA 
Spacer/repeat 145-
146, CRISPR locus 
3, pUC19 
S/R 145/146_lo3_rev AGTCGGAAGCTTAGACAGATCCTGGCGTCTCC 
Spacer/repeat 145-
146, CRISPR locus 
3, pUC19 
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Table 3.6: Oligonucleotides used for hybridization and subsequent ligation into 
pUC19 for in vitro run-off transcription. T7 promoter sequences are underlined. 
Name Sequence 5'-3' pUC19 insert 
S/R 23-25 
lo3_fwd1 
GATCCTAATACGACTCACTATAGAGATTCAGGCG
AAAATCTGAACTTGAAGGTCAGATATGCGTTTTT
ATCGTACCTATGAGGAATTGAAACTCTTCCGTGTT
GCCTGGGAGACGCCAGG 
S-R-S-R-S lo3 
S/R 23-25 
lo3_fwd2 
ATCTGTCTGTTTTTATCGTACCTATGAGGAATTGA
AACATGATGTAAATAATAAAAGTCTCGATAAACT
TAGGAACCAGGA 
S-R-S-R-S lo3 
S/R 23-25 
lo3_rev1 
AGCTTCCTGGTTCCTAAGTTTATCGAGACTTTTAT
TATTTACATCATGTTTCAATTCCTCATAGGTACGA
TAAAAACAGACAGATCCTGGCGTCTCCCAGGCAA
CACGGAAGAGTTTCAA 
S-R-S-R-S lo3 
S/R 23-25 
lo3_rev2 
TTCCTCATAGGTACGATAAAAACGCATATCTGAC
CTTCAAGTTCAGATTTTCGCCTGAATCTCTATAGT
GAGTCGTATTAG 
S-R-S-R-S lo3 
R/S 33-34 
lo1_fwd 
GATCCTAATACGACTCACTATAGATCGTACCTAT
GAGGAATTGAAACTCTATCATGTAAACGGTAATG
CATCCCATACACGCTGTTTGTATCGTACCTATGAG
GAATTGAAACCAGGA 
R-S-R lo1 
R/S 33-34 
lo1_rev 
AGCTTCCTGGTTTCAATTCCTCATAGGTACGATAC
AAACAGCGTGTATGGGATGCATTACCGTTTACAT
GATAGAGTTTCAATTCCTCATAGGTACGATCTATA
GTGAGTCGTATTAG 
R-S-R lo1 
Anti-R/S 33-
34 lo1_fwd 
GATCCTAATACGACTCACTATAGGTTTCAATTCCT
CATAGGTACGATACAAACAGCGTGTATGGGATGC
ATTACCGTTTACATGATAGAGTTTCAATTCCTCAT
AGGTACGATCCAGGA 
R-S-R lo1 reverse 
Anti-R/S 33-
34 lo1_rev 
AGCTTCCTGGATCGTACCTATGAGGAATTGAAAC
TCTATCATGTAAACGGTAATGCATCCCATACACG
CTGTTTGTATCGTACCTATGAGGAATTGAAACCTA
TAGTGAGTCGTATTAG 
R-S-R lo1 reverse 
S 19 lo1_fwd GATCCTAATACGACTCACTATAGAGGTCGCTGGT
TCAAATCCAGTCACTCCGACCAT C CAGGA 
Spacer19 lo2 
S 19 lo1_rev 
AGCTTCCTGGATGGTCGGAGTGACTGGATTTGAA
CCAGCGACCTCTATAGTGAGTCGTATTAG 
Spacer19 lo2 
Anti- S19 
lo1_fwd 
GATCCTAATACGACTCACTATAGATGGTCGGAGT
GACTGGATTTGAACCAGCGACCTCCCAGGA 
Spacer19 lo2 reverse 
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Anti- S19 
lo1_rev 
AGCTTCCTGGGAGGTCGCTGGTTCAAATCCAGTC
ACTCCGACCATCTATAGTGAGTCGTATTAG 
Spacer19 lo2 reverse 
 
Table 3.7: Oligonucleotides used for hybridization and subsequent in vitro 
transcription. T7 promoter sequences are underlined. 
Name Sequence 5'-3' Description 
(8G)S/R 3 
lo4_fwd 
GTAGGGTAATACGACTCACTATAGGGGGGGGATCTTTT
GTATATCAAAGGAAGCTACTTCTGTAATTAGTTGAAGT
GGTACTTCCAGTAAAACAAGGATTGAAAC 
8xG-residues-spacer3-
repeat3 of CRISPR 
locus 4 
(8G)S/R 3 
lo4_rev 
GTTTCAATCCTTGTTTTACTGGAAGTACCACTTCAACTA
ATTACAGAAGTAGCTTCCTTTGATATACAAAAGATCCC
CCCCCTATAGTGAGTCGTATTACCCTAC 
8xG-residues-spacer3-
repeat3 of CRISPR 
locus 4 
R/S3(4nt) 
lo4_fwd 
GTAGGGTAATACGACTCACTATAGGGAGTTGAAGTGGT
ACTTCCAGTAAAACAAGGATTGAAACATCTTTTGTATA
TCAAAGGAAGCTACTTCTGTAATTAGTTG 
repeat3-spacer3-(4nt) 
of CRISPR locus 4  
R/S3(4nt) 
lo4_rev 
CAACTAATTACAGAAGTAGCTTCCTTTGATATACAAAA
GATGTTTCAATCCTTGTTTTACTGGAAGTACCACTTCAA
CTCCCTATAGTGAGTCGTATTACCCTAC 
repeat3-spacer3-(4nt) 
of CRISPR locus 4 
 
Table 3.8: DNA oligonucleotides used as Cascade interference targets. All sequences 
contain spacer9 of CRISPR locus 4 (underlined) with adjacent PAM sequences (red). 
Name Sequence 5'-3' 
TTC_fwd 
GTCGACTAATACGACTCACTATAGTTCATCTTTTGTATATCAAAGGAAGCTA
CTTCTGTAATTACTAGTTATTGCTCAGCGGTAAGCTT 
TTC_rev 
AAGCTTACCGCTGAGCAATAACTAGTAATTACAGAAGTAGCTTCCTTTGATA
TACAAAAGATGAACTATAGTGAGTCGTATTAGTCGAC 
AAT_fwd 
GTCGACTAATACGACTCACTATAGAATATCTTTTGTATATCAAAGGAAGCTA
CTTCTGTAATTACTAGTTATTGCTCAGCGGTAAGCTT 
AAT_rev 
AAGCTTACCGCTGAGCAATAACTAGTAATTACAGAAGTAGCTTCCTTTGATA
TACAAAAGATATTCTATAGTGAGTCGTATTAGTCGAC 
GGG_fwd 
GTCGACTAATACGACTCACTATAGGGGATCTTTTGTATATCAAAGGAAGCTA
CTTCTGTAATTACTAGTTATTGCTCAGCGGTAAGCTT 
GGG_rev 
AAGCTTACCGCTGAGCAATAACTAGTAATTACAGAAGTAGCTTCCTTTGATA
TACAAAAGATCCCCTATAGTGAGTCGTATTAGTCGAC 
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CCA_fwd 
GTCGACTAATACGACTCACTATAGCCAATCTTTTGTATATCAAAGGAAGCTA
CTTCTGTAATTACTAGTTATTGCTCAGCGGTAAGCTT 
CCA_rev 
AAGCTTACCGCTGAGCAATAACTAGTAATTACAGAAGTAGCTTCCTTTGATA
TACAAAAGATTGGCTATAGTGAGTCGTATTAGTCGAC 
TCA_fwd 
GTCGACTAATACGACTCACTATAGTCAATCTTTTGTATATCAAAGGAAGCTA
CTTCTGTAATTACTAGTTATTGCTCAGCGGTAAGCTT 
TCA_rev 
AAGCTTACCGCTGAGCAATAACTAGTAATTACAGAAGTAGCTTCCTTTGATA
TACAAAAGATTGACTATAGTGAGTCGTATTAGTCGAC 
TTG_fwd 
GTCGACTAATACGACTCACTATAGTTGATCTTTTGTATATCAAAGGAAGCTA
CTTCTGTAATTACTAGTTATTGCTCAGCGGTAAGCTT 
TTG_rev 
AAGCTTACCGCTGAGCAATAACTAGTAATTACAGAAGTAGCTTCCTTTGATA
TACAAAAGATCAACTATAGTGAGTCGTATTAGTCGAC 
 
Table 3.9: RNA oligonucleotides  
Name Sequence 5'-3' Description 
Repeat_30 GUUUUUAUCGUACCUAUGAGGAAUUGAAAC 30 nt repeat sequence 
dRepeat_30 GUUUUUAUCGUACCUAUGAGGdAAUUGAAAC 
30 nt repeat sequence 
with dNTP substitution  
Repeat_37 
GUUGAAGUGGUACUUCCAGUAAAACAAGGAUUGAAA
C 
37 nt repeat sequence 
dRepeat_37 
GUUGAAGUGGUACUUCCAGUAAAACAAGdGAUUGAA
AC 
37 nt repeat sequence 
with dNTP substitution  
Repeat_WT_
f 
UCGUACCUAUGAGGAAUUGAAACC Shortened 30 nt repeat  
Repeat_WT_
r 
GGUUUCAAUUCCUCAUAGGUACGA 
Shortened 30 nt repeat 
reverse 
Repeat_left_f UCGUACCUGUAAGGAAUUGAAACC 
Shortened 30 nt repeat 
with GA substitution 
Repeat_left_r GGUUUCAAUUCCUUACAGGUACGA 
Shortened 30 nt repeat 
with GA substitution 
reverse 
Repeat_right
_f 
UCGUACCUAUGAGAACUUGAAACC 
Shortened 30 nt repeat 
with AC substitution 
Repeat_right
_r 
GGUUUCAAGUUCUCAUAGGUACGA 
Shortened 30 nt repeat 
with AC substitution 
reverse 
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3.4 Working with DNA 
3.4.1 Preparation of plasmid DNA from E. coli 
Plasmid DNA was prepared from E. coli overnight cell cultures using the QIAGEN 
Plasmid Mini kit and the QIAGEN Plasmid Maxi-Plus kit (QIAGEN) according to the 
manufacturer’s instructions.  
3.4.2 Phenol/chloroform extraction of DNA 
For DNA preparations from DNA/protein solution, the sample was mixed with 1 volume 
of phenol/chloroform (1:1) and vortexed for 1 min. After centrifugation for 1 min at 15,000 
x g at RT, the upper aqueous phase was carefully transferred into a fresh tube. 1 voulme of 
chloroform was added to the sample, vortexed for 1 min and centrifuged again for 1 min at 
15,000 x g at RT. Subsequently, the upper aqueous phase was transferred into a fresh tube 
and DNA precipitation was performed (3.4.3) 
3.4.3 DNA precipitation 
DNA preparations were concentrated via ethanol or isopropanol precipitation 120. 2 
volumes of 100 % ethanol (v/v) and 0.1 volume of 3 M Na-acetate were added to the 
sample and incubated for at least 30 min at -20°C. The sample was centrifuged at 12,000 x 
g for 10 min at RT. Afterwards, the supernatant was removed and the DNA pellet was 
washed with 70 % ethanol (v/v) and centrifuged again. This procedure was repeated, the 
supernatant was discarded, and the DNA pellet was dried for 5 min at RT. The pellet was 
resuspended in 30-300 µl of ddH2O.  
 
3.4.4 Quantitative and qualitative analysis of DNA 
The concentration of DNA preparations in aqueous solutions was measured 
photometrically at a wavelength of λ=260 nm using a spectrophotometer (NanoDrop, 
Thermo Scientific, Wilmington, USA). The A260/A280 ratio provides information on the 
purity oft the DNA. Sufficiently pure DNA preparations showed a ratio of ~ 1.8. Lower 
ratios indicated contamination with protein or phenol. 
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3.4.5 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis of DNA molecules (plasmid DNA and PCR products) was 
carried out to determine their size and amount. Agarose gels with 1 % to 1.5 % (w/v) 
agarose in TAE buffer (40 mM Tris-acetate, 1 mM EDTA pH 8) and 0.5 µg/mL ethidium 
bromide were prepared depending on the size of the analyzed DNA fragments. Before the 
DNA samples were applied into the sample wells of the gels, they were mixed with loading 
dye (6x stock: 0.2 % bromphenol blue, 0.2 % xylene cyanol FF, 60 % (v/v) glycerol, 60 
mM EDTA pH 8). 5 µl of 2-Log DNA ladder (New England Biolabs) were also applied on 
each gel. Electrophoresis was performed at 80-120 V at RT in TAE buffer. The DNA was 
visualized by UV irradiation at 254 nm (BioDocd-IT system, UVP).  
3.4.6 Purification of DNA fragments 
3.4.6.1 Gel extraction of agarose gels 
For the extraction and purification of DNA fragments from agarose gels, DNA fragments 
were sliced out of the gel. Afterwards, the QIAquick gel extraction kit (QIAGEN) was 
used according to the instructions of the manufacturer. After dissolving the DNA from the 
gel matrix by incubation for 10 min at 50°C, the DNA bound to a silica gel column was 
washed several times and eluted in 25-50 µl ddH2O.  
3.4.6.2 Purification of PCR fragments 
For purification of PCR fragment from the PCR assay, the QIAquick PCR purification kit 
(QIAGEN) was used according to the instructions of the manufacturer. The DNA bound to 
a silica gel column was eluted in 25-50 µl ddH2O. 
3.4.7 Polymerase chain reactions (PCR) 
The PCR technique was utilized for the exponential amplification of DNA 124, 125. 
Appropriate PCR primers for standard PCR were designed using the PCR primer design 
tool from MWG Operon (www.eurofinsdna.com). For manually designed primers the 
melting temperature was calculated using the following formula 126: 
Tm= 64.9 + 41 x (nG+nC-16.4)/(nA+nT+nG+nC) 
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3.4.7.1 Amplification of genomic DNA and plasmid DNA 
The PCR amplifications were performed using 50-100 ng of template DNA (genomic or 
plasmid DNA), 1 µM of each primer (forward and reverse), 200 µM dNTPs and 1 µl 
dimethyl sulfoxide (DMSO) in a 50 µl reaction volume. The reaction buffer of the Phusion 
polymerase (Finnzymes) supplied by the manufacturer was used. 1 U of the phusion 
polymerase was added directy to the sample prior to the PCR reaction that was carried out 
in a thermal cycler (BioRad). Standard cycling conditions are shown in table 3.10 and 
optimal cycling conditions were determined empirically for each DNA fragment. 
Table 3.10: Standard PCR assay using Phusion polymerase 
 Step 1 Step 2-31 Step 32 
Denaturing 98°C, 5 min 98°C, 30 sec  
Annealing  Tm+3°C, 30 sec  
Elongation  72°C, 15-13 sec/kb 72°C, 10 min 
 
3.4.7.2 PCR mutagenesis 
Designed primer sets were used to introduce desired restriction sites at the 5' ends of DNA 
fragments. The restriction site overhang was considered in the calculation of the melting 
temperature of the primers.  
 
3.4.7.3 Site-directed mutagenesis of plasmid DNA (Quik Change PCR) 
Site directed mutagenesis was used to introduce mutations into plasmid DNA. Mutagenic 
primers were designed using the QuikChange Primer Design Program from Stratagene 
(www.stratagene.com) that contain the desired mutation, flanked by non-mutated 
sequences. 2 PCR reactions are carried out that contain 50 ng of the plasmid, 0.2 µM dNTP 
mix, 2 U of Phusion polymerase and 1 x of the corresponding polymerase buffer. Each 
reaction contains one of the mutagenic primers in a 0.8 µM concentration. After 
denaturation at 98°C for 1 min, 10 cycles followed of 98°C for 1 min; 1 min of the 
respective annealing temperature and 72°C for 3.5 min. Both samples were pooled and 
subjected to 18 cycles using the same conditions. The methylated template DNA was 
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digested with 20 U of the methylation specific restriction endonuclease DpnI for 8 h at 37 
°C. Afterwards, 2.5 µl, of the non-methylated intact PCR product was directly transformed 
into chemically competent E. coli DH5α cells. 
 
3.4.8 Enzymatic modification of DNA 
3.4.8.1 Restriction of DNA 
Plasmid DNA and PCR products were designed using the respective restriction 
endonucleases (New England Biolabs) in appropriate buffers following the instructions of 
the manufacturer. The reaction mixture usually contained 5-20 U enzyme/µg DNA and 
were incubated at 37°C for 2 h. 
3.4.8.2 5'-dephosphorylation of linearized vector-DNA 
In order to avoid re-ligation of the digested plasmid DNA during the ligation reaction, 
Antarctic Phosphatase (New England Biolabs) treatment was used to remove the 5'-end 
phosphoryl groups. 1 U/ng DNA of Antarctic Phosphatase was added to the restriction 
mixture which was then further incubated at 37°C for 30 min. Afterwards, the phosphatase 
was inactivated by incubating of the sample for 5 min at 65°C. 
3.4.8.3 Ligation 
Ligation of restricted DNA fragments into vector DNA was performed using T4 DNA 
ligase 127. 50 ng of digested, dephosphorylated plasmid DNA and ~150 ng of digested 
insert DNA (ration 1:3) were mixed. 200 cohesive end units of the T4 DNA ligase and 1 x 
supplied reaction buffer were added in a reaction volume of 20 µl and incubated overnight 
at 16°C. After inactivation of the T4 DNA ligase for 10 min at 70°C, the recombinant 
vector molecules were used for transformation. 
For the generation of recombinant pec-A-HI-SUMO vectors, the respective inserts and 
linearized vector were processed with T4 DNA Polymerase LIC qualified (Novagen) 
according to the protocol of Prof. Dr. Elena Conti (MPI Munich) and subsequently ligated 
with a 2:1 insert:vector ratio. 
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3.4.8.4 Annealing of DNA oligonucleotides 
1 or more sets of DNA oligonucleotides in forward and reverse direction were designed to 
contain the desired DNA sequence, flanked by terminal restriction sites that form sticky 
ends after annealing. 1 nmol of each oligonucleotide was 5'-phosphorylated in separate 
reactions that contained 50 U of T4-polynucleotide kinase (PNK), 1 x of the corresponding 
reaction buffer, and 10 mM ATP in 20 µl reaction volume. After incubation for 1 h at 
37°C, 1 µl of the phophorylated forward primer was mixed with 1 µl of the corresponding 
phosphorylated reverse primer together with 1 U of T4 DNA ligase and 1 x of the 
respective reaction buffer in a 10 µl reaction volume. The samples were incubated for 5 
min at 95°C on a heating block and then gradually cooled down over 2-3 h to RT. 4 µl of 
the hybridization mix was then ligated into appropriate vectors as described in 3.5.8.3 or 
directly used for in vitro run-off transcription (3.5.3). 
3.4.9 Transformation 
3.4.9.1 Preparation of chemical competent E. coli cells 
Competent cells of all used E. coli strains were treated with CaCl2 and RbCl (rubidium 
chloride). Therefore, 0.25 mL of an E. coli overnight culture was used for inoculation of 25 
mL LB medium. Cells were incubated at 37°C and 200 rpm up to an OD600 of 0.3-0.5. 
Then, the culture was centrifuged at 2,300 x g for 10 min at 4°C and after discarding the 
supernatant, the cell pellet was gently resuspended in 10 mL of ice-cold solution A (10 
mM MOPS, 50 mM RbCl, 50 mM CaCl2) and subsequently pelleted again. The cell pellet 
was gently resuspended in 10 mL of ice-cold solution B (100 mM MOPS, 50 mM CaCl2, 
10 mM RbCl, pH 6.5) and incubated for 30 min on ice. The solution was centrifuged at 
700 x g for 15 min at 4°C and the competent cells were carefully resuspended in 2 mL of 
ice cold solution B and 40 % glycerol and stored at -80°C for several months.  
 
3.4.9.2 Transformation of competent E. coli cells 
Plasmid DNA was gently mixed with 200-300 µl of competent E. coli cells (3.5.9.1). After 
incubation on ice for 1 h, the cells were subjected to a heat shock at 42°C for 45 sec and 
subsequently placed on ice. 1 mL of LB medium was added to the sample which was then 
incubated at 38°C for 1 h at 200 rpm. 100 µl of the freshly transformed cells were plated 
on LB agar plates that contained the respective antibiotics. The remaining cells were 
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pelleted and carefully resuspended in 100 µl of LB medium prior to plating. The LB agar 
plates were incubated at 37°C overnight and colonies were screened for positive clones 
that contained the recombinant plasmid. 
 
3.4.10 Sequencing 
Automated sequencing of DNA 128 was performed by Eurofins MWG GmbH (Ebersberg). 
Primer sets that were used in addition to the standard sequencing primers from MWG 
operon for sequencing of cas genes as well as codon-optimized cas genes from C. 
Thermocellum over 1.5 kb are listed in table 3.11. 
Table 3.11: Additional primers used for sequencing 
Primer  Sequence 5'-3‘ Primer binding site 
Cas3_seq_rev TCTGTCAAGCCTCTCCTTC 
Position 1653-1671 in 
Cas3 ORF 
Cas8b_seq_fwd ATCCTGTCTGTTCTTGTTGC 
Position 694-713 in Cas8b 
ORF 
Cas3_co_seq_fwd ATTCGCATGGCGGAATGG 
Position 760-778 in codon-
optimized Cas3 ORF 
Cas8b_co_seq_rev CGAAATTGCCTTCGGTTTTATTGT 
Position 1192-1216 in 
codon-optimezed Cas8b 
ORF 
 
3.4.11 5'- terminal radioactive labeling of DNA 
Single-stranded DNA oligonucleotides, synthesized by MWG Operon were used for 
radioactive labeling. 5 pmol of the respective template was mixed with 5 pmol of γ[32P]-
ATP (Hartmann Analytic), 10 U of T4 PNK and 1 x of the corresponding reaction buffer 
were mixed in a reaction volume of 10 µl and incubated for 1 h at 37°C. 
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3.4.12 Denaturing polyacrylamide gel electrophoresis of radiolabeled DNA 
Denaturing 8 M urea, 12 % polyacrylamide TBE gels (mixed in a 40 mL volume with the 
addition of 0.1 % (v/v) APS and 0.01 / (v/v) TEMED. Gels were placed into a gel chamber 
(PROTEAN II Electrophoresis Chamber, BioRad). Prior to loading onto the gel, the 
reactions were mixed with 1 volume of formamide loading buffer (100 % formamide, 0.01 
% bromphenol blue, 0.01 % xylene cyanol FF) and incubated at 95°C for 5 min. The 
separation was carried out for 1-2 h at 12 W, depending on the size oft the DNA fragments. 
3.4.13 Detection of radiolabeled DNA by phosphorimaging 
Gels were put into plastic bags and subsequently exposed to phosphor screens overnight at 
-20°C. The Storm 840 phosphorimager was used to visualize the bands on the phosphor 
screens. 
3.4.14 Extraction of radiolabeled DNA from urea-polyacrylamide gels 
After determining the location of the desired DNA fragments by phosphorimaging, the 
respective bands were cut out from the gel and dissolved in 500 µl of gel elution buffer (20 
mM Tris/HCl pH 7.5, 250 mM sodium acetate, 1 mM EDTA, 0.25 % SDS) using a fresh 
reaction tube. The samples were incubated for 30 min at -20°C and then placed on ice on a 
shaker overnight. After pelleting the gel pieces (1 min, 13,000 rpm, RT), the supernatant 
was transferred into a fresh reaction tube. After EtOH precipitation, the activity of 
radiolabeled nucleid acid was measured in a scintillation counter (Beckmann LS 6500). 
 
3.5 Working with RNA 
3.5.1 Treatment of solutions, glassware and equipment 
0.1 % (v/v) diethyl pyrocarbonate (DEPC) was mixed with all applied buffers and 
solutions, incubated overnight at RT and autoclaved to ensure protection against RNases. 
Glassware and tubes were sterilised at 210°C for 2 h before use. Equipment that is not 
heat-resistant was treated with 3 % RNase Exitus Plus (Applichem).  
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3.5.2 Isolation of small and total RNA from C. thermocellum 
For the preparation of small RNAs, the mirVanaTM miRNA Isolation Kit (Ambion) was 
used. 0.1 g of pelleted cells were resuspended in 0.9 mL lysis/binding buffer. After 
incubation with lysozyme for 20 min on ice, the cells were sonicated (Branson Sonifier 
250, Danbury, CT, USA). The sample was centrifuged for 10 min at 4°C and 13.000 rpm 
and the supernatant was transferred to a fresh reaction tube for phenol/chloroform 
extraction. In order to separate the small RNAs (up to 200 nt) from the total RNA, the 
large RNAs were immobilized on the glass-fiber filter at a 25% ethanol concentration. 
Small RNAs were collected in the filtrate. Then, the ethanol concentration was increased to 
55% in the filtrate and passed through a second glass-fiber filter to immobilize small 
RNAs. Both RNA fractions were washed and subsequently eluted using 100 µl elution 
solution. 
3.5.3 In vitro run-off transcription 
To generate RNA transcripts in vitro, run-off transcription was carried out using linearized 
plasmids (table 3.4 and 3.6) or hybridized oligonucleotides (table 3.7) that contained a T7 
RNA promoter sequence as DNA templates. The reaction mixtures contained 40 mM 
Hepes/KOH, pH 8, 22 mM MgCl2, 5 mM dithiothreitol (dTT), 1 mM spermidine, 4 mM of 
each NTP, 20 U RNase Inhibitor, 30 nM T7 RNA polymerase and 50 µg/mL linearized 
plasmid or 10-20 µg/mL hybridized oligonucleotides. The reaction volume varied from 20 
µl up to 10 mL. The reaction mixture was incubated for 3–4 h at 37 °C. Afterwards, the 
samples were subjected to phenol/chloroform extraction and ethanol precipitation, 
followed by denaturing polyacrylamide gel electrophoresis, gel-extraction and ethanol 
precipitation before usage.  
3.5.4 Denaturing polyacrylamide gel electrophoresis and gel extraction of RNA 
Electrophoretic separation of RNA fragments obtained via in vitro transcription was 
performed using 8 M urea, 12 % polyacrylamide gels as described for radiolabeled DNA 
(3.4.12). The low range ssRNA ladder was used as a size standard. The gels were stained 
with a 0.1 % toluidine blue solution for 5 min and subsequently destained using water. The 
RNA fragments of choice were sliced out of the gel and transferred into a fresh reaction 
tube. Extraction of the RNA from the gel pieces was performed as described for 
radiolabeled DNA (3.4.14).  
 ______________________________________________________________________Material and Methods 
67 
 
3.5.5 RNA precipitation and quantitative and qualitative analysis of RNA 
Precipitation of small RNA transcripts was performed as described for DNA in 3.4.3 with 
the exception that glycerol was added to the sample mixed with 100 % ethanol in a 1/100 
ratio. Quantitative analysis of the RNA was carried out as described for DNA in 3.4.15. 
Sufficiently pure RNA samples showed a A260/A280 ratio higher than 1.8. A lower ratio 
indicates protein or phenol contaminations of the preparation. 
3.5.6 5'- terminal radioactive labeling of RNA 
Single-stranded RNA oligonucleotides (MWG Operon), as well as RNA transcripts 
generated via in vitro run-off transcription, were used for 5'-terminal radioactive labeling 
with γ[32P] in a T4 PNK reaction as described for DNA in 3.4.11. One exception to the 
protocol is that RNA transcripts were 5'-dephosphorylated as described in 3.5.8.2 prior to 
labeling. 
3.5.7 RNA-sequencing 
3 µg of small RNA from C. thermocellum was incubated for 3 h at 37°C with 20 U T4-
PNK and 1 x of the respective reaction buffer to obtain dephosphorylation of 2'-3'-cyclic 
phosphate termini. Then, 2 mM ATP and another 10 U of T4 PNK were added to the 
mixture and incubated for 1 h at 37°C to generate monophosphorylated 5'-termini. The 
preparation of the RNA libraries was carried out using an Illumina TruSeq RNA Sample 
Prep Kit. Sequencing on an Illumina HiSeq2000 sequencer was performed at the Max 
Planck Genomecentre, Köln (Max Planck Institute for Plant Breeding Research). 
3.5.8 Identification of crRNA abundance 
Sequencing reads were trimmed by the removal of Illumina TruSeq linkers and poly-A 
tails as well as the removal of sequences using a quality score limit of 0.05. The trimmed 
reads were mapped to the reference genome of C. thermocellum (GenBank: CP000568) 
with CLC Genomics Workbench 5.0 (CLC Bio, Aarhus, Denmark). The following 
mapping parameters were used: mismatch cost: 2, insertion cost: 3, deletion cost: 3, length 
fraction: 0.5, similarity: 0.8. Additionally, reads <15 nt were removed. Gene annotations 
were obtained from GenBank. 
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3.6 Biochemical methods 
3.6.1 Heterologous production of C. thermocellum proteins in E. coli 
For the heterologous production of proteins from C. thermocellum, the respective genes 
that were cloned with the T7 RNA polymerase pET vector system (Novagen) and the pec-
A-HI-SUMO vector were used. The heterologous expression was performed in E. coli 
BL21(DE)pLysS and Rosetta(DE)pLysS strains as described in 3.3.1. The pLys plasmid 
encodes T7 lysozyme which is a natural inhibitor of the T7 RNA polymerase. The 
transformed vector constructs are under the control of a T7 lac promoter which can be 
induced by the addition of IPTG. The used E. coli strains ensure minimal low-level 
expression of the genes before IPTG induction. Culture conditions are described in 3.2.1. 
3.6.2 Enrichment and purification of recombinant enzymes 
3.6.2.1 Enrichment of recombinant Cas8b protein 
Recombinant E. coli Rosetta(DE)pLysS cells were resuspended in chilled buffer 1 (100 
mM potassium phosphate pH 7.5, 500 mM NaCl and 1 mM ß-Me) and incubated with 1.5 
mg lysozyme for 30 min on ice. Cells were sonicated 6 x 30 sec (40 % duty cycle, output 
control 4, Branson Sonifier 250) unbroken cells and cell debris were removed via 
ultracentrifugation (30,000 x g, 4°C, 30 min). The protein solution was injected into an 
FPLC system (ÄKTApurifierTM, GE Healthcare) and purified via affinity chromatography 
using a nickel-NTA column (HisTrap HP, GE Healthcare). The column was equilibrated 
for 10 min with a flow-rate of 1 mL/min in buffer 1, and the protein was loaded onto the 
column (10 min; flow rate 1 mL/min). Afterwards, the protein solution was washed with 
buffer 1 for 10 min at 1 mL/min, buffer 2 (50 mM KCl, 1000 mM NaCl, 10 mM MgSO4 
and 2 mM ATP) for 5 min at 1 mL/min and again buffer 1 for 10 min. The protein was 
eluted from the column using buffer 3 (500 mM NaCl, 100 mM potassium phosphate pH 
7.5, 1 mM ß-Me and 500 mM imidazole) with a linear imidazole gradient (0-500 mM, 20 
min, 1mL/min). Fractions that contained protein were identified via absorption at 280 nm 
wavelength. The 1 mL peak fractions were collected and analyzed via SDS-PAGE (3.6.3). 
The fractions that contained Cas8b protein were pooled and dialysed in buffer 4 (50 mM 
Tris/HCl pH 7.5, 1mM dTT and 100 mM NaCl) overnight at 4°C. The protein solution was 
concentrated with Amicon filters units (Amicon Ultra-15, 30,000 MW, Millipore) to a 
volume of 10 mL and further purified using cation-exchange chromatography with a 
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Heparin column (HiTrap Heparin HP, GE healthcare). The solution was loaded onto the 
column (equilibration with purification buffer 4, 10 mL; 1 mL/min) and directly eluted 
with a linear salt gradient of 100-1000 mM NaCl for 20 min, 1mL/min using buffer 5 
(50 mM Tris/HCl pH 7.5, 1 mM dTT and 1000 mM NaCl). The 1 mL peak fractions were 
collected and analyzed by SDS-PAGE (3.6.3). 
3.6.2.2 Enrichment of recombinant Cas7 protein 
Recombinant E. coli Rosetta(DE)pLysS cells were resuspended in chilled buffer 1 (100 
mM potassium phosphate pH 7.5, 500 mM NaCl and 1 mM ß-Me) and incubated with 1.5 
mg lysozyme for 30 min on ice. Cells were sonicated 6 x 30 sec (40 % duty cycle, output 
control 4, Branson Sonifier 250) unbroken cells and cell debris were removed via 
ultracentrifugation (30.000 x g, 4°C, 30 min). The protein solution was injected into an 
FPLC system (ÄKTApurifierTM, GE Healthcare) and purified via affinity chromatography 
using a nickel-NTA column (HisTrap HP, GE Healthcare). The column was equilibrated 
for 10 min with a flow-rate of 1 mL/min in buffer 1, and protein was loaded onto the 
column (10 min; flow rate 1 mL/min). Afterwards, the protein solution was washed with 
buffer 1 for 10 min at 1 mL/min, buffer 2 (50 mM KCl, 1000 mM NaCl, 10 mM MgSO4 
and 2 mM ATP) for 5 min at 1 mL/min and again buffer 1 for 10 min. Afterwards the 
protein was eluted from the column using buffer 3 (500 mM NaCl, 100 mM potassium 
phosphate pH 7.5, 1 mM ß-Me and 500 mM imidazole) with a linear imidazole gradient 
(0-500 mM, 20 min, 1mL/min). Fractions that contained protein were identified via 
absorption at 280 nm wavelength. The 1 mL peak fractions were collected and analyzed 
via SDS-PAGE (3.6.3). The fractions that contained Cas7 protein were pooled.  
3.6.2.3 Enrichment of recombinant Cas5 protein 
Recombinant E. coli Rosetta(DE)pLysS cells were resuspended in chilled buffer 1 (100 
mM potassium phosphate pH 7.5, 500 mM NaCl and 1 mM ß-Me) and incubated with 1.5 
mg lysozyme for 30 min on ice. Cells were sonicated 6 x 30 sec (40 % duty cycle, output 
control 4, Branson Sonifier 250) unbroken cells and cell debris were removed via 
ultracentrifugation (30,000 x g, 4°C, 30 min). The protein solution was injected into an 
FPLC system (ÄKTApurifierTM, GE Healthcare) and purified via affinity chromatography 
using a nickel-NTA column (HisTrap HP, GE Healthcare). The column was equilibrated 
for 10 min with a flow-rate of 1 mL/min in buffer 1, and the protein was loaded onto the 
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column (10 min; flow rate 1 mL/min). Afterwards, the protein solution was washed with 
buffer 1 for 10 min at 1 mL/min, buffer 2 (50 mM KCl, 1000 mM NaCl, 10 mM MgSO4 
and 2 mM ATP) for 5 min at 1 mL/min and again buffer 1 for 10 min. Afterwards the 
protein was eluted from the column using buffer 3 (500 mM NaCl, 100 mM potassium 
phosphate pH 7.5, 1 mM ß-Me and 500 mM imidazol) with a linear imidazole gradient (0-
500 mM, 20 min, 1mL/min). Fractions that contained protein were identified via 
absorption at 280 nm wavelength. The 1 mL peak fractions were collected and analyzed 
via SDS-PAGE (3.6.3). The fractions that contained Cas5 protein were pooled.  
3.6.2.4 Enrichment of recombinant Cas3 protein 
Recombinant E. coli Rosetta(DE)pLysS cells were resuspended in chilled buffer 1 (100 
mM potassium phosphate pH 7.5, 500 mM NaCl and 1 mM ß-Me) and incubated with 1.5 
mg lysozyme for 30 min on ice. Cells were sonicated 6 x 30 sec (40 % duty cycle, output 
control 4, Branson Sonifier 250) unbroken cells and cell debris were removed via 
ultracentrifugation (30,000 x g, 4°C, 30 min). The protein solution was injected into an 
FPLC system (ÄKTApurifierTM, GE Healthcare) and purified via affinity chromatography 
using a nickel-NTA column (HisTrap HP, GE Healthcare). The column was equilibrated 
for 10 min with a flow-rate of 1 mL/min in buffer 1, then the protein was loaded onto the 
column (10 min; flow rate 1 mL/min). Afterwards, the protein solution was washed with 
buffer 1 for 10 min at 1 mL/min, buffer 2 (50 mM KCl, 1000 mM NaCl, 10 mM MgSO4 
and 2 mM ATP) for 5 min at 1 mL/min and again buffer 1 for 10 min. Afterwards the 
protein was eluted from the column using buffer 3 (500 mM NaCl, 100 mM potassium 
phosphate pH 7.5, 1 mM ß-Me and 500 mM imidazole) with a linear imidazole gradient 
(0-500 mM, 20 min, 1mL/min). Fractions that contained protein were identified via 
absorption at 280 nm wavelength. The 1 mL peak fractions were collected and analyzed 
via SDS-PAGE (3.6.3). The fractions that contained Cas3 protein were pooled and 
dialysed in 50 mM Hepes/KOH pH 7, 1mM dTT and 300 mM NaCl overnight at 4°C. 
3.6.2.5 Enrichment of recombinant Cas6 (Cthe_2303 and Cthe3205) proteins 
Recombinant E. coli BL21(DE)pLysS cells were resuspended in chilled buffer 1 (100 mM 
potassium phosphate pH 7.5, 500 mM NaCl and 1 mM ß-Me) and incubated with 1.5 mg 
lysozyme for 30 min on ice. Cells were sonicated 6 x 30 sec (40 % duty cycle, output 
control 4, Branson Sonifier 250) unbroken cells and cell debris were removed via 
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ultracentrifugation (30,000 x g, 4°C, 30 min). The protein solution was injected into an 
FPLC system (ÄKTApurifierTM, GE Healthcare) and purified via affinity chromatography 
using a nickel-NTA column (HisTrap HP, GE Healthcare). The column was equilibrated 
for 10 min with a flow-rate of 1 mL/min in buffer 1, then the protein was loaded onto the 
column (10 min; flow rate 1 mL/min). Afterwards, the protein solution was washed with 
buffer 1 for 10 min at 1 mL/min, buffer 2 (50 mM KCl, 1000 mM NaCl2, 10 mM MgSO4 
and 2 mM ATP) for 5 min at 1 mL/min and again buffer 1 for 10 min. Afterwards the 
protein was eluted from the column using buffer 3 (500 mM NaCl, 100 mM potassium 
phosphate pH 7.5, 1 mM ß-Me and 500 mM imidazole) with a linear imidazole gradient 
(0-500 mM, 20 min, 1mL/min). Fractions that contained protein were identified via 
absorption at 280 nm wavelength. The 1 mL peak fractions were collected and analyzed 
via SDS-PAGE (3.6.3). The fractions that contained Cas6 protein were pooled and 
dialysed in 50 mM Hepes/KOH pH 7, 1mM dTT and 300 mM NaCl2 overnight at 4°C. 
3.6.2.6 Enrichment of recombinant wildtype and mutant RNase III proteins 
Recombinant E. coli BL21(DE)pLysS cells were resuspended in chilled buffer 1 (50 mM 
Tris/HCl pH 7, 300 mM NaCl and 1 mM dTT) and incubated with 1.5 mg lysozyme for 30 
min on ice. Cells were sonicated 6 x 30 sec (40 % duty cycle, output control 4, Branson 
Sonifier 250) unbroken cells and cell debris were removed via ultracentrifugation (30,000 
x g, 4°C, 30 min). The protein solution was injected into an FPLC system 
(ÄKTApurifierTM, GE Healthcare) and purified via affinity chromatography using a nickel-
NTA column (HisTrap HP, GE Healthcare). The column was equilibrated for 10 min with 
a flow-rate of 1 mL/min in buffer 1, then the protein was loaded onto the column (10 min; 
flow rate 1 mL/min). Afterwards, the protein solution was washed with buffer 1 for 10 min 
at 1 mL/min and eluted from the column using buffer 2 (50 mM Tris pH 7, 300 mM NaCl, 
1 mM dTT and 500 mM imidazole) with a linear imidazole gradient (0-500 mM, 20 min, 
1mL/min). Fractions that contained protein were identified via absorption at 280 nm 
wavelength. The 1 mL peak fractions were collected and analyzed via SDS-PAGE (3.6.3). 
The fractions that contained wildtype or mutant RNase III protein were pooled and 
dialysed in 50 mM Tris pH 7, 1mM dTT and 300 mM NaCl overnight at 4°C. The protein 
solution was concentrated with Amicon filters units (Amicon Ultra-15, 30,000 MW, 
Millipore) to a volume of 10 mL and further purified using cation exchange 
chromatography with a Heparin column (HiTrap Heparin HP, GE healthcare) and eluted 
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with a linear salt gradient (100-1000 mM). The 1 mL peak fractions were collected and 
analyzed by SDS-PAGE (3.6.3). 
3.6.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Denaturing sodium dodecylsulphate (SDS) polyacrylamide gel electrophoresis (PAGE) 
was used for protein analysis 129. Polyacrylamide gels (10.5 x 11.5 x 1, Mini Protean 
system, BioRad) that comprise an upper stacking and a lower separation gel were used as 
support matrix in electrophoresis. The stacking gels (125 mM Tris/HCl pH 6.8, 0.1 % (v/v) 
SDS, 0.03 % (v/v) APS and 0.005 % TEMED) contained 6 % polyacrylamide, whereas 
separating gels (125 mM Tris/HCl pH 6.8, 0.1 % (v/v) SDS, 0.03 % (v/v) APS and 0.005 
% TEMED) were prepared with 12 % polyacrylamide. The ingredients of the separating 
gels were mixed and subsequently poured into the gel casting chamber. The gel was 
covered with ddH2O and polymerised. Afterwards, the stacking gel solution was poured on 
top and a 10-sample well was placed within the stacking gel. After polymerisation, the 
comb was removed and the freshly prepared gels were directly used for electrophoresis or 
stored at 4°C. The protein samples were mixed with 1 volume of 5 x loading buffer (100 
mM Tris/HCl pH 6.8, 40 % (v/v) glycerin, 10 % (v/v) ß-Me, 3.2 % (w/v) SDS, 0.2 % (w/v) 
bromphenol blue) and incubated at 95°C for 5 min for denaturation prior to loading on the 
gel. Gel runs were performed in a Mini-Protein Tetra Cell (Biorad) that contained 
electrophoresis buffer (25 mM Tris/HCl pH8, 190 mM glycine and 0.1 % (v/v) SDS) at 
200 V for 45 min. Proteins were visualized by gel staining (25 % (v/v) ethanol, 10 % (v/v) 
acetic acid, 0.25 % (v/v) Coomassie Brilliant Blue R-250) for 30 min at 37°C subsequently 
destained (5 % (v/v) methanol and 7.5 % (v/v) acetic acid) 130.  
3.6.4 Protein quantitation 
The Bio-Rad protein assay based on Bradford protein quantitation method 131 was used by 
following the instructions of the manufacturer to determine protein concentrations. Protein 
extinction was measured photometrically at 595 nm. Bovine serum albumin (BSA) 
concentrations of 2, 4, 6, 8 and 10 mg/mL served as a standard to create a calibration 
curve. 
3.6.5 Molecular mass determination of proteins under native conditions 
The approximate molecular mass of protein complexes was determined using gel-filtration 
chromatography. A gel-filtration Superdex column (Superdex 200 10/300GL, Separation 
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10.000 – 600.000 Da, volume: 24 mL, GE Healthcare) was used in a buffered solution (50 
mM Hepes/KOH pH 7, 1 mM dTT and 300 mM NaCl) and equilibrated (3 h, 0.3 mL/min) 
before sample loading. Prior to the analysis of protein complexes, a mixture of calibration 
proteins (with known molecular weight) was applied to the column. The elution volumes 
Ve were monitored for each protein and together with the exclusion volume (void volume) 
V0, a calibration curve was generated. The ratio of elution volume and exclusion volume 
Ve/Vo for each calibration protein is blotted against the size of the respective protein. The 
calibration curve is then used to calculate the molecular weight of the analyzed protein 
complexes. Appoferritin (used as Vo; MW 443,000 Da, 1 mg), ß-Amylase (MW 200,000 
Da, 1.125 mg), Alcohol Dehydrogenase (MW 148,000 Da, 1 mg), BSA (MW 66,000 Da, 
1 mg), Carbonic Anhydrase (MW 29,000 Da, 1.125 mg) and Cytochrome C (MW 12,400 
Da, 1 mg) were used as calibration proteins. 
3.6.6 Trichloroacetate precipitation of proteins 
Protein samples were supplied with 20 % (v/v) TCA to precipitate the proteins. After 
incubation for 10 min on ice, precipitated proteins were pelleted at 14,000 rpm for 5 min. 
The supernatant was discarded and the pelleted proteins were washed two times with 200 
µl of ice-cold acetone. Pellets were dried for 5 min at 95°C and subsequently solved in 50 
mM Tris/HCl pH 7.  
3.6.7 Assembly of recombinant Cas proteins 
For the assembly of the Cascade complex, the recombinant proteins Cas6 (C-terminal 6 x 
His-tag), Cas5 (N-terminal SUMO tag), Cas7 (N-terminal SUMO tag) and Cas8b (C-
terminal His-tag) were purified as described in 3.6.2. A 1:1:2 ratio of Cas5:Cas8b:Cas7 
protein was used for the assembly, depending on the amount of protein that was obtained 
from the individual purified preparations. Cas5 and Cas7 proteins were mixed together 
with 100 µl of SUMO protease and dialysed overnight in 50 mM Hepes/KOH pH 7, 1 mM 
dTT and 300 mM NaCl. Cas8b was added and the mixture was concentrated to a volume 
of ~ 2 mL using Amicon filters units (Amicon Ultra-15, 30.000 MW, Millipore) and 
centrifuged for 10 min at 14.000 rpm. Meanwhile, the respective RNA precursors were 
processed using the Cas6 endonuclease as described in 3.6.9 for 2 h at 37°C. 5 µM of Cas6 
was used in a total reaction volume of 2 mL to obtain 1.5 nmol of the respective crRNA 
variants. The Cas protein mixture and the endonuclease reaction were pooled and 
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incubated for 30 min at 50°C. Afterwards, precipitates were pelleted and the sample was 
concentrated to a volume of ~ 500 µl and subjected to gel-filtration chromatography using 
an equilibrated Superdex 200 column. The protein complexes were separated at a flow rate 
of 0.4 mL/min and 1 mL fractions were collected. Afterwards, the 1 mL fractions A7-B12 
(Ve: 6,6-12,6 mL) were further analyzed. From each fraction sample, 300 µl were used for 
TCA precipitation (3.6.6) and subsequent SDS-PAGE (3.6.3). 700µl of the fraction 
samples were used for phenol/chloroform extraction, ethanol precipitation (3.5.5) followed 
by urea-PAGE analysis (3.5.4). 
3.6.8 Cascade interference assay 
To test the cleavage of dsDNA, 5 pmol of ssDNA oligonucleotides (table 3.8) were 5'-
terminal radiolabeled (3.5.6), purified and hybridized with a 1.5-fold molar excess of the 
respective unlabeled complementary strand. Therefore, both DNA strands were mixed, 
heated up to 95°C for 5 min and slowly cooled down to RT in hybridization buffer (10 mM 
Tris pH 8, 1 mM EDTA, 100 mM NaCl). For the interference reaction, 500 nM assembled 
Cascade complex and 500 nM of Cas3 (C-terminal 6 x His-tag) were mixed in 50 mM 
Hepes/KOH pH7, 1 mM dTT, 300 mM NaCl, 5 mM MgCl2, 5 mM MnCl2 and 2 mM ATP 
in a 12 µl reaction volume. The reaction was started by adding 20,000 cpm of 5'-labeled 
hybridized dsDNA to the mixture that was incubated for 20 min at 50°C. To stop the 
reaction, EtOH precipitation was performed. Subsequently, the samples were loaded onto 
20 % denaturing polyacrylamide gels (3.5.4).  
3.6.9 Cas6 endonuclease assay 
1 µM of the respective Cas6 enzyme was incubated with 5'-terminal radiolabeled RNA 
(3.5.6) in 20 mM Hepes/KOH pH 8, 250 mM KCl, 2 mM MgCl2, in 10 µl reaction volume 
and incubated at 37°C for 10 min. Afterwards, the samples were mixed with 2 x 
formamide buffer and incubated at 95°C for 5 min. The reactions were then loaded on 12 
% denaturing polyacrylamide gels (3.5.4).  
3.6.10 RNase III cleavage assay 
5 pmol of ssRNA transcripts were 5'-terminal radiolabeled (3.5.6), purified and hybridized 
with 1.5-fold molar excess of the respective unlabeled complementary strand. Therefore, 
both strands were mixed, heated up to 95°C for 5 min and slowly cooled down to RT in 
hybridization buffer 10 mM Tris/HCl pH 7. For the cleavage reaction, 2 µM of the 
 ______________________________________________________________________Material and Methods 
75 
 
respective enzyme was incubated with the 5'-labeled hybridized dsRNA in 5 mM MgCl2, 1 
mM dTT, 20 mM KCl, 50 mM Tris/HCl pH 7 in a 10 µl reaction volume and incubated for 
5 min at 50 °C. The samples were mixed with 2 x formamide buffer and incubated for 5 
min. The reactions were loaded on 12 % denaturing polyacrylamide gels (3.5.6) alongside 
an two markers using an RNase T1 digest (cleaves after each G residue) and an alkaline 
hydrolysis marker (fragments RNA substrate) that were obtained using the RNase T1 
(Biochemistry Grade) Kit from Ambion according to the manufacturer’s instructions. 
3.6.11 Electromobility shift assay 
20,000 cpm of 5'-terminal radiolabeled crRNA substrate was used in each reaction with 50 
mM Tris/HCl pH 7, 1 mM dTT, 75 ng yeast RNA and indicated concentrations of 
assembled Cascade complex in a volume of 10 µl. The samples were incubated at 50°C for 
5 min, mixed with 2.5 µl GelPilot DNA loading dye (QIAGEN) and then loaded onto an 
8 % non-denaturing TBE polyacrylamide gel.  
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4. Discussion 
4.1 Cas6 processing and its association with Cascade 
Previous studies have shown that Cas6 endonucleases of different CRISPR-Cas subtypes 
generate mature crRNAs that comprise an 8 nt 5'-terminal repeat tag 24, 26, 47, 50-52, 132. 
Clostridium thermocellum contains two type I-B Cas6 endonucleases (Cthe_2303 and 
Cthe_3205). According to an older nomenclature, Cas6 Cthe_2303 is classified as type I-B 
“Tneap”, mainly found in bacteria, and Cas6 Cthe_3205 belongs to type I-B “Hmari” that 
is present in many archaea. Cas6 “Tneap” is associated with CRISPR clusters that contain 
30 nt long repeat elements, whereas Cas6 “Hmari” is associated with CRISPR loci that 
comprise repeats of 37 nt length. Both Cas6 enzymes generate crRNAs that comprise an 
8 nt 5'-terminal repeat tag, which is in agreement with the universal Cas6 processing 
pattern.  
Cas6 proteins are a heterogeneous group of endonucleases with highly diverse sequences, 
structures and catalytic site compositions. In addition, the sequence and secondary 
structures of the CRISPR repeats differ between the subtypes. Thus, Cas6 diversity might 
result from the adaptation to their respective repeat sequences and/or structures 50. 
Different mechanisms of Cas6 repeat RNA recognition have evolved. One general 
mechanism is exemplified by Cas6 from Pyrococcus furiosus (PfCas6) of type III-B. This 
enzyme is proposed to use a wrap-around mechanism, wherein unstructured repeats of long 
pre-crRNAs are bound in a bead chain-like manner and are subsequently processed 133. In 
contrast, the Cas6 enzymes of type I-E, found e.g. in Thermus thermophilus and E. coli, as 
well as of type I-F present in Pseudomonas aeruginosa, specifically recognize repeats that 
form hairpin structures 26, 51, 52, 56. As shown in section 2.2.1, Cas6 Cthe_2303 preferably 
cleaves the corresponding 30 nt repeat sequence, whereas Cas6 Cthe_3205 preferably 
processes the associated 37 nt repeat RNA. A hairpin structure was predicted to be formed 
in the 5'-terminal region of the 37 nt repeat using the “RNAfold” software (fig 2.21) 134. 
However, C. thermocellum is a thermophilic organism that grows at an elevated 
temperature of 60 °C. Considering this parameter in the RNA folding prediction showed 
that this four bp stem is unlikely to be retained. According to the CRISPRmap tree, a 
CRISPR repeat classification based on sequence and structure similarities that represents 
evolutionary relationships, both repeat sequences of C. thermocellum are not predicted to 
contain a conserved structure motif 12, indicating that the Cas6 repeat recognition is likely 
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not based on a conserved RNA structure. Furthermore, the two repeat sequences are 
classified into different superclasses. The 30 nt repeat belongs to superclass A, whereas the 
37 nt repeat is grouped into superclass E, indicating that the two types of CRISPR 
repeats/clusters are phylogenetically distant 12. Together with the finding that the two Cas6 
enzymes are diverse in sequence and mainly distributed in different prokaryotic domains, 
this underlines the hypothesis that Cas6 enzymes and the respective CRISPR repeat 
elements co-evolved.  
The archaeon Methanococcus maripaludis contains a single type I-B CRISPR-Cas system 
with a Cas6 endonuclease that is highly homologous to the Cas6 Cthe_3205 enzyme of 
Clostridium thermocellum (40 % aa identity and 62 % aa similarity). Furthermore, the 
CRISPR cluster of M. maripaludis contains 37 nt long, unstructured repeat elements that 
are classified into superclass E and are closely related to the 37 nt repeat elements of C. 
thermocellum. Together, these similarities in repeat sequences and Cas6 enzymes hint at a 
horizontal gene transfer event between archaea and bacteria and exemplify the mobility of 
CRISPR-Cas systems. In accordance with this, the Cas6 enzymes from M. maripaludis and 
C. thermocellum were shown to cleave both 37 nt repeat sequence (PhD thesis of Hagen 
Richter). The analysis of UV induced protein:RNA cross-links of Cas6 Cthe_3205 with the 
respective non-hydrolysable 37 nt repeat RNA and subsequent mass-spectrometry 
identified the methionine residue at position 184 of the protein to cross-link with a uridine 
base in a UGA sequence of the repeat as described in section 2.4.7. Using the same 
technique, the homologous methionine residue 185 of the Cas6 protein from M. 
maripaludis was identified to cross-link with UUGC of the repeat RNA and shown to be 
involved in RNA binding as the mutation of the respective residue resulted in a decreased 
binding affinity (PhD thesis of Hagen Richter). Recently, the co-crystal structure of Cas6 
from M. maripaludis with non-hydrolysable repeat RNA was obtained (Richter et al., 
unpublished). The data support a model wherein Cas6 dimerizes upon substrate binding 
and reshapes the RNA to form a 2-base pair stem-loop immediately upstream of the 
cleavage site. Similar base pairs that would also form this stem-loop can be observed in the 
C. thermocellum repeat. However, the RNA cross-link site UUGC at position 14-17 in the 
37 nt repeat from M. maripaludis is not identical with any of the eight possible cross-
linked UGA positions in the 37 nt repeat RNA of C. thermocellum. Therefore, the two 
Cas6 enzymes might display variations in repeat recognition.  
 _______________________________________________________________________________Discussion 
78 
 
After pre-crRNA processing, type I-E Cas6 endonucleases stay bound to the 3'-terminal 
end of mature crRNAs with a hairpin structure, forming the head of Cascade after complex 
assembly 52, 54. Consequently, the crRNAs harbor complete 3'-tags. This was also shown 
for type I-F systems which contain similar structured repeat elements 26. In contrast to this, 
all type III as well as type I-A and I-D systems comprise crRNAs with trimmed 3'-ends 43, 
135, 136. Here, the Cas6 homologues deliver the crRNAs to the crRNP complexes and are not 
associtaed as permanent subunits 43, 136. It has been proposed that the presence or absence 
of stem-loop structures in the repeats correlates with the varying Cas6 affinity to the 
crRNA 53. In C. thermocellum, the unstructured 3'-terminal repeat tags of mature crRNAs 
are trimmed as described in section 2.2.2. Together with the fact that the type I-B Cascade 
can be assembled in the absence of Cas6, this indicates that Cas6 is only a temporarily 
associated member of the complex. It was shown in section 2.4.3 that the Cascade 
assembly efficiency using a crRNA with a shortened 3'-terminal repeat tag is much lower 
than for a wildtype crRNA. Nevertheless, all crRNAs that were isolated from C. 
thermocellum and analyzed via RNA-Seq methodology harbored trimmed 3' ends. Hence, 
it is possible that in vivo crRNAs with intact 3'-termini are preferred for the initial Cascade 
assembly but once a stable complex is formed, Cas6 dissociates which results in the loss of 
3'-end protection and crRNA trimming occurs. Additionally, crRNA cycling could occur, 
wherein the stable complexes would exchange the crRNAs with other trimmed crRNAs. 
This crRNA cycling ability of the type I-B Cascade could be shown by the electrophoretic 
mobility shift assays that were performed using fully assembled Cascade complexes that 
containing unlabeled crRNA and showed binding of the added radiolabeled crRNA.  
To address the question, whether crRNAs that are associated with the different type I-B 
C. thermocellum CRISPR systems can be loaded into either of the two Cascade complexes, 
the investigated recombinant type I-B “Hmari” Cascade was assembled with Cas6 
Cthe_2303 and crRNA of the type I-B “Tneap” system. Cas6 cleavage of the pre-crRNA 
substrate with 30 nt long repeats yields a mature crRNA that contains an 8 nt 5'-terminal 
repeat tag that is identical in sequence with the 8 nt 5'-terminal tag of the crRNAs 
associated with the “Hmari” CRISPR system. The experiment revealed an assembled type 
I-B “Hmari” complex including the Cas6 endonuclease of type I-B “Tneap” with low 
amounts of the respective crRNA. Compared to the wildtype assembly, a great amount of 
protein elutes at the void volume indicating protein complex sizes >600 kDa. The 
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corresponding fractions A7 / A8 contain oligomerized Cas7 protein. Cas7 proteins have 
been shown to multimerize by RNA binding independent of the sequence, forming long 
helical filaments 43. It is possible that Cas7 oligomerized along unspecific E. coli RNA that 
was co-purified with the recombinantly produced Cas proteins that is too long to be 
detected in the performed urea-PAGE. A relatively large amount of monomeric Cas7 
protein can be observed and only a small amount of crRNA can be detected in the urea-
PAGE. This indicates low affinity of the Cas proteins to the respective crRNA. Unbound 
crRNA was probably lost during concentration of the assembly mixture volume, prior to 
gel-filtration chromatography. The crRNA used for the assembly contains a spacer 
sequence of a CRISPR locus associated with the type I-B “Tneap” Cas6 endonuclease 
Cthe_2303 and therefore differs from the spacer sequence of the crRNAs used in all other 
assembly experiments. It has been proposed that the variations of crRNA abundance 
observed in vivo is influenced by varying processing and Cascade loading efficiency of 
crRNAs due to the spacer content 101, 137, 138. Hence, the spacer sequence could have an 
impact on the efficiency of Cascade assembly. A complementary assembly experiment 
using the type I-B “Tneap” Cascade with the Cas6 endonuclease Cthe_3205 and a crRNA 
of type I-B “Hmari” could be performed to further investigate the interchangeability of 
crRNAs between the associated Cascade complexes in C. thermocellum. 
 
4.2 Assembly of the type I-B Cascade 
Type I Cascade complexes can differ in their composition with permanently and 
temporarily associated subunits. The type I-E and I-F Cascade complexes consist of the 
permanent subunits (Cas6)1, (Cas5)1, (Cas7)6 and the respective large and small subunits of 
type I-E (Cse1)1 and (Cse2)2 or of type I-F (Csy1)1 in an uneven stoichiometry. The Cas3 
proteins of both subtypes are transiently recruited for target cleavage 27, 49, 55, 58, 59. 
Similarly, the type I-C Cascade is composed of (Cas7)6, the large subunit (Cas8)1, and 
(Cas5)2, wherein Cas5 also performs pre-crRNA cleavage in a Cas6-like manner 48. In 
contrast, in type I-A CRISPR systems, Cas6 is not an integral part of the core complex, 
whereas Cas3 is a permanent subunit together with Cas7, Cas5 and the proposed small and 
large subunits Csa5 and Cas8 43, 46. The type I-B Cascade of C. thermocellum is formed by 
(Cas5)1, (Cas7)6 and (Cas8b)2.5 and shown to bind crRNA. Cas3 was shown not to 
assemble with the complex (Mastermodule of Franka Schreiner). It has been reported that 
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target DNA binding induces a protein rearrangement of the type I-E large and small 
subunits that enables Cas3 recruitment 60, 64. Therefore, it is possible that the type I-B Cas3 
protein is also recruited to Cascade after target DNA recognition. The (Cas6)1 
endonuclease of C. thermocellum seems to be temporarily associated with the complex, as 
a small amount of protein assembles with the Cascade forming Cas proteins, but is not 
required for proper complex formation. This is in agreement with the Cascade interprotein 
cross-link analysis which revealed only one interprotein contact between Cas6 and Cas7 as 
well as Cas8b. The analysis of the type I-B CRISPR system in Haloferax volcanii showed 
that the type I-B Cascade interference reaction is independent of the presence of Cas6 in 
the complex in vivo 139.  
The assembly of recombinant Cascade was shown to strongly depend on the presence of 
crRNA. Without the addition of crRNA, the experiments only yielded unassembled protein 
and minor amounts of Cas7 protein multimers interacting with Cas8b, probably caused by 
the presence of unspecific E. coli RNA. So far, only the Cascade complexes from type I-A 
of Thermoproteus tenax and from type I-E of E. coli were shown to be produced without 
the presence of crRNA 140, 141.  
In general, type I and type III crRNP complexes have been observed to display a common 
core architecture that is built up by the crRNA binding proteins that were classified as 
RAMPs (repeat associated mysterious proteins) 57, 79. The crRNA-binding helical backbone 
of the crRNP complexes are composed of six Cas7 homologues that interact with one 
Cas5-like protein. This stoichiometry was confirmed for the type I-B Cascade complex of 
C. thermocellum. Furthermore, Cas7 and Cas5 were identified to be arranged in close 
proximity within the complex. The structure prediction of Cas5 revealed a thumb and a 
palm domain which are conserved among Cas5 family members 48, 54, 142, 143. Cross-links 
between Cas5 and Cas7 were identified within Cas5 that are mostly located in the thumb 
domain. This is in agreement with the Cas subunit arrangement of the type I-E Cascade, 
wherein the thumb domain of Cas5 interacts with the 5'-terminal tag of the crRNA and 
contacts the adjacent Cas7 subunit at the finger domain. As multiple copies of Cas7 are 
part of the C. thermocellum Cascade, it is not possible to distinguish between cross-linked 
sites of different Cas7 copies. Nevertheless, cross-links with Cas5 were identified in the 
predicted Cas7 finger domain. Together, these results indicate a distinct core backbone 
architecture of the type I-B Cascade. In the type I-E Cascade, Cas6 and Cas5 are the most 
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distal located subunits, forming the head and the tail of the complex 54, 60. In 
C. thermocellum, one cross-link was identified for Cas6 with Cas8b and Cas7. 
Interestingly, no cross-link was observed between Cas6 and Cas5. This underlines the 
assumption that Cas6 is associated with the 3'-terminal end of the crRNA and therefore 
located most distant to Cas5.  
In contrast to the conservation of the Cascade backbone, the large and small subunits of the 
type I and type III crRNP complexes differ in structure and their number of copies between 
the subtypes 21. The respective Cascade subunits are proposed to mediate target interaction 
and probably adjusted to the requirements of specialized features for diverse target 
recognition events and the retention of the surveillance effectiveness (ssRNA versus 
dsDNA targets, various PAMs) 30, 57. The crystal structure of the type I-E Cascade revealed 
that Cas5 interacts with the large subunit Cse1, and that both of these subunits are attached 
to the Cas7 backbone 54, 60. Similar to this, cross-links were observed between Cas8b, Cas7 
and Cas5 in C. thermocellum. Interestingly, 2.5 copies of Cas8b were identified in the type 
I-B Cascade. It has been proposed that in type I-B, I-C, I-D and I-F Cascades, the small 
subunit is fused to the large subunit 79. The Cas8b protein of C. thermocellum co-purifies 
with a small protein fragment that was identified to represent the C-terminal part of Cas8b 
in addition to the full-length protein. This fragment was also detected in vivo (Masterthesis 
of Kristina Rau). Both, the full-length protein and the fragment assemble in the complex. It 
is possible that the C-terminal part of the protein has a similar function as the small 
subunit. Interestingly, cross-links between Cas5 and Cas8b can only be observed in the N-
terminal part of the Cas8b protein, which could indicate that this part of the protein 
interacts with Cas5, whereas the C-terminal part of the full-length protein and the protein 
fragment acts as small subunits. However, bottom-up mass-spectrometric methods such as 
iBAQ (intensity-based absolute quantification) used for the analysis of the stoichiometry 
exhibit a limited accuracy in the determination of high protein copy numbers within 
complexes. This can influence the accuracy of the ratio of proteins that are present in more 
than one copy, such as Cas8b 115, 116. Thus, to further investigate the exact copy number of 
full-length Cas8b protein and the additional Cas8b fragment, an absolute quantification 
approach (AQUA) is planned in collaboration with Prof. Dr. Henning Urlaub (MPI for 
biophysical chemistry, Göttingen). In this approach, peptides are chemically synthesized 
that are identical to N- and C-terminal parts of the protein sequence and contain stable 
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isotopes. These are then used as internal standards in the Cascade complex mixture to 
estimate the absolute amount of proteins 144. This approach will provide the exact number 
of full-length and small fragment Cas8b protein copies. Furthermore, the Cas8b protein 
was sent to our collaboration partner Dr. Scott Bailey (Johns Hopkins University, USA) for 
crystallization experiments (Masterthesis of Kristina Rau).  
In order to investigate the interaction of Cas proteins with the repeat termini of the crRNA, 
recombinant Cascade was assembled using crRNAs with modified repeat tags (3'G RNA 
and 5'G RNA) as described in section 2.4.3. The substitution of the 3'-terminal tag with G 
residues does not seem to have an impact on Cascade formation as it looks very similar to 
the wildtype assembly. A distinct protein peak can be observed that represents the 
assembled Cascade consisting of all four Cas proteins and a significant amount of crRNA. 
In contrast, the analysis of the Cascade assembly using crRNA with a modified 5'-terminal 
repeat tag revealed some disparities. A distinct peak in the gel-filtration chromatogram 
corresponding to Cascade was not observed. Limited amounts of Cascade formed by Cas5, 
Cas7 and Cas8b but without Cas6 were detected. A large amount of Cas7 protein elutes in 
the void volume indicating that it likely oligomerized with E. coli RNA. The overall 
amount of extracted crRNA is very low which indicates that it did not assemble efficiently 
with the proteins and therefore most likely got lost during the concentration of the 
assembled protein mixture prior to gel-filtration chromatography. This also explains the 
relatively high amount of unassembled, monomeric Cas7 protein. Hence, the data suggest 
that the 5'-terminal repeat tag is essential for proper complex formation, whereas the 
sequence of the 3'-terminal end is dispensable for protein assembly after crRNA maturation 
in vitro. These results are in agreement with the in vivo analysis of the type I-B 
interference reaction of Haloferax volcanii, which showed that mutations of the 3'-terminal 
repeat end of the crRNA do not influence Cascade activity, whereas the manipulation of 
the 5'-tag causes the loss of interference activity 139. Furthermore, in the type I-E Cascade, 
the 5'-terminal end of the crRNA is positioned between Cas5 and the adjacent Cas7 subunit 
and base-specifically interacts with Cas5 54. This verifies the crucial role of the 5'-terminal 
tag in Cascade backbone assembly. 
In general, the in vitro analyses of Cas proteins assemblies with modified crRNAs exhibit 
methodic limitations. Four individual Cas proteins are recombinantly produced in E. coli 
and three of these proteins contain RRM motifs which indicates that they can bind RNA. 
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As a consequence, it is plausible that Cas6, Cas5 and Cas7 can be unspecifically 
complexed with E. coli RNA. Thus, individual assembly experiments have to be compared 
to the wildtype assembly. Defective Cascade formation around modified crRNAs is 
reflected in a relatively low amount of crRNA uptake. This suggests a low affinity to the 
respective crRNA which results in the observation of monomeric Cas7 protein and the 
formation of Cas7 oligomers with E. coli RNA. In addition to this, Cas6 is present in the 
assembly using the 3'G RNA, whereas it is absent from the assembly that was performed 
with the 5'G RNA. According to the data discussed in section 4.1, it would be assumed that 
the modification of the 3'-terminal tag hinders Cas6 interaction with the crRNA. The fact 
that Cas6 is not associated with the Cas protein assembly using the crRNA with a modified 
5'-terminal tag indicates hindered complex formation. In contrast, the assembly experiment 
using a modified 3'-terminal tag showed proper Cascade formation, which indicates that 
Cas6 is rather associated on a protein:protein level to Cas7 than via crRNA contact in the 
in vitro studies. In order to get a better understanding of crRNA:Cas protein interactions, 
the use of modified crRNAs and subsequent in vitro assembly monitoring seems rather 
challenging as the crRNA binding Cas proteins interact unspecifically with RNA in vitro. 
As the crystallographic structures of the crRNA binding Cas protein homologues are 
available, it seems plausible to perform a single molecule Förster resonance energy transfer 
(smFRET) analysis, wherein dye molecules could be incorporated at predicted interaction 
sites between Cas proteins as well as crRNA, which could be used to monitor the order 
complex formation. Additionally, this would also give a better understanding on the 
localization of the crRNA within the Cascade complex 145.  
4.3 Cascade interference 
Prior to Cascade mediated DNA interference, the target DNA needs to be recognized. First, 
Cascade scans dsDNA with regard to a potential PAM sequence 59, 65. Usually, a defined 2-
3 bp PAM sequence is identified by Cascade 44, 65. The type I-B CRISPR system of 
Haloferax volcanii forms an exception though, as six PAM sequences were identified to 
permit target recognition in the system in vivo using plasmid-invader assays 146. For type  
I-E, the large subunit Cse1 was shown to mediate PAM recognition 60, 64, 67. Second, target 
pairing between spacer and protospacer sequences triggers R-loop formation 147. The small 
and large subunits stabilize the formed R-loop and undergo structural rearrangements 
which results in the recruitment of Cas3 64, 71. Two metal ions are required for the HD 
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nuclease domain of Cas3 to nick the target DNA that activates the helicase which is 
responsible for ATP-dependent dsDNA hydrolysis 72, 148. As described in section 2.4.5, a 
Cascade-mediated interference reaction could not be observed for the type I-B Cascade 
from C. thermocellum in vitro. Several factors could be responsible for this.  
First, the PAM sequences used in the interference assays could differ from the one that 
mediates target recognition, as the PAM sequence specific for C. thermocellum has not 
been determined yet. The fact that the PAM sequences that were identified for the type I-B 
CRISPR systems of Haloferax volcanii and Listeria monocytogenes differ in sequence, 
indicates that the PAM is not subtype specific but has to be identified for each organism 
individually 113, 114. The CRISPRtarget tool was utilized to identify potential DNA targets 
of the CRISPR system in C. thermocellum. Three potential PAM sequences were identified 
adjacent to protospacers from different prophages/plasmids of Clostridia species. Out of 
these, the 3'-AGT-5' PAM sequence represents the most promising hit as it was found in a 
Clostridium thermocellum prophage. However, one viral evasion strategy to escape 
CRISPR-Cas is to introduce variations in the PAM sequence in the own genome 44. Thus, 
it is possible that the PAM sequences identified in the prophages/plasmid represents a 
modified PAM that can escape Cascade interference. Recently, EMSA experiments 
performed with Cas8 from Methanothermobacter thermautotrophicus showed that the 
protein responds to a 3'-GGG-5' PAM in dsDNA, which could also be tested for 
interference assays using recombinant Cascade from C. thermocellum.  
Second, R-loop stabilization by the large subunit Cas8b of the complex could be 
inefficient. It was shown that Cas8b co-purifies together with a protein fragment that 
represents an additional C-terminal part of Cas8b. Consequently, the question arises 
whether this protein fragment plays a functional role or if it is artificially produced and 
hinders interference. To exclude internal translation and proteolytic self-cleavage of the 
protein, mutations were introduced within the region of a potential RBS adjacent to first 
amino acids of the Cas8b fragment and N-terminal protein truncations were generated. 
Analysis of the respective mutants revealed that production of the protein fragment is not 
prevented. Western blot analysis using a poly-clonal anti-Cas8b antibody and C. 
thermocellum cell extract confirmed the production of the additional protein fragment in 
vivo and excludes proteolytic cleavage of Cas8b during heterologous expression in E. coli. 
Interestingly, the expression of a truncated Cas8b protein, lacking the C-terminal part that 
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represents the small fragment only yielded insoluble protein. This could indicate that the 
small fragment is produced by a split of the full-length Cas8b protein which causes 
subsequent precipitation of the remaining N-terminal part of the protein (Masterthesis of 
Kristina Rau). To investigate whether Cas8b is a functional large subunit of Cascade in the 
presence of the small protein fragment, EMSAs could be performed using Cascade and 
radiolabeled dsDNA targets to ensure target binding. Furthermore, an enzymatic or 
chemical footprint analysis specific for ssDNA using Cascade and the respective dsDNA 
target could confirm proper R-loop formation 49, 149. Alternatively, once the crystal 
structure of the Cas8b protein is solved, smFRET could be used to monitor R-loop 
formation and investigate the interaction between the different copies of Cas8b within the 
complex 145.  
A final explanation for the absence of Cascade DNA interference activity is the possibility 
that the Cas3 protein of C. thermocellum is not active in vitro. Recombinant Cas3 was 
produced with a 6-fold C-terminal His-tag and purified from E. coli. It is possible that the 
protein is misfolded due to the addition of the His-tag, but still remains soluble. 
Furthermore, the recombinant Cas3 protein could be loaded with unspecific nucleic acids 
from E. coli. The crystal structure of the Cas3 protein from Thermobifida fusca revealed 
ssDNA that was captured in the precleavage state. The DNA was of endogenous origin and 
copurified with the protein 150. An additional purification step using ion-exchange 
chromatography could not be applied to Cas3 of C. thermocellum, as the protein started to 
precipitate shortly after affinity purification. Cas3 contains an N-terminal HD helicase 
domain which represents the proposed metal-dependent exo- and endonuclease 73. The 
crystal structures of different Cas3 homologues revealed the interaction of iron (II), nickel 
or calcium ions with the HD residues 73, 150, 151. In addition to this, Cas3 ssDNAse activity 
was observed with divalent magnesium, manganese, cobalt, copper and zinc ions 72, 73, 150, 
152. Hence, a wide range of cofactors could possibly be required for the activation of the 
Cas3 HD nuclease 57. The nuclease assay using a ssDNA substrate with increasing 
concentrations of Cas3, magnesium and manganese ions showed that even at a 4 µM 
protein concentration, the substrate is not cleaved efficiently. This could indicate that 
magnesium and manganese are not the corresponding Cas3 cofactors. Therefore, the Cas3 
cleavage assay was performed under varying metal conditions. Efficient DNA degradation 
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could not be observed under any of the used metal conditions. Hence, further metal 
combinations have to be tested to determine optimal cleavage conditions for Cas3.  
 
4.4 CRISPR RNA regulation patterns 
The RNA-Seq analyses of the small RNome profiles of different archaea and bacteria e.g. 
Methanococcus maripaludis 50, Methanopyrus kandleri 102, Methanosarcina acetivorans 
153, Nanoarchaeum equitans 154, Pyrococcus furiosus 137, Sulfolobus solfataricus 155, 
Clostridium difficile 156 and Thermus thermophilus 157 revealed that crRNA abundance 
follows a gradual decline from the leader-proximal to the leader-distal end of the locus. 
This is in agreement with the crRNA abundance pattern observed for C. thermocellum. In 
addition to the promoters that are located within the leader and drive CRISPR 
transcription, promoters have also been identified to be located within spacer and repeat 
sequences. In Neisseria meningitidis, repeat embedded promoters can be observed that 
enable the production of mature crRNAs independent of an RNA processing enzyme 158. 
As described in section 2.2.2, CRISPR locus 3 of C. thermocellum also encodes a pair of 
promoter elements within a consecutive repeat and spacer element that initiates internal 
transcription of the locus. The final base of the 8 nt 5'-terminal tag of the crRNAs that are 
produced from the subsequent repeats is exchanged. Together, this indicates that the 
internal promoter might originate from the fusion of two CRISPR loci, wherein part of a 
leader was incorporated within this region. The production of high amounts of leader-distal 
crRNAs could facilitate a selective advantage for the host cell in case of an infection by a 
virus with complementary DNA 101. 
The presence of CRISPR transcripts in reverse direction (anti-CRISPR transcripts) has 
been described for P. furiosus 137, Sulfolobus acidocaldarius 16 and S. solfataricus 155. In S. 
acidocaldarius, potential BRE/TATA elements were identified in the leader-distal regions 
of the CRISPR loci that could be responsible for anti-CRISPR transcription. Internal 
promotion of anti-CRISPR transcription in P. furiosus was found to be initiated by a spacer 
sequence that contains promoter elements. It has been suggested that these anti-crRNAs 
could protect crRNAs from degradation 159. In P. furiosus, the antisense RNA was shown 
to be cleaved in vitro by the respective type III-B crRNP complex CMR that targets RNA 
34, 137. C. thermocellum was also shown to contain antisense RNA transcripts starting either 
from the leader-distal end or within CRISPR clusters. The production of these antisense 
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RNAs is most likely driven by highly AT-rich leader-distal and internal spacer sequences. 
The analysis of the antisense RNAs revealed small anti-crRNAs that comprise a conserved 
processing pattern resulting in a defined 5'-terminal repeat tag. As described in section 
2.2.4, the processing pattern is identical with the in vitro RNase III cleavage of anti/crRNA 
duplex transcripts. Thus, anti-crRNAs are proposed to play a regulatory role. These 
proposed contrasting roles of antisense RNA transcripts in bacteria and archaea could be 
explained by the fact that RNase III enzymes are found in bacteria, and were shown to be 
involve in type II crRNA maturation, whereas RNase III-like domain containing enzymes 
are not found in archaea 32. However, antisense CRISPR transcripts appear to be absent in 
most organisms 101.  
The general abundance of anti-crRNAs observed in the RNA-Seq data of C. thermocellum 
is significantly lower than that of their crRNA counterparts. However, it should be noted 
that anti-crRNAs are not protected by Cas7 oligomers in the cell and might exhibit a 
shorter half-life. Furthermore, unprocessed antisense transcripts longer than 200 bp are 
excluded from the RNA-Seq libraries due to the preparation protocol. In fact, crRNAs or 
precursor crRNAs have to hybridize with long antisense transcripts as RNase III cleavage 
is double-strand specific and Cas6 does not process single-stranded anti-crRNA precursors. 
Furthermore, the observed anti-crRNAs in vivo most likely result from RNase III cleavage 
of a duplex formed by untrimmed crRNAs and long antisense transcript, as the processed 
anti-crRNAs display randomly shortened 3'-ends which is probably caused by 
exonucleolytic trimming of the unpaired 3'-terminal region of the anti-crRNAs.  
It was observed that the abundance of distinct processed anti-crRNAs correlates with the 
abundance of their crRNA counterparts. This could indicate that anti-crRNAs neutralize 
the matching crRNAs in the absence of invaders. The assumption results from the 
observation that in bacteria, antisense RNAs can manipulate the stability of target RNAs 
by promoting or blocking endo- or exoribonucleolytic cleavage 90. One of the major 
endoribonucleases in bacteria that has been linked to mRNA cleavage induced by antisense 
RNA is the described double-strand specific RNase III 160. The observation that RNase III 
cleaves repeat RNA duplexes in C. thermocellum indicates that the sequence elements (pb 
and db) that are required for RNase III reactivity are present. RNase III cleavage of a 
wildtype repeat RNA duplex yielded a prominent cleavage site and additional minor 
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cleavage products, shifted by one nucleotide. This suggests the presence of different 
recognition motifs within the substrate.  
In order to identify the db- and pb-elements that are recognized by RNaseIII and 
responsible for repeat duplex processing in C. thermocellum, two nucleotides that were 
shown to influence RNase III cleavage 94 were modified within the pb-elements on each 
side of the prominent cleavage site. Interestingly, none of the modifications caused 
complete loss of RNase III cleavage but induced additional cleavage sites, indicating that 
both sets of recognition motifs facilitate RNase III cleavage. The additional cleavage sites 
also display the characteristic 2 nt 3'-overhang. This suggests a certain flexibility in the 
architecture of the db/pb elements that are recognized by RNase III in vitro. E. coli RNase 
III cleavage action has been shown to be determined by positive as well as negative 
sequence elements that cooperate. This has been proposed to establish varying affinities 
among subatrates 94. 
Apart from the potential impact of anti-crRNAs, other factors also have to be considered 
that could influence the abundance patterns of individual crRNAs in the cell. Cas6 
cleavage activity of the repeats could be influenced by adjacent spacer sequences. It was 
shown in M. maripaludis that spacer sequences can influence Cas6 activity in vitro, using a 
set of consecutive spacer-repeat-spacer substrates 138. In addition to secondary structures 
within and between spacer sequences of the CRISPR precursors that can influence Cas6 
cleavage, loading efficiency as well as stability and turnover of crRNAs within the crRNP 
complexes could influence the crRNA abundance pattern 101.  
The RNA-Seq analyses revealed the presence of a spacer sequence complementary to the 
host tRNAPro. Consequently, the question arises how this spacer was incorporated into the 
CRISPR array as it could mediate self-targeting. In the absence of crRNP complexes, 
chromosome-derived spacer acquisition has been described, but was observed to occur 
around 100-fold less frequently than the acquisition of foreign invader DNA 23. It has been 
proposed that self-targeting is not a regulatory mechanism but mediates autoimmunity 161. 
Another possible explanation is that the acquisition of the tRNA fragment originates from 
a viral attachment site. Temperate bacteriophages encode an identity block that comprises 
the crossover segment followed by tDNA which is used for integration into tRNA genes. 
After integration, tRNA gene function is retained 162. As the tRNA targeting crRNA could 
inhibit precursor-tRNA folding, it is very likely that an RNA duplex is formed with the 
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counter-crRNA, comprising the complementary spacer sequence that acts as an “RNA 
sponge”. As described in section 2.2.4, the spacer RNA hybrid displays a potential target 
for RNase III cleavage which would facilitate degradation of the harmful crRNA.  
Overall, these results show that individual spacer sequences and repeat elements in forward 
and reverse direction can have an influence on the abundance of individual crRNAs and 
therefore impact CRISPR-Cas functionality 101. 
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7. Appendix 
 
A1: Nucleotide sequences of C. thermocellum cas genes codon-optimized for E. coli 
usage 
Sequence cas3 
ATGCTGCTGTCTCACCCGGGCAAACTGCTGCTGGACCACCTGAAAAATGTGTTCCTGATCGGCGAC
TGTATCCTGATGCAGAAAAAGACCGAATTTGAAAGTTTCTCCGAACATGATATTCGTCAGCTGAAC
AAACTGAATCTGCTGACCCACGATCTGGGCAAAGCAACGAGCTATTTTCAGGACTACATTCGCAAC
CTGGATGACAATACCCAGAAAAACGATGAACGTAAACGCCATGGCCTGCTGTCTGGTGTTCTGAGT
TTTAAAATCGTGAACGCAGTTATGAAAAACGAAATTCTGGCTTTCCTGTCCTATATGGTGGTTTCA
AAACATCACGGCGAACTGGATGACTTTACGAATTTCATCAGCGTGATTTCTGGTGATGAGAAAAAC
AAAACCCTGCTGAAACTGCAGTTTGAAAGCATCGATAAAGGCAAACTGCAAGAAGTGATTACCCGT
CTGGGTATCGACTTTGATATTCTGTCCTATACGGTTGATGAATTTGAAAACGACATCGATTACATC
ACCTCACGTAAAGTCCGCAAAAAAGTGAAAGAACTGATGGGTCTGGAAATCTTCCTGCTGATTGAT
TACCTGTTTAGCCTGCTGATCTTCAGCGACAAACTGGAAGCAATTTACAACTCGGAAAACATGAAC
ATCGAAGAATTTATCGAGAAAAACACCAATCGTCCGCGCATTAGCTCTGATTGCGTGGACAAATTC
AAAAAATCTCTGGAAATCAAAAACATTCGCATGGCGGAATGGCGTAACCGCGCCTATCAGGATGTT
CTGGGCTCTGTCGAAAATCTGAGTCTGGAAGAAAAAATCCTGTCGATTAACCTGCCGACGGGCAGC
GGTAAAACCCTGACGGCTCTGAAAGCGGCCCTGCGTCTGAAAGAACGCCTGATTGAAGAAAAAGGT
TATAATCCGCGTATTATCTACGTGCTGCCGTTTACCTCCATTATCGAACAGAATTTTGATGTGTTC
CAAAAAGTTCTGGGCACCACGGAATCTAACGTTCTGCTGAAACATCACTATCTGAGTCAGCGCGTC
TACCAATGGGAAAAAGAAGGTGAAATTGAATCACTGTCGGATACCGTTAGCGAACATCTGGTCGAA
AGTTGGGACTCCGAAATCGTCGTGTCTACCTTTGTGCAGCTGCTGCATAGTATTTTCACGAACCGT
AACCGCAAACTGAAAAAATTCCACAACATCGTCAATTCGATCATCATTCTGGATGAAGTGCAGAGC
ATTCCGCATCGTTATTGGAATCTGGTTCGCGAAACCTTTTCTGCAATGGCTAAATACCTGAACTGC
CACTTTATTTTCATGACCGCAACGATGCCGCTGATCTTCTCGGAAGAAAACAAAGAAATCTACGAA
CTGGTGAAAGATAAACGTAAATACTTCGAAGAATTTAGCCGTATCACCATTGACGCTAAACGCCTG
ACGGATAAAACCACGCTGGACGAATATAAAACCCTGCTGCTGGATGACATTCTGCGTTACAAAAAA
GATGACTTTCTGATCGTTATGAACACCATTCGCACGTCCATCGAAATCTACTCATTCATCAAAGAA
GAACTGAAAGATGAAGCCGAAATCTACTACCTGTCTACGAACATCATCCCGAAAGAACGTCTGGAT
CGCATTAAGAAAATTAAAGAATCCAAAAACCGTAAAATCATTGTGTCAACCCAGATGATCGAAGCA
GGCGTGGACATCGATATTGACCGTGTTTATCGCGATTTTGGCCCGATGGACAGTATTAATCAAACG
GCTGGTCGTTGTAACCGCGAATGGGGCGATAAAAAAGGTCTGGTCACCCTGGTGAATCTGGTTAAC
GAAAATCATCACTCTCGCCCGTACGCGACCTATATCTACGATAACGTTCTGATTGAAGAAACGAAA
AAAGCCCTGAGTGGTCTGGAAATGATCGAAGAAAAAGAAATCTTCCATCTGGCGGAAAAATATTAC
GTGGGCCTGAAATCACACGGTTCGGATGAAAGCCAGAAACTGCTGGACTGCATCAAAGAACTGCGT
TATCGCGAAGCCTTTGAATGTGGCAAAGATGACAAAAATAGCGGTGTCTTCGAACTGATTCGTCAG
GATTTTAACACGGTTGACGTCTTCATCGAAATTGATGACGATGCGACCGAAGTGTGGCAGGAATAC
CAATCTATTAAGAAAATTAAAGACCGCTTCGAACGTAAACGCAAATTCAACCAGTTCAAAAAAGAC
CTGTACATGTACGTTCTGTCACTGCCGGAATTTGCCGTCCGTAAACAAGTGGATATTGACGAAAAA
GATATTACCTTCATCAACCGCGAAATGGTCTTCAACACCTACGATAAAGATACGGGCTTCATGCGT
GACCTGGAAAAAGATTACTTCTTCTAA 
 
Sequence cas5 
ATGGTGGAAAAATACCTGGTGTTCGACATTTCGGCAAGCTATGGCCACTTCAAAAAACCGTACACG
ACGACGAGCCCGCTGACCTACTCAATTCCGACCCGCACGGCAGTTTCGGGCATTATCGCGGCCGTC
CTGGGCTTTGGTAAAGAAGATTATCAGGAACATTTCACCAAACCGCAAGCAAAAATTGCTATCGGT
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ATTCGCAACCCGGTCAAAAAAGTGCGTATCAGCGAAAACCTGATCAACACCAAAAAATCTATGAAC
ATCATCCACGAACGCACCCAGATCAAAATTGAATTTCTGAAAGATGCGTGCTATCGTATCTACTTC
ACCCATACGGACAAACAAATTTACGAACGCCTGAAAGAATCCCTGAAAGAACACCGTACCGTGTAT
ACGATCAGTATGGGCCTGTCCGAAAACCTGGCCAATTACACCTTTACGGGCGAATTTGATGGTCGC
GAAGTGAAAGGCAACAAAGAAATCGTTGAATTTAGCTCTGTGGTTCCGCTGGATATTCTGAAAAAA
GGTGACATTGAATTTGAAGATGACCGTGAATATTTCACCGAAACGATCCCGGTTGAAATGGACGCC
GAACGTAACATTAATGAATACCGCGAAGTCCTGTTCGAACGTAATGGTTGTAAAGTTCGTGCTCGT
GTGGACTCGTACATTAAAATTGAAGGTATTGATGAAAACATTCTGATTATTTAA 
Sequence cas6 
ATGGACATCAAAATCCTGACCGTGCGTCTGGAAGGCAACCGTGTGGAATCCCGTGACATCCCGAAA
ATCCGTGGCTACCTGGCTGGCCGTTTCCCGCAGTATCTGGAACTGCATAACCACCTGGGCGAAAAC
AAATTCAACTACGGTTACCCGGTTATCCAATACAAAAGTATTAACGGCGTCCCGAATATCCTGGCG
ATTAATGAAGCCTCCAAAATTCTGATCGATATTTTCTATGACGTGAAAGAAATCGATATGAAAGAC
AAAGTTATGTCAATTCTGGAAAAAGGTTACGTCCTGAAAACCCGTGAACTGAAAACCACGGAACGT
ATGATCGAATATCGCTTCCTGTCGCCGTGGCTGGCACTGAACCAGGAAAACTACGAAAAATTCATC
AACAGCGATTCTGGCGAACGCGTTGAAATCCTGAAGAAAATTCTGACCGGTAATATCCTGTCTATG
GCGAAAGGCCTGGGTTATTGCGTGGACAAACCGATTGAAGTGTTTGTTAACCTGCGTCCGGTCCAA
GTGAACTACAAAAATCGCAAAATGATCGGCTTCAAGGGTGAATTTATCACGAACTTCATCATCCCG
GATTATCTGGGCCTGGGTAAATCAGTCGCCCGTGGTTTCGGCACCGTGGAACGTGTGGGTAAAGGT
TTCGTGTAA 
 
Sequence cas7 
ATGATCAAAAACCGCCAAGAAATCCTGTTCCTGTATGACGTTACCGATGCTAATCCGAATGGTGAC
CCGCTGGACGAAAATAAACCGCGCATTGACGAAGAAACCGGTATTAACATCGTTACGGATGTCCGT
CTGAAACGCACCATCCGTGACTATCTGTACGATTATAAAGGCTTTGACGGTAGTAATGGCAAAGAT
ATTTTCGTGCGCGAAATCGAATCCGAAAAAGGCGGTATTAAAGATGGCAAAGCACGTGCTAAAGAC
TTCAACGAAAACGTCGATGAAATCCTGCAGAAAGCGATTGATATTCGCCTGTTCGGCGGTGTGATT
CCGCTGGATAAAGCCTCAATCACCTTTACGGGTCCGGTGCAATTCAACATGGGCCGTTCGCTGAAC
AAAGTTAACCTGAAACATATCAAAGGCACCGGTGCGTTTGCCAGCGGCGAGGGTAAAGCACAGAAA
ACGTTCCGCGAAGAATACATCGTTCCGTATTCTATTATCGCGTTTCACGGTATTATCAACGAAAAT
GCGGCCAAACGTACCGGCCTGACGGATGAAGACGTCGATCTGCTGGATGACGCGATGTGGAACGGT
ACCAAAAATCTGATTACGCGCTCCAAAATGGGCCATATGCCGCGCCTGATGCTGCGTGTGGTTTAC
AAACCGGGTGAAAACTTTTTCATTGGCGACCTGCAAAACCGCATCAGCCTGAACTTCGATGTGGAA
GAAGAAAAAATCCGTAGCATCAAAGATTTCTCTATTAAACTGGACGAACTGATCGATGAACTGGCA
AACTACGGTGACAAAATTGAAAAAGTCGTGTTTGTTGCTGATAAAAATCTGCGTCTGAGTTATAAA
GGCCGTGAAATCAACCTGAAAGACATCAAAGACATCCGCTTCGAAGAAAAAACGTTCTAA 
 
Sequence cas8b  
ATGCTGGCTGGTGTGCTGCAACTGGGTCAATACGCTCTGAATAAAAAATCCACGGATACCGAAGAA
TACCTGCAAGTCATCGAAAACCCGAACGATAAAGGCAACTACAACCATGTTCTGAAAATTGCGTTC
GAAAGTACCGAAGGCAATATCGTGTATCGTGGTGTTGAATACGAAGAATTTAGCAGCAAGAAAATT
AACAACTACGCGTACAAAAAAGGTTCCGCCCGCGGCGGTGATGTGACCCCGACGAGTAAATATACG
GACTCCAT 
 ___________________________________________________________________________________Appendix 
103 
 
GAAAACCCTGAACAAAATCATGATCAGTTTCAACGATATTCTGAAATCCGCGAATCAGAACAATGA
CGAACAAAAAATCTTCAAAGGCATCTACGAATACATGGTGAGCAACCAGGAAAACATCGCCAACGA
TATTACGGAAAAAATCAAAAGTATCTCCCTGAAAAAAGGCGAATCGTTCATTATCACCGTGACGCT
GTTCGATAACAACACCGAAAAATACATGGGTAACTTCCAGCTGATCCGTAACCATCTGGCCCGCAT
CCTGAACGAACAATACTACAACAAATACGGCAAAACGAGCAAAGGCAAAGGTATCTGCTATTACTG
TAAAAACGAAGGCGAAGTCTTTGGTTTCGTGAATACGTATAACTCTTACACCGTGGATAAAATTGG
TTTCGTTACCGGCGGTTTTAAACAGGAAAATGCGTGGAAAAACTATCCGGTTTGCTCATGCTGTGC
CCAGAAACTGGAACAAGGCAAAAAATATATCCGTGAAAATCTGACGAGCAAATTCTCTGGTTTCGA
TTACTTCGTCATCCCGAAAGCAGTGATCAGCGATGAACACGACGAAGCTGAATTTATTGAAACCCT
GGAAGAATTTGAGAAAAACACCAACTTCTCAACGCAGGAATCGACCAAACAAAACCTGCTGGGCAG
CGAAAAAGATTTTCTGGAAATCATGAAAGACTCTAAAAACTACCTGAACTACAACATGCTGGTCTT
CAAAGAAGAACAGTCAGGTTCGGTGTTCCGTATTCTGCTGTACATCGAAGATATTGTTCCGAGCCG
CGTCAAAAACATCCTGCGTGTGAAAGATCGCGTTGACGAAACGGTCCTGTTTAAAAATCTGCCGGG
CAAAGATAACGCGACCTACGACCTGAAATTCGGTTTCGATAAAATCCGTACGTTTTTCCCGAACAA
TAAAACCGAAGGCAATTTCGACAAAAGTTTTCTGGAAATCCTGAACAACGTTTTCACCTACAAGAA
AATTAGCTACAAATTCCTGCTGGGTCGCATGATTAGCAAAATCCGTTCTGATTTCGCACGCGAAGA
ATATGTGAAAAACCTGGTTCTGCAGGCTCTGATGTGTATCATGTTCATCGACAAACTGAATCTGCT
GTCTGGCAAGGGTAAAGAAGTGCAAAAAATCATGATCGAAAAAACCGAGAAAAACAAAAAATATCT
GGATTTCTTTGAAAACGAATCATACAAAGATGTTTTCAACTCGGACTACAAACGTGCAGTTTTTCT
GACGGGCGTCCTGACCGAAAAACTGCTGAACATTCAGTATAAAGAACGTGGCTCAAAACCGTTTTA
CTCGCGCCTGAATGGTCTGAAACTGAACAAAAACATCGTGAAACGCATCTACACCGAAGCTATCAA
CAAACTGAACGAATACAACAAAAATTATTACAAAGAACTGGAATATCTGATCGGCATGTACATGCT
GAGTGAAGAATCCCAGAAAAACGTTAGCGATGACGAAATTTCTTTTTATTTCGTCCTGGGTATGAG
CCTGGCACGTTTCTTTAATGAAGAAAAGAAAGACGGTGAAGATGAAGAATAA 
 
A2: Cross-linked peptides from Cas7, Cas8b and Cas5. The cross-linked lysine residue 
of each peptide is indicated in parenthesis. The lysine residues oft the peptides from Cas5 
and Cas7 were marked in the aa sequence of the respective phyre2 models. 
Peptides Cas7                                 Peptides Cas8b                             Spectra                 Score 
 EIESEKGGIK(6) KGSAR(1) 3 2,450996738 
 EIESEKGGIKDGK(6)  KGSAR(1) 1 2,007446482 
 EIESEKGGIKDGK(6)  YGKTSK(3) 1 2,454692884 
 EIESEKGGIKDGK(6)  FGFDKIR(5) 1 4,692503962 
 EIESEKGGIK(6)  KISYK(1) 1 4,30980392 
 EIESEKGGIKDGK(6)  KISYK(1) 2 6,815308569 
 EIESEKGGIKDGK(6)  LLNIQYKER(7) 1 4,166215625 
 AKDFNENVDEILQK(2)  KINNYAYK(1) 1 3,528708289 
 AKDFNENVDEILQK(2)  KGSAR(1) 1 4,690369833 
 AKDFNENVDEILQK(2)  VDETVLFKNLPGK(8) 1 3,064492734 
 SLNKVNLK(4)  KISYK(1) 27 11,27164622 
 SLNKVNLK(4)  GKEVQK(2) 7 9,139063379 
 LNGLKLNK(5)  VNLKHIK(4) 1 4,361510743 
 HIKGTGAFASGEGK(3)  KINNYAYK(1) 1 8,759450752 
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 HIKGTGAFASGEGK(3)  KGSAR(1) 2 3,542118103 
 HIKGTGAFASGEGK(3)  YTDSMKTLNK(6) 1 2,966576245 
 HIKGTGAFASGEGK(3)  GSKPFYSR(3) 9 10,98296666 
 HIKGTGAFASGEGK(3)  LNGLKLNK(5) 26 11,4424928 
 HIKGTGAFASGEGK(3)  LNKNIVK(3) 1 4,203425667 
 HIKGTGAFASGEGK(3)  LNEYNKNYYK(6) 52 16,66554625 
 GTGAFASGEGKAQK(11)  GVEYEEFSSKK(10) 1 2,785156152 
 GTGAFASGEGKAQK(11)  KINNYAYK(1) 1 3,616184634 
 GTGAFASGEGKAQK(11)  KGSAR(1) 5 2,759450752 
 GTGAFASGEGKAQK(11)  YTDSMKTLNK(6) 2 4,643974143 
 GTGAFASGEGKAQK(11)  TSKGK(3) 1 3,077274542 
 GTGAFASGEGKAQK(11)  KYIR(1) 1 10,31247104 
 GTGAFASGEGKAQK(11)  VKNILR(2) 1 6,879426069 
 GTGAFASGEGKAQK(11)  KISYK(1) 1 7,133712661 
 GTGAFASGEGKAQK(11)  TEKNKK(3) 4 7,596879479 
 GTGAFASGEGKAQK(11)  TEKNKK(5) 2 3,468521083 
 GTGAFASGEGKAQK(11)  LLNIQYKER(7) 22 19,56224944 
 GTGAFASGEGKAQK(11)  GSKPFYSR(3) 10 10,37675071 
 GTGAFASGEGKAQK(11)  LNGLKLNK(5) 1 10,76700389 
 GTGAFASGEGKAQK(11)  NIVKR(4) 1 3,844663963 
 AQKTFR(3)  KGSAR(1) 4 5,514278574 
 AQKTFR(3)  LEQGKK(5) 2 6,634512015 
 AQKTFR(3)  VKNILR(2) 1 4,754487332 
 AQKTFR(3)  KISYK(1) 1 2,151195299 
 AQKTFR(3)  TEKNKK(3) 1 4,270025714 
 GVEYEEFSSKKINNYAYK(11)  VVYKPGENFFIGDLQNR(4) 2 10,84771166 
SLNFDVEEEKIR(11)  LNKNIVK(3) 4 14,59859946 
SLNFDVEEEKIR(11)  NIVKR(4) 4 4,761953897 
 SIKDFSIK(3)  KGSAR(1) 2 4,011441043 
 KINNYAYK(1)  LSYKGR(4) 1 3,074172425 
 YTEAINKLNEYNK(8)  LSYKGR(4) 1 2,431798276 
 EINLKDIK(5)  KGSAR(1) 2 2,387216143 
 DIKDIR(3)  KGSAR(1) 1 2,248720896 
 DIKDIR(3)  LEQGKK(5) 1 5,272458743 
 
 
Peptides Cas7                                                   Peptides Cas5                        Spectra                Score 
GFDGSNGKDIFVR(8) ISENLINTKK(9) 5 13,00217692 
GFDGSNGKDIFVR(8) KSMNIIHER(1) 2 11,14387556 
EIESEKGGIKDGK(6) ISENLINTKK(9) 37 20,54060751 
EIESEKGGIKDGK(6) KSMNIIHER(1) 30 15,44129143 
KSMNIIHER(1) EIESEKGGIK(6) 25 12,75448733 
EIESEKGGIKDGK(10) ISENLINTKK(9) 2 4,540607512 
KSMNIIHER(1) GGIKDGK(4) 12 5,612610174 
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TQIKIEFLK(4) GGIKDGK(4) 2 4,031517051 
KSMNIIHER(1) DGKAR(3) 19 2,707743929 
AKDFNENVDEILQK(2) ISENLINTKK(9) 10 12,76700389 
AKDFNENVDEILQK(2) KSMNIIHER(1) 10 13,05601112 
SLNKVNLK(4) NPVKK(4) 12 10,11804503 
ISENLINTKK(9) SLNKVNLK(4) 2 8,866461092 
IEFLKDACYR(5) SLNKVNLK(4) 6 12,60554832 
VNLKHIK(4) NPVKK(4) 7 5,35261703 
ISENLINTKK(9) VNLKHIK(4) 6 19,0428718 
TQIKIEFLK(4) VNLKHIK(4) 12 15,14448084 
KGDIEFEDDREYFTETIPVEMDAER(1) VNLKHIK(4) 1 3,354577731 
HIKGTGAFASGEGK(3) NPVKK(4) 5 6,119186408 
HIKGTGAFASGEGK(3) ISENLINTKK(9) 12 12,99139983 
HIKGTGAFASGEGK(3) KSMNIIHER(1) 12 15,326058 
HIKGTGAFASGEGK(3) TQIKIEFLK(4) 20 13,1580152 
HIKGTGAFASGEGK(3) IEFLKDACYR(5) 1 4,183096161 
KGDIEFEDDREYFTETIPVEMDAER(1) HIKGTGAFASGEGK(3) 1 3,420216403 
GTGAFASGEGKAQK(11) NPVKK(4) 4 5,552841969 
GTGAFASGEGKAQK(11) ISENLINTKK(9) 6 15,95467702 
GTGAFASGEGKAQK(11) KSMNIIHER(1) 15 9,987162775 
GTGAFASGEGKAQK(11) TQIKIEFLK(4) 14 12,22694531 
ISENLINTKK(9) AQKTFR(3) 9 9,057000407 
GTGAFASGEGKAQKTFR(14) KSMNIIHERTQIK(1) 1 2,913640169 
KSMNIIHER(1) AQKTFR(3) 14 7,26760624 
KSMNIIHERTQIK(1) AQKTFR(3) 1 3,244125144 
TQIKIEFLK(4) AQKTFR(3) 9 6,374687549 
ISENLINTKK(9) SKMGHMPR(2) 7 12,68824614 
KSMNIIHER(1) SKMGHMPR(2) 5 11,21112488 
LDELIDELANYGDKIEK(14) ESLKEHR(4) 4 8,279014256 
VVFVADKNLR(7) KSMNIIHER(1) 1 2,567030709 
 
 
Peptides Cas5                                                  Peptides Cas8b                            Spectra               Score                   
KISYK(1) NPVKK(4) 4 7,329754147 
ISENLINTKK(9) YGKTSK(3) 9 15,07262964 
QENAWKNYPVCSCCAQK(6) KSMNIIHER(1) 10 19,52287875 
TFFPNNKTEGNFDK(7) KSMNIIHER(1) 3 9,649751982 
QENAWKNYPVCSCCAQK(6) TQIKIEFLK(4) 11 11,06854213 
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Figure 2.11 C und Figure 2.18 A stammen aus ihrer Bachelorarbeit. 
Franka Schreiner 
Hat im Rahmen ihres Mastermoduls die Konstrukte pEC-A-HI-SUMO+cas5 und pEC-A-
HI-SUMO+cas7 erstellt, die zur Anfertiugung von Figure 2.11 A verwendet wurden. 
Kristina Rau 
Hat im Rahmen ihrer Masterarbeit das Protein Cas8b zur massenspektrometrischen 
Analyse von Jörg Kahnt (MPI Marburg) hergestellt. Figure 2.18 stammt aus ihrer 
Masterarbeit. 
Kundan Sharma (MPI Göttingen) 
Hat im Rahmen der DFG Forschergruppe FOR1680 als Kollaborationspartner u.a. die 
massenspektrometrischen Analysen der Protein:Protein und Protein:RNA Cross-link 
Experimente durchgeführt. Von ihm stammen Figure 2.20 und 2.21 A. 
 
 
 
 
 
 
 
 
